PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23572494-7 2013 Treatment of wild-type mice with LPS and the PPARgamma agonist, rosiglitazone, but not the PPARalpha agonist (WY-14643), increased fatty acid oxidation, prevented LPS-mediated reduction of mitochondria, and treated cardiac dysfunction, as well as it improved survival, despite continued increases in the expression of cardiac inflammatory markers. Rosiglitazone 64-77 peroxisome proliferator activated receptor gamma Mus musculus 45-54 22841546-8 2013 Upon treatment with rosiglitazone, an agonist of PPARgamma, intestine proinflammatory indicators were markedly decreased in wild-type mice, but to a much lesser degree in PFKFB3/iPFK2-disrupted mice. Rosiglitazone 20-33 peroxisome proliferator activated receptor gamma Mus musculus 49-58 23373812-0 2013 Neuroprotective effects of PPAR-gamma agonist rosiglitazone in N171-82Q mouse model of Huntington"s disease. Rosiglitazone 46-59 peroxisome proliferator activated receptor gamma Mus musculus 27-37 23373812-6 2013 We now report that the PPAR-gamma agonist, rosiglitazone (RSG), significantly attenuated mutant HTT-induced toxicity in striatal cells and that the protective effect of RSG is mediated by activation of PPAR-gamma. Rosiglitazone 43-56 peroxisome proliferator activated receptor gamma Mus musculus 23-33 23373812-6 2013 We now report that the PPAR-gamma agonist, rosiglitazone (RSG), significantly attenuated mutant HTT-induced toxicity in striatal cells and that the protective effect of RSG is mediated by activation of PPAR-gamma. Rosiglitazone 43-56 peroxisome proliferator activated receptor gamma Mus musculus 202-212 23373812-6 2013 We now report that the PPAR-gamma agonist, rosiglitazone (RSG), significantly attenuated mutant HTT-induced toxicity in striatal cells and that the protective effect of RSG is mediated by activation of PPAR-gamma. Rosiglitazone 58-61 peroxisome proliferator activated receptor gamma Mus musculus 23-33 23373812-6 2013 We now report that the PPAR-gamma agonist, rosiglitazone (RSG), significantly attenuated mutant HTT-induced toxicity in striatal cells and that the protective effect of RSG is mediated by activation of PPAR-gamma. Rosiglitazone 58-61 peroxisome proliferator activated receptor gamma Mus musculus 202-212 23373812-6 2013 We now report that the PPAR-gamma agonist, rosiglitazone (RSG), significantly attenuated mutant HTT-induced toxicity in striatal cells and that the protective effect of RSG is mediated by activation of PPAR-gamma. Rosiglitazone 169-172 peroxisome proliferator activated receptor gamma Mus musculus 23-33 23373812-6 2013 We now report that the PPAR-gamma agonist, rosiglitazone (RSG), significantly attenuated mutant HTT-induced toxicity in striatal cells and that the protective effect of RSG is mediated by activation of PPAR-gamma. Rosiglitazone 169-172 peroxisome proliferator activated receptor gamma Mus musculus 202-212 23620818-2 2013 In this study, we examined molecular mechanisms that explain differential effects of a PPARalpha agonist (fenofibrate) and a PPARgamma agonist (rosiglitazone) on macrophages during obesity-induced atherogenesis. Rosiglitazone 144-157 peroxisome proliferator activated receptor gamma Mus musculus 125-134 23628590-2 2013 We demonstrated that in the presence of LIF, the activation of PPARgamma by Rosiglitazone led to an increased proliferation of mESCs whereas PPARgamma antagonist (GW9662) reversed this effect. Rosiglitazone 76-89 peroxisome proliferator activated receptor gamma Mus musculus 63-72 23270804-7 2013 In addition, both Sumo1-null cells and Sumo1-null mice responded less efficiently to rosiglitazone, a PPARgamma agonist. Rosiglitazone 85-98 peroxisome proliferator activated receptor gamma Mus musculus 102-111 23646053-5 2013 The lung mRNA levels of PPARalpha and PPAR-gamma increased significantly in obese mice with OVA challenge compared to that in other types of mice and decreased after rosiglitazone administeration. Rosiglitazone 166-179 peroxisome proliferator activated receptor gamma Mus musculus 38-48 23212557-7 2013 The inhibitory effect of TNF-alpha on PPARgamma and CTRP9 was reversed by Tiron or rosiglitazone. Rosiglitazone 83-96 peroxisome proliferator activated receptor gamma Mus musculus 38-47 23103499-6 2013 Pretreatment with the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone significantly restored ACh-dependent vasodilation in Pkd2 mice. Rosiglitazone 79-92 peroxisome proliferator activated receptor gamma Mus musculus 22-70 24009864-1 2013 High risk of cardiovascular diseases caused by existing PPAR-gamma agonists such as rosiglitazone and pioglitazone has been recently reported. Rosiglitazone 84-97 peroxisome proliferator activated receptor gamma Mus musculus 56-66 22951341-6 2013 Similarly, mechanical strain (3600 cycles, 2% strain daily) inhibited adipogenesis at 3 days, preventing rosiglitazone-induced PPARgamma upregulation as well as aP2 and adiponectin protein expression. Rosiglitazone 105-118 peroxisome proliferator activated receptor gamma Mus musculus 127-136 23326314-12 2013 NIH/3T3 adipocytes induced in the presence of rosiglitazone showed higher 2-deoxyglucose transport rate after insulin stimulation, expressed less Agt (angiotensinogen) and more PPARgamma. Rosiglitazone 46-59 peroxisome proliferator activated receptor gamma Mus musculus 177-186 23032483-1 2013 Rosiglitazone, a synthetic peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist, prevents cell death after cerebral ischemia in animal models, but the underlying mechanism has not been clarified. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 27-75 23032483-1 2013 Rosiglitazone, a synthetic peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist, prevents cell death after cerebral ischemia in animal models, but the underlying mechanism has not been clarified. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 77-86 23175826-0 2012 Cognitive enhancement with rosiglitazone links the hippocampal PPARgamma and ERK MAPK signaling pathways. Rosiglitazone 27-40 peroxisome proliferator activated receptor gamma Mus musculus 63-72 24489534-0 2013 PPARgamma Agonist Rosiglitazone Suppresses Renal mPGES-1/PGE2 Pathway in db/db Mice. Rosiglitazone 18-31 peroxisome proliferator activated receptor gamma Mus musculus 0-9 23917405-3 2013 Rosiglitazone (RSG), a PPARgamma agonist, ameliorates hepatosteatosis and enhances insulin sensitivity. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 23-32 23917405-3 2013 Rosiglitazone (RSG), a PPARgamma agonist, ameliorates hepatosteatosis and enhances insulin sensitivity. Rosiglitazone 15-18 peroxisome proliferator activated receptor gamma Mus musculus 23-32 23105093-2 2012 In this study, we show that, in L6 cells, rosiglitazone- as well as pioglitazone-dependent activation of peroxisome proliferator-activated receptor-gamma (PPARgamma) represses transcription of the ped/pea-15 gene, whose increased activity impairs glucose tolerance in mice and humans. Rosiglitazone 42-55 peroxisome proliferator activated receptor gamma Mus musculus 155-164 23105093-4 2012 The ability of PPARgamma to affect ped/pea-15 expression was also lost in cells and in C57BL/6J transgenic mice expressing ped/pea-15 under the control of an exogenous promoter, suggesting that ped/pea-15 repression may contribute to rosiglitazone action on glucose disposal. Rosiglitazone 234-247 peroxisome proliferator activated receptor gamma Mus musculus 15-24 23175826-1 2012 We previously reported that the peroxisome proliferator-activated receptor gamma (PPARgamma) agonist rosiglitazone (RSG) improved hippocampus-dependent cognition in the Alzheimer"s disease (AD) mouse model, Tg2576. Rosiglitazone 101-114 peroxisome proliferator activated receptor gamma Mus musculus 32-80 23175826-1 2012 We previously reported that the peroxisome proliferator-activated receptor gamma (PPARgamma) agonist rosiglitazone (RSG) improved hippocampus-dependent cognition in the Alzheimer"s disease (AD) mouse model, Tg2576. Rosiglitazone 101-114 peroxisome proliferator activated receptor gamma Mus musculus 82-91 23175826-1 2012 We previously reported that the peroxisome proliferator-activated receptor gamma (PPARgamma) agonist rosiglitazone (RSG) improved hippocampus-dependent cognition in the Alzheimer"s disease (AD) mouse model, Tg2576. Rosiglitazone 116-119 peroxisome proliferator activated receptor gamma Mus musculus 32-80 23175826-1 2012 We previously reported that the peroxisome proliferator-activated receptor gamma (PPARgamma) agonist rosiglitazone (RSG) improved hippocampus-dependent cognition in the Alzheimer"s disease (AD) mouse model, Tg2576. Rosiglitazone 116-119 peroxisome proliferator activated receptor gamma Mus musculus 82-91 23175826-7 2012 In addition, we found the RSG-mediated augmentation of PPARgamma and ERK2 activity during Tg2576 cognitive enhancement was reversed when hippocampal PPARgamma was pharmacologically antagonized, revealing a coordinate relationship between PPARgamma transcriptional competency and phosphorylated ERK that is reciprocally affected in response to chronic activation, compared with acute inhibition, of PPARgamma. Rosiglitazone 26-29 peroxisome proliferator activated receptor gamma Mus musculus 55-64 23175826-7 2012 In addition, we found the RSG-mediated augmentation of PPARgamma and ERK2 activity during Tg2576 cognitive enhancement was reversed when hippocampal PPARgamma was pharmacologically antagonized, revealing a coordinate relationship between PPARgamma transcriptional competency and phosphorylated ERK that is reciprocally affected in response to chronic activation, compared with acute inhibition, of PPARgamma. Rosiglitazone 26-29 peroxisome proliferator activated receptor gamma Mus musculus 149-158 23175826-7 2012 In addition, we found the RSG-mediated augmentation of PPARgamma and ERK2 activity during Tg2576 cognitive enhancement was reversed when hippocampal PPARgamma was pharmacologically antagonized, revealing a coordinate relationship between PPARgamma transcriptional competency and phosphorylated ERK that is reciprocally affected in response to chronic activation, compared with acute inhibition, of PPARgamma. Rosiglitazone 26-29 peroxisome proliferator activated receptor gamma Mus musculus 149-158 23175826-7 2012 In addition, we found the RSG-mediated augmentation of PPARgamma and ERK2 activity during Tg2576 cognitive enhancement was reversed when hippocampal PPARgamma was pharmacologically antagonized, revealing a coordinate relationship between PPARgamma transcriptional competency and phosphorylated ERK that is reciprocally affected in response to chronic activation, compared with acute inhibition, of PPARgamma. Rosiglitazone 26-29 peroxisome proliferator activated receptor gamma Mus musculus 149-158 22988119-5 2012 Reversal of the metabolic phenotype with the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone abrogated diet-induced mammary growth. Rosiglitazone 102-115 peroxisome proliferator activated receptor gamma Mus musculus 45-93 22912368-4 2012 Differentiation was enhanced by chronic treatment with the PPARgamma agonist rosiglitazone plus the sympathetic neurotransmitter norepinephrine. Rosiglitazone 77-90 peroxisome proliferator activated receptor gamma Mus musculus 59-68 22652199-6 2012 PPAR-gamma signaling was activated by administration of rosiglitazone. Rosiglitazone 56-69 peroxisome proliferator activated receptor gamma Mus musculus 0-10 22807489-0 2012 Rosiglitazone promotes PPARgamma-dependent and -independent alterations in gene expression in mouse islets. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 23-32 22982856-1 2012 The effect of rosiglitazone, an agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma), was investigated in a mouse parent-to-F1 GVHD model. Rosiglitazone 14-27 peroxisome proliferator activated receptor gamma Mus musculus 43-91 22982856-1 2012 The effect of rosiglitazone, an agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma), was investigated in a mouse parent-to-F1 GVHD model. Rosiglitazone 14-27 peroxisome proliferator activated receptor gamma Mus musculus 93-102 22700433-7 2012 15d-PGJ2-G and other PPARgamma agonists, such as rosiglitazone and ciglitazone, decreased PMA/I0-mediated elevation in intracellular calcium concentration ([Ca2+](i)) in activated Jurkat cells. Rosiglitazone 49-62 peroxisome proliferator activated receptor gamma Mus musculus 21-30 22732454-4 2012 However, ASX was unable to activate transcription in PPARgamma reporter assays, although it antagonized transcriptional activation by the PPARgamma agonist rosiglitazone (RGZ). Rosiglitazone 156-169 peroxisome proliferator activated receptor gamma Mus musculus 138-147 22580003-5 2012 Ascofuranone induced expression of adiponectin, and increases the promoter activity of adiponectin and PPRE, PPAR response element, as comparably as a PPARgamma agonist, rosiglitazone, that stimulates lipid accumulation in the preadipocyte cell line. Rosiglitazone 170-183 peroxisome proliferator activated receptor gamma Mus musculus 151-160 22173916-0 2012 Activation of peroxisome proliferator-activated receptor-gamma by rosiglitazone improves lipid homeostasis at the adipose tissue-liver axis in ethanol-fed mice. Rosiglitazone 66-79 peroxisome proliferator activated receptor gamma Mus musculus 14-62 22169011-5 2012 Herein, we demonstrate in mice that rosiglitazone (RGZ), a PPARgamma ligand, increases body weight and abdominal fat pad fluid content and reduces hematocrit. Rosiglitazone 36-49 peroxisome proliferator activated receptor gamma Mus musculus 59-68 22319216-7 2012 The PPARgamma-dependence of four of these miRNA loci was demonstrated by PPARgamma knock-down and the loci of miR-103-1 (Pank3), miR-205 and miR-378 (Ppargc1b) were also responsive to the PPARgamma ligand rosiglitazone. Rosiglitazone 205-218 peroxisome proliferator activated receptor gamma Mus musculus 4-13 22472882-5 2012 RESULTS: Pronounced expression of PPARgamma was demonstrated in HCC cells (MHCC97L, BEL-7404) treated with Ad-PPARgamma, rosiglitazone or Ad-PPARgamma plus rosiglitazone, compared with control (Ad-LacZ). Rosiglitazone 121-134 peroxisome proliferator activated receptor gamma Mus musculus 34-43 22472882-5 2012 RESULTS: Pronounced expression of PPARgamma was demonstrated in HCC cells (MHCC97L, BEL-7404) treated with Ad-PPARgamma, rosiglitazone or Ad-PPARgamma plus rosiglitazone, compared with control (Ad-LacZ). Rosiglitazone 156-169 peroxisome proliferator activated receptor gamma Mus musculus 34-43 22472882-9 2012 Activation of PPARgamma by rosiglitazone significantly reduced the incidence and severity of lung metastasis in an orthotopic HCC mouse model. Rosiglitazone 27-40 peroxisome proliferator activated receptor gamma Mus musculus 14-23 22463744-5 2012 Moreover, a luciferase reporter assay indicated that pipierine significantly represses the rosiglitazone-induced PPARgamma transcriptional activity. Rosiglitazone 91-104 peroxisome proliferator activated receptor gamma Mus musculus 113-122 22463744-6 2012 Finally, GST-pull down assays demonstrated that piperine disrupts the rosiglitazone-dependent interaction between PPARgamma and coactivator CBP. Rosiglitazone 70-83 peroxisome proliferator activated receptor gamma Mus musculus 114-123 22034049-14 2012 The use of statins or peroxisome proliferator-activated receptor gamma agonists (e.g., rosiglitazone) could be a strategy for interfering with the progression of OA. Rosiglitazone 87-100 peroxisome proliferator activated receptor gamma Mus musculus 22-70 22173916-3 2012 The present study investigated the effects of PPAR-gamma activation by rosiglitazone on lipid homeostasis at the adipose tissue-liver axis. Rosiglitazone 71-84 peroxisome proliferator activated receptor gamma Mus musculus 46-56 22173916-5 2012 Ethanol exposure downregulated adipose PPAR-gamma gene and reduced the WAT mass in association with induction of inflammation, which was attenuated by rosiglitazone. Rosiglitazone 151-164 peroxisome proliferator activated receptor gamma Mus musculus 39-49 22173916-12 2012 These results demonstrated that activation of PPAR-gamma by rosiglitazone reverses ethanol-induced adipose dysfunction and lipid dyshomeostasis at the WAT-liver axis, thereby abrogating alcoholic fatty liver. Rosiglitazone 60-73 peroxisome proliferator activated receptor gamma Mus musculus 46-56 22108913-12 2012 In our type 2 diabetes/obesity model, rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist compensated for the HFD-induced PepT1 down-regulation, whereas metformin reversed rosiglitazone activity at the translational level. Rosiglitazone 38-51 peroxisome proliferator activated receptor gamma Mus musculus 55-103 22333133-2 2012 In this work, we address this issue by feeding a green tea extract (TEAVIGO ) with a high content of epigallocatechin gallate (EGCG) or the thiazolidinedione PPAR-gamma agonist rosiglitazone, as positive control, to db/db mice, an animal model for diabetes. Rosiglitazone 177-190 peroxisome proliferator activated receptor gamma Mus musculus 158-168 22304921-4 2012 Moreover, FGF21-KO mice are refractory to both the beneficial insulin-sensitizing effects and the detrimental weight gain and edema side effects of the PPARgamma agonist rosiglitazone. Rosiglitazone 170-183 peroxisome proliferator activated receptor gamma Mus musculus 152-161 21762184-3 2012 Therefore, we hypothesized that the PPARgamma ligand, rosiglitazone, would attenuate alcohol-induced NADPH oxidase expression and pulmonary barrier dysfunction. Rosiglitazone 54-67 peroxisome proliferator activated receptor gamma Mus musculus 36-45 21952104-10 2012 Interestingly, adiponectin expression was inducible by the PPARgamma agonist rosiglitazone. Rosiglitazone 77-90 peroxisome proliferator activated receptor gamma Mus musculus 59-68 21465278-0 2012 PPAR-gamma agonist rosiglitazone attenuates the inflammation caused by carrageenan in the mouse model of pleurisy. Rosiglitazone 19-32 peroxisome proliferator activated receptor gamma Mus musculus 0-10 22286232-1 2012 Rosiglitazone has the potential to activate peroxisome proliferator-activated receptor-gamma (PPARgamma), which in turn can affect bone formation and resorption. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 44-92 21917419-9 2012 The enhancement of glucose homeostasis was comparable to the effect induced by rosiglitazone, a commercial peroxisome proliferator-activated receptor-gamma agonist, but it did not match the level of glucose homeostasis in the non-diabetic mice. Rosiglitazone 79-92 peroxisome proliferator activated receptor gamma Mus musculus 107-155 22286232-1 2012 Rosiglitazone has the potential to activate peroxisome proliferator-activated receptor-gamma (PPARgamma), which in turn can affect bone formation and resorption. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 94-103 22286232-5 2012 Rosiglitazone also suppressed the receptor activator of nuclear factor (NF)-kappaB ligand (RANKL) receptor(RANK) expression but increased PPARgamma2 expression in the cells. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 138-148 22286232-8 2012 These results suggest that PPARgamma activation by rosiglitazone inhibits osteoblast differentiation with increased adipogenesis in bone marrow cells and also may prevent osteoclast formation and bone resorptionin the cells. Rosiglitazone 51-64 peroxisome proliferator activated receptor gamma Mus musculus 27-36 21994940-7 2011 In contrast, PPARgamma in PP5-KO cells was hyperphosphorylated at serine 112 but had reduced rosiglitazone-induced activity at lipogenic genes. Rosiglitazone 93-106 peroxisome proliferator activated receptor gamma Mus musculus 13-22 22192475-1 2012 We evaluate the immunomodulation of Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists 15d-PGJ(2) and rosiglitazone (RGZ) in a model of chronic eosinophilia. Rosiglitazone 122-135 peroxisome proliferator activated receptor gamma Mus musculus 86-96 23316104-0 2012 Activation of peroxisome proliferator-activated receptor gamma by rosiglitazone inhibits lipopolysaccharide-induced release of high mobility group box 1. Rosiglitazone 66-79 peroxisome proliferator activated receptor gamma Mus musculus 14-62 23316104-3 2012 Among the ligands of PPAR, the effect of rosiglitazone, a specific ligand for PPARgamma, was superior in the inhibition of HMGB1 release induced by LPS. Rosiglitazone 41-54 peroxisome proliferator activated receptor gamma Mus musculus 78-87 23316104-5 2012 Ablation of PPARgamma with small interfering RNA or GW9662-mediated inhibition of PPARgamma abolished the effect of rosiglitazone on HMGB1 release. Rosiglitazone 116-129 peroxisome proliferator activated receptor gamma Mus musculus 12-21 23316104-5 2012 Ablation of PPARgamma with small interfering RNA or GW9662-mediated inhibition of PPARgamma abolished the effect of rosiglitazone on HMGB1 release. Rosiglitazone 116-129 peroxisome proliferator activated receptor gamma Mus musculus 82-91 23316104-6 2012 Furthermore, the overexpression of PPARgamma markedly potentiated the inhibitory effect of rosiglitazone on HMGB1 release. Rosiglitazone 91-104 peroxisome proliferator activated receptor gamma Mus musculus 35-44 21926265-0 2011 The PPARgamma ligand rosiglitazone attenuates hypoxia-induced endothelin signaling in vitro and in vivo. Rosiglitazone 21-34 peroxisome proliferator activated receptor gamma Mus musculus 4-13 22114064-13 2011 Our results showed that Hcy suppressed rosiglitazone-induced adipogenesis in a similar fashion as this by insulin, suggesting that inhibition of PPAR-gamma transactivation was critically involved in the Hcy-induced inhibitory effect on adipogenesis. Rosiglitazone 39-52 peroxisome proliferator activated receptor gamma Mus musculus 145-155 21907283-8 2012 The above protective effects appeared to be exerted by a direct activation of the PPARgamma agonist (rosiglitazone) because rosiglitazone protected a neuroblastoma cell line (N2A) from mHtt-evoked mitochondrial deficiency. Rosiglitazone 101-114 peroxisome proliferator activated receptor gamma Mus musculus 82-91 21907283-8 2012 The above protective effects appeared to be exerted by a direct activation of the PPARgamma agonist (rosiglitazone) because rosiglitazone protected a neuroblastoma cell line (N2A) from mHtt-evoked mitochondrial deficiency. Rosiglitazone 124-137 peroxisome proliferator activated receptor gamma Mus musculus 82-91 23166672-4 2012 In the present study, we determined the gene signatures that were unique to classical brown adipocytes and to beige cells induced by a specific PPARgamma agonist rosiglitazone in mice. Rosiglitazone 162-175 peroxisome proliferator activated receptor gamma Mus musculus 144-153 22529965-1 2012 BACKGROUND: PPARgamma plays a key role in adipocyte biology, and Rosiglitazone (Rosi), a thiazolidinedione (TZD)/PPARgamma agonist, is a potent insulin-sensitizing agent. Rosiglitazone 65-78 peroxisome proliferator activated receptor gamma Mus musculus 113-122 21666107-1 2011 Rosiglitazone (RGZ), a peroxisome proliferator-activated receptor (PPAR)-gamma agonist, has been demonstrated to possess cardioprotective properties during ischemia-reperfusion. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 23-78 21839812-10 2011 Rosiglitazone administration to MPTPp-treated mice, reverted PPAR-gamma overexpression in microglia without affecting TH-positive neurons. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 61-71 21839812-19 2011 Results suggest that PPAR-gamma expression in microglia and TNF-alpha production by these cells are crucial changes by which rosiglitazone exerts neuroprotection in PD. Rosiglitazone 125-138 peroxisome proliferator activated receptor gamma Mus musculus 21-31 21189228-6 2011 Supplementation with rosiglitazone, a PPARgamma ligand, during the early stage of adipocyte differentiation partially rescued curcumin-inhibited adipocyte differentiation. Rosiglitazone 21-34 peroxisome proliferator activated receptor gamma Mus musculus 38-47 21397693-5 2011 We found that GW9662 has a 10-fold shorter half-life in cell culture than do PPARgamma activators such as rosiglitazone (ROSI), accounting for previous observations that GW9662 did not inhibit TBT-mediated adipogenesis. Rosiglitazone 106-119 peroxisome proliferator activated receptor gamma Mus musculus 77-86 21397693-5 2011 We found that GW9662 has a 10-fold shorter half-life in cell culture than do PPARgamma activators such as rosiglitazone (ROSI), accounting for previous observations that GW9662 did not inhibit TBT-mediated adipogenesis. Rosiglitazone 121-125 peroxisome proliferator activated receptor gamma Mus musculus 77-86 21892191-1 2011 PPARgamma is the functioning receptor for the thiazolidinedione (TZD) class of antidiabetes drugs including rosiglitazone and pioglitazone. Rosiglitazone 108-121 peroxisome proliferator activated receptor gamma Mus musculus 0-9 21651979-8 2011 The aforementioned protective effects appeared to be exerted by a direct activation of the PPARgamma agonist (rosiglitazone) because rosiglitazone reduced mHtt aggregates and rescued energy deficiency in a hepatoma cell line (HepG2). Rosiglitazone 110-123 peroxisome proliferator activated receptor gamma Mus musculus 91-100 21651979-8 2011 The aforementioned protective effects appeared to be exerted by a direct activation of the PPARgamma agonist (rosiglitazone) because rosiglitazone reduced mHtt aggregates and rescued energy deficiency in a hepatoma cell line (HepG2). Rosiglitazone 133-146 peroxisome proliferator activated receptor gamma Mus musculus 91-100 21651979-10 2011 Treatment with PPARgamma agents (TZD and rosiglitazone) enhanced the function of PPARgamma, and might lead to therapeutic benefits. Rosiglitazone 41-54 peroxisome proliferator activated receptor gamma Mus musculus 15-24 21651979-10 2011 Treatment with PPARgamma agents (TZD and rosiglitazone) enhanced the function of PPARgamma, and might lead to therapeutic benefits. Rosiglitazone 41-54 peroxisome proliferator activated receptor gamma Mus musculus 81-90 21836474-6 2011 Both pharmacological activation and overexpression of PPARgamma significantly inhibited TGF-beta1-induced extracellular matrix molecule expression in isolated cardiac fibroblasts, whereas treatment with the PPARgamma agonist rosiglitazone inhibited, and treatment with the PPARgamma antagonist T0070907 exacerbated chronic pressure overload-induced cardiac fibrosis and remodeling in wild-type mice in vivo. Rosiglitazone 225-238 peroxisome proliferator activated receptor gamma Mus musculus 207-216 21836474-6 2011 Both pharmacological activation and overexpression of PPARgamma significantly inhibited TGF-beta1-induced extracellular matrix molecule expression in isolated cardiac fibroblasts, whereas treatment with the PPARgamma agonist rosiglitazone inhibited, and treatment with the PPARgamma antagonist T0070907 exacerbated chronic pressure overload-induced cardiac fibrosis and remodeling in wild-type mice in vivo. Rosiglitazone 225-238 peroxisome proliferator activated receptor gamma Mus musculus 207-216 21537328-1 2011 We recently showed that the bradykinin B2 receptor (B2R) blocker icatibant (Icat) and the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone (Ros) exerted anti-inflammatory effects in renal tubular cells exposed to a diabetic milieu. Rosiglitazone 147-160 peroxisome proliferator activated receptor gamma Mus musculus 90-138 21537328-1 2011 We recently showed that the bradykinin B2 receptor (B2R) blocker icatibant (Icat) and the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone (Ros) exerted anti-inflammatory effects in renal tubular cells exposed to a diabetic milieu. Rosiglitazone 162-165 peroxisome proliferator activated receptor gamma Mus musculus 90-138 21873987-5 2011 The proliferation of peroxisomes in POMC neurons induced by the PPAR-gamma agonist rosiglitazone decreased ROS levels and increased food intake in lean mice on high-fat diet. Rosiglitazone 83-96 peroxisome proliferator activated receptor gamma Mus musculus 64-74 21585338-3 2011 Because the PPARgamma agonist rosiglitazone was found to increase DLK expression in 3T3-L1 cells, we hypothesized that PPARgamma is required for the transcriptional activation of the DLK gene. Rosiglitazone 30-43 peroxisome proliferator activated receptor gamma Mus musculus 12-21 21585338-3 2011 Because the PPARgamma agonist rosiglitazone was found to increase DLK expression in 3T3-L1 cells, we hypothesized that PPARgamma is required for the transcriptional activation of the DLK gene. Rosiglitazone 30-43 peroxisome proliferator activated receptor gamma Mus musculus 119-128 21501147-6 2011 PPARgamma agonists 15-deoxy-Delta(12,14) -prostaglandin J(2) (15d-PGJ(2)) and rosiglitazone mimicked the effects of 2-AG on NF-kappaB-p65 phosphorylation, COX-2 expression and mEPSCs, and these effects were eliminated by antagonism of PPARgamma. Rosiglitazone 78-91 peroxisome proliferator activated receptor gamma Mus musculus 0-9 21501147-6 2011 PPARgamma agonists 15-deoxy-Delta(12,14) -prostaglandin J(2) (15d-PGJ(2)) and rosiglitazone mimicked the effects of 2-AG on NF-kappaB-p65 phosphorylation, COX-2 expression and mEPSCs, and these effects were eliminated by antagonism of PPARgamma. Rosiglitazone 78-91 peroxisome proliferator activated receptor gamma Mus musculus 235-244 21507897-7 2011 In precision-cut liver slices (PCLSs) and hepatocytes, rosiglitazone either alone or in combination with oleic acid increased triglyceride accumulation, an effect that was blocked by the PPARgamma antagonist biphenol A diglycidyl ether (BADGE). Rosiglitazone 55-68 peroxisome proliferator activated receptor gamma Mus musculus 187-196 21507897-8 2011 PCLSs and hepatocytes from PPARgamma(Deltahep) mice showed blunted responses to rosiglitazone and oleic acid, whereas the response to these compounds remained intact in PCLSs from PPARgamma(Deltamac) mice. Rosiglitazone 80-93 peroxisome proliferator activated receptor gamma Mus musculus 27-36 21571064-5 2011 The PPARgamma agonist rosiglitazone significantly up-regulated luciferase expression in RAW264.7 cells, while it remained unaltered in RAW264.7 AF2 macrophages. Rosiglitazone 22-35 peroxisome proliferator activated receptor gamma Mus musculus 4-13 21723508-1 2011 Rosiglitazone is a PPARgamma agonist commonly used to treat diabetes. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 19-28 21723508-4 2011 In db/db and diet-induced obese mice, PPARgamma activation by rosiglitazone restores endothelium-dependent relaxation of aortae, whereas diabetic mice lacking adiponectin or treated with an anti-adiponectin antibody do not respond. Rosiglitazone 62-75 peroxisome proliferator activated receptor gamma Mus musculus 38-47 21531777-0 2011 Hypoxia-induced inhibition of lung development is attenuated by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Rosiglitazone 125-138 peroxisome proliferator activated receptor gamma Mus musculus 68-116 22152244-8 2011 Administration of PPARg agonist rosiglitazone and/or Ad-PPARg significantly ameliorated hepatic steatosis, hepatocellular apoptosis, necro inflammation and fibrosis. Rosiglitazone 32-45 peroxisome proliferator activated receptor gamma Mus musculus 18-23 21435906-3 2011 METHODS: The therapeutic effects of the PPAR-gamma agonist, rosiglitazone, combined with anti-interleukin-5 are explored in a mouse model of MHC Class II-histoincompatible cardiac transplantation. Rosiglitazone 60-73 peroxisome proliferator activated receptor gamma Mus musculus 40-50 21544727-3 2011 Fenofibrate, a PPARalpha agonist, is commonly used to treat dyslipidemia, and rosiglitazone, a PPARgamma agonist, is effective in improving glycemic control. Rosiglitazone 78-91 peroxisome proliferator activated receptor gamma Mus musculus 95-104 21156825-10 2011 Likewise, the PPARgamma antagonist rosiglitazone attenuated U46619-induced contractions. Rosiglitazone 35-48 peroxisome proliferator activated receptor gamma Mus musculus 14-23 21346177-7 2011 Uric acid-induced increase in MCP-1 production was blocked by scavenging superoxide or by inhibiting NADPH oxidase and by stimulating peroxisome-proliferator-activated receptor-gamma with rosiglitazone. Rosiglitazone 188-201 peroxisome proliferator activated receptor gamma Mus musculus 134-182 20524105-1 2011 The neuroprotective effect of rosiglitazone, a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, has been investigated using both in vivo and in vitro models of global ischemia in CD1 mice. Rosiglitazone 30-43 peroxisome proliferator activated receptor gamma Mus musculus 47-95 20524105-1 2011 The neuroprotective effect of rosiglitazone, a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, has been investigated using both in vivo and in vitro models of global ischemia in CD1 mice. Rosiglitazone 30-43 peroxisome proliferator activated receptor gamma Mus musculus 97-106 21076077-3 2011 In the present study, we tested the hypothesis that the PPARG agonist rosiglitazone has a direct effect on the pituitary. Rosiglitazone 70-83 peroxisome proliferator activated receptor gamma Mus musculus 56-61 21076077-6 2011 Depletion of PPARG using a lentivirally encoded short hairpin RNA abolishes the effect of rosiglitazone to suppress activation of JNKs and induction of the transcription factors EGR1 and FOS as well as the gonadotropin genes Lhb and Fshb. Rosiglitazone 90-103 peroxisome proliferator activated receptor gamma Mus musculus 13-18 21514419-9 2011 The protective effect of rosiglitazone was abrogated by the specific PPARgamma small interference RNA, but not a control small interference RNA. Rosiglitazone 25-38 peroxisome proliferator activated receptor gamma Mus musculus 69-78 21514419-10 2011 We conclude that MtD is involved in Aldo-induced podocyte injury, and that the PPARgamma agonist rosiglitazone may protect podocytes from this injury by improving mitochondrial function. Rosiglitazone 97-110 peroxisome proliferator activated receptor gamma Mus musculus 79-88 21575348-1 2011 OBJECTIVE: To study the expression of Galectin-9 and Tim-3 in lungs of mice with asthma and the effect of rosiglitazone (PPAR-gamma agonist) on their expression. Rosiglitazone 106-119 peroxisome proliferator activated receptor gamma Mus musculus 121-131 21245029-6 2011 The PPARgamma receptor agonists LY171883 and rosiglitazone increased GIPR expression in differentiated 3T3-L1 adipocytes, whereas the antagonist GW9662 ablated expression. Rosiglitazone 45-58 peroxisome proliferator activated receptor gamma Mus musculus 4-13 21352814-2 2011 The treatment of leptin inhibited the rosiglitazone-induced adipocyte differentiation with a decreased expression of peroxisome proliferator-activated receptor gamma (PPARgamma) a key adipogenic transcription factor, both in mRNA and protein levels. Rosiglitazone 38-51 peroxisome proliferator activated receptor gamma Mus musculus 117-165 21352814-2 2011 The treatment of leptin inhibited the rosiglitazone-induced adipocyte differentiation with a decreased expression of peroxisome proliferator-activated receptor gamma (PPARgamma) a key adipogenic transcription factor, both in mRNA and protein levels. Rosiglitazone 38-51 peroxisome proliferator activated receptor gamma Mus musculus 167-176 21734368-2 2011 Agonists of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), such as rosiglitazone, have been recently demonstrated to regulate inflammation by modulating the production of inflammatory mediators. Rosiglitazone 87-100 peroxisome proliferator activated receptor gamma Mus musculus 16-64 21047783-4 2011 In 3T3-L1 preadipocyte cells, overexpression of ASXL1 inhibited the induction of PPARgamma activity by rosiglitazone, as shown by transcription assays, and completely suppressed adipogenesis, as shown by Oil Red O staining. Rosiglitazone 103-116 peroxisome proliferator activated receptor gamma Mus musculus 81-90 21047783-5 2011 In contrast, overexpression of ASXL2 greatly enhanced rosiglitazone-induced PPARgamma activity and enhanced adipogenesis. Rosiglitazone 54-67 peroxisome proliferator activated receptor gamma Mus musculus 76-85 21734368-10 2011 Furthermore, in the LPS-stimulated HK-2 cells, rosiglitazone downregulated MCP-1, IL-8 and IL-6 expression as well as NF-kappaB activation and increased PPAR-gamma expression (p < 0.05). Rosiglitazone 47-60 peroxisome proliferator activated receptor gamma Mus musculus 153-163 21734368-12 2011 CONCLUSION: These results showed that pretreatment with rosiglitazone could attenuate kidney inflammation through the activation of PPAR-gamma, suppression of MCP-1 overproduction and NF-kappaB activation. Rosiglitazone 56-69 peroxisome proliferator activated receptor gamma Mus musculus 132-142 21734368-13 2011 Rosiglitazone had a protective effect via a PPAR-gamma-dependent pathway in LPS-treated HK-2 cells. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 44-54 21123490-4 2011 In this study, we examined whether the PPARgamma agonist rosiglitazone inhibited Aldo-induced MC proliferation by modulating ROS-dependent EGFR intracellular signaling. Rosiglitazone 57-70 peroxisome proliferator activated receptor gamma Mus musculus 39-48 21123490-6 2011 The inhibitory effect was blocked by the PPARgamma antagonist PD-68235, indicating that the rosiglitazone effect acted through PPARgamma activation. Rosiglitazone 92-105 peroxisome proliferator activated receptor gamma Mus musculus 41-50 21123490-6 2011 The inhibitory effect was blocked by the PPARgamma antagonist PD-68235, indicating that the rosiglitazone effect acted through PPARgamma activation. Rosiglitazone 92-105 peroxisome proliferator activated receptor gamma Mus musculus 127-136 21123490-9 2011 These results suggest that the PPARgamma agonist rosiglitazone may inhibit Aldo-induced MC proliferation directly, by affecting ROS/EGFR/PI3K/Akt signaling pathways and cell cycle-regulatory proteins. Rosiglitazone 49-62 peroxisome proliferator activated receptor gamma Mus musculus 31-40 21734368-2 2011 Agonists of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), such as rosiglitazone, have been recently demonstrated to regulate inflammation by modulating the production of inflammatory mediators. Rosiglitazone 87-100 peroxisome proliferator activated receptor gamma Mus musculus 66-76 21734368-9 2011 Rosiglitazone also restored PPAR-gamma expression and protein activity, which were reduced significantly in the LPS only group (p < 0.05). Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 28-38 20709114-2 2011 In this study, we used the Tg2576 AD mouse model to test the hypothesis that cognitive improvement following 1 month of PPAR gamma agonism with rosiglitazone (RTZ) correlates with peripheral gluco-regulatory status. Rosiglitazone 144-157 peroxisome proliferator activated receptor gamma Mus musculus 120-130 21720023-8 2011 Our findings suggest that PPARgamma-activating antidiabetic drugs such as rosiglitazone and pioglitazone induce FGF21 expression in mouse and human hepatocytes, and that PPARgamma rather than PPARalpha might play an important role in human FGF21 production. Rosiglitazone 74-87 peroxisome proliferator activated receptor gamma Mus musculus 26-35 20709114-2 2011 In this study, we used the Tg2576 AD mouse model to test the hypothesis that cognitive improvement following 1 month of PPAR gamma agonism with rosiglitazone (RTZ) correlates with peripheral gluco-regulatory status. Rosiglitazone 159-162 peroxisome proliferator activated receptor gamma Mus musculus 120-130 21637537-6 2011 JMJD2C significantly reduced the rosiglitazone stimulated PPARgamma activation. Rosiglitazone 33-46 peroxisome proliferator activated receptor gamma Mus musculus 58-67 21931813-8 2011 The decrease in RLIP76 protein expression by rosiglitazone and metformin is associated with an up-regulation of PPARgamma and AMPK. Rosiglitazone 45-58 peroxisome proliferator activated receptor gamma Mus musculus 112-121 20955583-4 2010 The aim of this work was to elucidate the action of the insulin sensitizing PPARgamma on T-lymphocyte infiltration during development of IR, and comparison of the PPARgamma-mediated anti-inflammatory effects of rosiglitazone and telmisartan in diet-induced obesity model (DIO-model) in mice. Rosiglitazone 211-224 peroxisome proliferator activated receptor gamma Mus musculus 163-172 22013433-1 2011 Growing evidence indicates that PPARgamma agonists, including rosiglitazone (RSG), induce adipose mitochondrial biogenesis. Rosiglitazone 62-75 peroxisome proliferator activated receptor gamma Mus musculus 32-41 22013433-1 2011 Growing evidence indicates that PPARgamma agonists, including rosiglitazone (RSG), induce adipose mitochondrial biogenesis. Rosiglitazone 77-80 peroxisome proliferator activated receptor gamma Mus musculus 32-41 20552250-5 2010 Moreover, APMAP expression was strongly induced by the PPARgamma ligand rosiglitazone in adipocytes in vitro and in vivo in adipose tissue. Rosiglitazone 72-85 peroxisome proliferator activated receptor gamma Mus musculus 55-64 21159608-4 2010 Activation of PPAR-gamma by synthetic ligands (troglitazone and rosiglitazone) or by a constitutively active form of PPAR-gamma prevents TGF-beta-induced loss of E-cadherin expression and inhibits the induction of mesenchymal markers (vimentin, N-cadherin, fibronectin) and matrix metalloproteases. Rosiglitazone 64-77 peroxisome proliferator activated receptor gamma Mus musculus 14-24 20851881-4 2010 Therefore, we tested the responsiveness of FXR-deficient mice (FXR(-/-)) and cells to the PPARgamma activator rosiglitazone. Rosiglitazone 110-123 peroxisome proliferator activated receptor gamma Mus musculus 90-99 20802255-8 2010 In db/db diabetic mice, the lack of adiponectin aggravated the hyperglycemia-induced decrease in circulating EPCs and also diminished the stimulatory effects of the PPARgamma agonist rosiglitazone on EPC production and reendothelialization. Rosiglitazone 183-196 peroxisome proliferator activated receptor gamma Mus musculus 165-174 20622120-3 2010 We demonstrated that rosiglitazone, a synthetic agonist of the peroxisome proliferator-activated receptor-gamma (PPARgamma), attenuated hypoxia-induced pulmonary hypertension, vascular remodeling, Nox4 induction, and reactive oxygen species generation in the mouse lung. Rosiglitazone 21-34 peroxisome proliferator activated receptor gamma Mus musculus 63-111 20668093-6 2010 The protective effects described above appear to have been exerted, at least partially, via direct activation of PPARgamma in the brain, as TZD was detected in the brains of mice treated with TZD and because a PPARgamma agonist (rosiglitazone) protected striatal cells from mHTT-evoked energy deficiency and toxicity. Rosiglitazone 229-242 peroxisome proliferator activated receptor gamma Mus musculus 113-122 20668093-6 2010 The protective effects described above appear to have been exerted, at least partially, via direct activation of PPARgamma in the brain, as TZD was detected in the brains of mice treated with TZD and because a PPARgamma agonist (rosiglitazone) protected striatal cells from mHTT-evoked energy deficiency and toxicity. Rosiglitazone 229-242 peroxisome proliferator activated receptor gamma Mus musculus 210-219 20622120-3 2010 We demonstrated that rosiglitazone, a synthetic agonist of the peroxisome proliferator-activated receptor-gamma (PPARgamma), attenuated hypoxia-induced pulmonary hypertension, vascular remodeling, Nox4 induction, and reactive oxygen species generation in the mouse lung. Rosiglitazone 21-34 peroxisome proliferator activated receptor gamma Mus musculus 113-122 20207056-9 2010 ABA and Ros synergistically increased PPAR gamma activity and pretreatment with a cAMP-inhibitor or a PKA-inhibitor abrogated ABA-induced PPAR gamma activation. Rosiglitazone 8-11 peroxisome proliferator activated receptor gamma Mus musculus 38-48 20207056-9 2010 ABA and Ros synergistically increased PPAR gamma activity and pretreatment with a cAMP-inhibitor or a PKA-inhibitor abrogated ABA-induced PPAR gamma activation. Rosiglitazone 8-11 peroxisome proliferator activated receptor gamma Mus musculus 138-148 20207056-10 2010 CONCLUSIONS: ABA and Ros act synergistically to modulate PPAR gamma activity and macrophage accumulation in WAT and ABA enhances PPAR gamma activity through a membrane-initiated mechanism dependent on cAMP/PKA signaling. Rosiglitazone 21-24 peroxisome proliferator activated receptor gamma Mus musculus 57-67 20207056-10 2010 CONCLUSIONS: ABA and Ros act synergistically to modulate PPAR gamma activity and macrophage accumulation in WAT and ABA enhances PPAR gamma activity through a membrane-initiated mechanism dependent on cAMP/PKA signaling. Rosiglitazone 21-24 peroxisome proliferator activated receptor gamma Mus musculus 129-139 20531289-4 2010 Hence, we evaluated the efficacy of the PPAR-gamma agonist rosiglitazone (RSG) in ameliorating peritoneal membrane damage in a mouse PD model, and we analyzed the mechanisms underlying the protection offered by RSG. Rosiglitazone 74-77 peroxisome proliferator activated receptor gamma Mus musculus 40-50 20810566-5 2010 To analyze the role of PPARgamma in the later stage of placental development, when its expression peaks, we treated pregnant wild-type mice with the PPARgamma agonist rosiglitazone. Rosiglitazone 167-180 peroxisome proliferator activated receptor gamma Mus musculus 149-158 20374200-5 2010 Treatment of aged mice with antihyperglycemic PPARgamma-ligand class of thiazolidinedione drug, rosiglitazone caused robust thymic expression of classical pro-adipogenic transcripts. Rosiglitazone 96-109 peroxisome proliferator activated receptor gamma Mus musculus 46-55 20498376-4 2010 In wild-type littermate mice, PPARgamma activation (i.e. treatment with rosiglitazone) restored euglycemia and reversed high fat diet-induced insulin resistance and glucose intolerance. Rosiglitazone 72-85 peroxisome proliferator activated receptor gamma Mus musculus 30-39 20661713-6 2010 While aP2 promoter activity was increased by ectopic overexpression of PPARgamma or by rosiglitazone-induced endogenous PPARgamma activation, PPARgamma-induced aP2 promoter activity was inhibited in the presence of 15-MPA. Rosiglitazone 87-100 peroxisome proliferator activated receptor gamma Mus musculus 120-129 20661713-6 2010 While aP2 promoter activity was increased by ectopic overexpression of PPARgamma or by rosiglitazone-induced endogenous PPARgamma activation, PPARgamma-induced aP2 promoter activity was inhibited in the presence of 15-MPA. Rosiglitazone 87-100 peroxisome proliferator activated receptor gamma Mus musculus 120-129 20401461-0 2010 Sex dimorphic actions of rosiglitazone in generalised peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-deficient mice. Rosiglitazone 25-38 peroxisome proliferator activated receptor gamma Mus musculus 54-102 20401461-9 2010 CONCLUSIONS/INTERPRETATION: Stimulating fat growth by rosiglitazone is sufficient to improve insulin sensitivity in female mice with 95% PPAR-gamma deficiency. Rosiglitazone 54-67 peroxisome proliferator activated receptor gamma Mus musculus 137-147 20401461-12 2010 Further, the insulin-sensitising effect of rosiglitazone is dependent on PPAR-gamma in this male lipodystrophic model. Rosiglitazone 43-56 peroxisome proliferator activated receptor gamma Mus musculus 73-83 20516393-11 2010 In conclusion, these results demonstrate that rosiglitazone attenuated ET-1-induced vasoconstriction through the upregulation of endothelial ET(B)R, which is a peroxisome proliferator-activated receptor-gamma direct target. Rosiglitazone 46-59 peroxisome proliferator activated receptor gamma Mus musculus 160-208 20519122-0 2010 PGC1beta mediates PPARgamma activation of osteoclastogenesis and rosiglitazone-induced bone loss. Rosiglitazone 65-78 peroxisome proliferator activated receptor gamma Mus musculus 18-27 20519122-2 2010 PPARgamma suppresses osteoblastogenesis while activating osteoclastogenesis, suggesting that rosiglitazone decreases bone formation while sustaining or increasing bone resorption. Rosiglitazone 93-106 peroxisome proliferator activated receptor gamma Mus musculus 0-9 20519122-3 2010 Using mouse models with genetically altered PPARgamma, PGC1beta, or ERRalpha, here we show that PGC1beta is required for the resorption-enhancing effects of rosiglitazone. Rosiglitazone 157-170 peroxisome proliferator activated receptor gamma Mus musculus 44-53 20498072-4 2010 In BMSCs exposed to the PPAR-gamma (peroxisome proliferator-activated receptor-gamma) agonist rosiglitazone, Noc expression was enhanced 30-fold. Rosiglitazone 94-107 peroxisome proliferator activated receptor gamma Mus musculus 24-34 20498072-4 2010 In BMSCs exposed to the PPAR-gamma (peroxisome proliferator-activated receptor-gamma) agonist rosiglitazone, Noc expression was enhanced 30-fold. Rosiglitazone 94-107 peroxisome proliferator activated receptor gamma Mus musculus 36-84 20498072-11 2010 The inhibitory effect of this NOC-peptide was partially reversed by rosiglitazone, suggesting that effect of NOC on PPAR-gamma nuclear translocation may be independent of ligand-mediated PPAR-gamma activation. Rosiglitazone 68-81 peroxisome proliferator activated receptor gamma Mus musculus 116-126 20376096-5 2010 Our results show that PPARgamma-deficient (PPARgamma(+/-)) mice fed the methionine- and choline-deficient (MCD) diet developed more severe steatohepatitis than wild-type mice, and were unaffected by PPARgamma ligand rosiglitazone. Rosiglitazone 216-229 peroxisome proliferator activated receptor gamma Mus musculus 22-31 20156580-2 2010 We have previously shown that peroxisome proliferator-activated receptors gamma (PPARgamma) ligand, rosiglitazone, prevented the development of the methionine choline deficient (MCD) diet-induced fibrosing steatohepatitis. Rosiglitazone 100-113 peroxisome proliferator activated receptor gamma Mus musculus 81-90 20364085-4 2010 PPARgamma in visceral, but not subcutaneous, WAT from obese mice displayed increased sensitivity to activation by its agonist rosiglitazone. Rosiglitazone 126-139 peroxisome proliferator activated receptor gamma Mus musculus 0-9 20484415-4 2010 Here, we demonstrate that although the PPARgamma ligand, rosiglitazone, stimulates the murine Muc1 promoter in HEC1A, a human uterine epithelial cell line, rosiglitazone alone, has no significant effect on basal human MUC1 promoter activity. Rosiglitazone 57-70 peroxisome proliferator activated receptor gamma Mus musculus 39-48 20484415-4 2010 Here, we demonstrate that although the PPARgamma ligand, rosiglitazone, stimulates the murine Muc1 promoter in HEC1A, a human uterine epithelial cell line, rosiglitazone alone, has no significant effect on basal human MUC1 promoter activity. Rosiglitazone 156-169 peroxisome proliferator activated receptor gamma Mus musculus 39-48 20650758-9 2010 When PPAR gamma was specifically inhibited by GW9662 and PPARgamma-SiRNA, the protective effects of rosiglitazone and pioglitazone were almost undetectable, and the apoptotic rate increased and insulin secretion decreased to the level of the cytokine-treated cells. Rosiglitazone 100-113 peroxisome proliferator activated receptor gamma Mus musculus 5-15 20650758-9 2010 When PPAR gamma was specifically inhibited by GW9662 and PPARgamma-SiRNA, the protective effects of rosiglitazone and pioglitazone were almost undetectable, and the apoptotic rate increased and insulin secretion decreased to the level of the cytokine-treated cells. Rosiglitazone 100-113 peroxisome proliferator activated receptor gamma Mus musculus 57-66 20725514-5 2010 Notably, accumulating evidence has highlighted the therapeutic potential of PPARgamma ligands in the treatment of brain disorders such as Alzheimer"s disease (AD), leading to the testing of the TZDs pioglitazone and rosiglitazone in AD clinical trials. Rosiglitazone 216-229 peroxisome proliferator activated receptor gamma Mus musculus 76-85 20298677-0 2010 Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, decreases immunoreactivity of markers for cell proliferation and neuronal differentiation in the mouse hippocampus. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 29-77 20298677-1 2010 In the present study, we investigated the regulating effects of rosiglitazone (RSG), a synthetic agonist of peroxisome proliferator-activated receptor gamma, treatment for 28days on the cell proliferation and neuronal differentiation in the mouse hippocampal dentate gyrus by 5-bromo-2"-deoxyuridine (BrdU), Ki67 and doublecortin (DCX) immunohistochemistry. Rosiglitazone 64-77 peroxisome proliferator activated receptor gamma Mus musculus 108-156 19951259-1 2010 In the present study, we tested the hypothesis that the PPARgamma (peroxisome-proliferator-activated receptor gamma) activator rosiglitazone improves vascular structure and function in aged hyperhomocysteinaemic MTHFR (methylene tetrahydrofolate reductase) gene heterozygous knockout (mthfr+/-) mice fed a HCD (high-cholesterol diet), a model of high cardiovascular risk. Rosiglitazone 127-140 peroxisome proliferator activated receptor gamma Mus musculus 56-65 19520921-3 2010 Therefore, we hypothesized that activating PPARgamma with rosiglitazone would attenuate chronic hypoxia-induced pulmonary hypertension, in part, through suppressing NADPH oxidase-derived ROS that stimulate proliferative signaling pathways. Rosiglitazone 58-71 peroxisome proliferator activated receptor gamma Mus musculus 43-52 20093039-5 2010 In NIH 3T3 cells, the endogenous MIF mRNA level was up-regulated by rosiglitazone treatment in a dose-dependent manner, which was accompanied by a concurrent increase in peroxisome proliferator-activated receptor (PPAR)gamma2 transcription. Rosiglitazone 68-81 peroxisome proliferator activated receptor gamma Mus musculus 214-225 20093039-6 2010 Over-expression of porcine PPARgamma2 in NIH 3T3 cells could also up-regulate the transcription of MIF in the absence of rosiglitazone treatment. Rosiglitazone 121-134 peroxisome proliferator activated receptor gamma Mus musculus 27-37 20226009-5 2010 We also established that rosiglitazone (a PPARgamma agonist) elevated MKP-1 expression level in NSCLC cells and inhibited tumour metastasis. Rosiglitazone 25-38 peroxisome proliferator activated receptor gamma Mus musculus 42-51 20226009-12 2010 Pharmacologically, rosiglitazone, a peroxisome proliferator activated receptor-gamma (PPARgamma) agonist appeared to induce MKP-1 expression while reduce MMP-2 and CXCR4 expression. Rosiglitazone 19-32 peroxisome proliferator activated receptor gamma Mus musculus 36-84 20226009-12 2010 Pharmacologically, rosiglitazone, a peroxisome proliferator activated receptor-gamma (PPARgamma) agonist appeared to induce MKP-1 expression while reduce MMP-2 and CXCR4 expression. Rosiglitazone 19-32 peroxisome proliferator activated receptor gamma Mus musculus 86-95 20007851-3 2010 The aim of the present study was to test the ability of rosiglitazone, a known PPAR-gamma agonist, to reverse the inhibitory effects of ethanol on adiponectin expression and its hepatic signaling, and to attenuate alcoholic liver steatosis in mice. Rosiglitazone 56-69 peroxisome proliferator activated receptor gamma Mus musculus 79-89 20018933-3 2010 METHODS AND RESULTS: We integrated gene expression data in aorta specimens from mice treated with the PPARgamma ligand rosiglitazone with data from mice containing a globally expressed knockin of the PPARgamma P465L dominant-negative mutation. Rosiglitazone 119-132 peroxisome proliferator activated receptor gamma Mus musculus 102-111 20018933-5 2010 Many classic PPARgamma target genes were induced by rosiglitazone and repressed by dominant-negative PPARgamma. Rosiglitazone 52-65 peroxisome proliferator activated receptor gamma Mus musculus 13-22 19621015-3 2010 Rosiglitazone, a peroxisome proliferator activated receptor-gamma agonist, has been shown to attenuate Abeta-peptide neurotoxic effects, including the inflammatory response of microglia and astrocytes. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 17-65 20160124-5 2010 In vitro exposure to TBT, or the PPARgamma activator rosiglitazone increases adipogenesis, cellular lipid content, and expression of adipogenic genes. Rosiglitazone 53-66 peroxisome proliferator activated receptor gamma Mus musculus 33-42 20160124-6 2010 The adipogenic effects of TBT and rosiglitazone were blocked by the addition of PPARgamma antagonists, suggesting that activation of PPARgamma mediates the effect of both compounds on adipogenesis. Rosiglitazone 34-47 peroxisome proliferator activated receptor gamma Mus musculus 80-89 20160124-6 2010 The adipogenic effects of TBT and rosiglitazone were blocked by the addition of PPARgamma antagonists, suggesting that activation of PPARgamma mediates the effect of both compounds on adipogenesis. Rosiglitazone 34-47 peroxisome proliferator activated receptor gamma Mus musculus 133-142 20154695-5 2010 Treatment of Cftr-deficient mice with the synthetic PPAR-gamma ligand rosiglitazone partially normalizes the altered gene expression pattern associated with Cftr deficiency and reduces disease severity. Rosiglitazone 70-83 peroxisome proliferator activated receptor gamma Mus musculus 52-62 19951259-1 2010 In the present study, we tested the hypothesis that the PPARgamma (peroxisome-proliferator-activated receptor gamma) activator rosiglitazone improves vascular structure and function in aged hyperhomocysteinaemic MTHFR (methylene tetrahydrofolate reductase) gene heterozygous knockout (mthfr+/-) mice fed a HCD (high-cholesterol diet), a model of high cardiovascular risk. Rosiglitazone 127-140 peroxisome proliferator activated receptor gamma Mus musculus 67-115 19657050-4 2009 The purpose of this study was to evaluate pharmacological activation of PPARgamma in a murine model of postoperative ileus by use of the PPARgamma agonist rosiglitazone. Rosiglitazone 155-168 peroxisome proliferator activated receptor gamma Mus musculus 137-146 20445733-2 2010 Cellular infiltration and mediator production were assessed and shown to be therapeutically modulated by the PPARgamma agonist rosiglitazone. Rosiglitazone 127-140 peroxisome proliferator activated receptor gamma Mus musculus 109-118 19745605-4 2009 PPAR-gamma activation with rosiglitazone or pioglitazone induced a profound change of unilocular adipocytes into smaller, multilocular adipocytes in adult WAT in a time-dependent, dose-dependent, and reversible manner. Rosiglitazone 27-40 peroxisome proliferator activated receptor gamma Mus musculus 0-10 19997628-5 2009 In silico, both the PPAR signaling pathway and the transcriptional signature of Ppargamma agonist rosiglitazone overlapped with the longevity subnetwork, while in vivo, lowered expression of Pparg reduced lifespan in both the lipodystrophic Pparg1/2-hypomorphic and the Pparg2-deficient mice. Rosiglitazone 98-111 peroxisome proliferator activated receptor gamma Mus musculus 80-89 19997628-5 2009 In silico, both the PPAR signaling pathway and the transcriptional signature of Ppargamma agonist rosiglitazone overlapped with the longevity subnetwork, while in vivo, lowered expression of Pparg reduced lifespan in both the lipodystrophic Pparg1/2-hypomorphic and the Pparg2-deficient mice. Rosiglitazone 98-111 peroxisome proliferator activated receptor gamma Mus musculus 80-85 19956639-8 2009 In addition, rosiglitazone, a specific PPARgamma agonist, reduced giant cell differentiation, while inducing Gcm1, a key regulator in labyrinth. Rosiglitazone 13-26 peroxisome proliferator activated receptor gamma Mus musculus 39-48 19591806-2 2009 It has been previously established that thiazolidinedione (TZD) PPARgamma ligands such as rosiglitazone have potent anti-diabetic and adipogenic activities. Rosiglitazone 90-103 peroxisome proliferator activated receptor gamma Mus musculus 64-73 19591806-3 2009 A novel non-TZD ligand for PPARgamma, KR62980 has recently been characterized to increase insulin sensitivity and to be weakly adipogenic in 3T3-L1 cells or anti-adipogenic in rosiglitazone-induced adipocyte differentiation. Rosiglitazone 176-189 peroxisome proliferator activated receptor gamma Mus musculus 27-36 19657050-4 2009 The purpose of this study was to evaluate pharmacological activation of PPARgamma in a murine model of postoperative ileus by use of the PPARgamma agonist rosiglitazone. Rosiglitazone 155-168 peroxisome proliferator activated receptor gamma Mus musculus 72-81 19706614-0 2009 Peroxisome proliferator-activated receptor gamma agonist rosiglitazone increases expression of very low density lipoprotein receptor gene in adipocytes. Rosiglitazone 57-70 peroxisome proliferator activated receptor gamma Mus musculus 0-48 19657050-9 2009 In conclusion, these results indicate that rosiglitazone significantly attenuates postoperative ileus in mice by suppression of the muscularis inflammatory cascade through a PPARgamma-dependent down-regulation of Egr-1 and encourage the further clinical evaluation of synthetic PPARgamma agonists as pharmacological tool to prevent this postoperative event. Rosiglitazone 43-56 peroxisome proliferator activated receptor gamma Mus musculus 174-183 19657050-9 2009 In conclusion, these results indicate that rosiglitazone significantly attenuates postoperative ileus in mice by suppression of the muscularis inflammatory cascade through a PPARgamma-dependent down-regulation of Egr-1 and encourage the further clinical evaluation of synthetic PPARgamma agonists as pharmacological tool to prevent this postoperative event. Rosiglitazone 43-56 peroxisome proliferator activated receptor gamma Mus musculus 278-287 19684608-6 2009 RESULTS: A new thiophene-acetylene type of natural product, 7-chloroarctinone-b (CAB), isolated from the roots of Rhaponticum uniflorum, was discovered as a novel PPARgamma antagonist capable of inhibiting rosiglitazone-induced PPARgamma transcriptional activity. Rosiglitazone 206-219 peroxisome proliferator activated receptor gamma Mus musculus 163-172 19684608-7 2009 SPR analysis suggested that CAB bound tightly to PPARgamma and considerably antagonized the potent PPARgamma agonist rosiglitazone-stimulated PPARgamma-LBD/RXRalpha-LBD binding. Rosiglitazone 117-130 peroxisome proliferator activated receptor gamma Mus musculus 49-58 19684608-7 2009 SPR analysis suggested that CAB bound tightly to PPARgamma and considerably antagonized the potent PPARgamma agonist rosiglitazone-stimulated PPARgamma-LBD/RXRalpha-LBD binding. Rosiglitazone 117-130 peroxisome proliferator activated receptor gamma Mus musculus 99-108 19684608-7 2009 SPR analysis suggested that CAB bound tightly to PPARgamma and considerably antagonized the potent PPARgamma agonist rosiglitazone-stimulated PPARgamma-LBD/RXRalpha-LBD binding. Rosiglitazone 117-130 peroxisome proliferator activated receptor gamma Mus musculus 99-108 19684608-8 2009 Gal4/UAS and yeast two-hybrid assays were used to evaluate the antagonistic activity of CAB on rosiglitazone-induced recruitment of the coactivator for PPARgamma. Rosiglitazone 95-108 peroxisome proliferator activated receptor gamma Mus musculus 152-161 19289458-6 2009 Moreover, treatment of mice with the PPARgamma agonist rosiglitazone caused a greater improvement in in vivo insulin sensitivity in FoxO1 haploinsufficient animals, including reductions in circulating proinflammatory cytokines. Rosiglitazone 55-68 peroxisome proliferator activated receptor gamma Mus musculus 37-46 19417127-5 2009 Furthermore, PPARgamma activation by rosiglitazone strongly suppresses cytokine-induced transcript levels of the NF-kappaB-dependent genes intracellular adhesion molecule 1 (ICAM-1) and CXCL1 (KC), the murine homolog of IL-8, in myotubes. Rosiglitazone 37-50 peroxisome proliferator activated receptor gamma Mus musculus 13-22 19484746-4 2009 Newborn mice and mothers were exposed to room air (RA) or moderate hyperoxia (70% oxygen) for 10 days and fed a standard diet or chow impregnated with the PPARgamma agonist rosiglitazone (ROSI) for the duration of study. Rosiglitazone 173-186 peroxisome proliferator activated receptor gamma Mus musculus 155-164 19484746-14 2009 These findings suggest that rosiglitazone maintains downstream PPARgamma effects and may be beneficial in the prevention of severe CLD with AHR. Rosiglitazone 28-41 peroxisome proliferator activated receptor gamma Mus musculus 63-72 19353690-5 2009 Luteolin inhibited the PPARgamma transactivation stimulated by rosiglitazone, a synthetic agonist, in COS-7 cells and inhibited rosiglitazone-induced adipogenic differentiation in 3T3-L1 cells. Rosiglitazone 63-76 peroxisome proliferator activated receptor gamma Mus musculus 23-32 19338578-10 2009 Also in normal primary pancreatic islets of transgenic mice, known to express high levels of PPARgamma, rosiglitazone inhibited glucose-stimulated insulin gene transcription. Rosiglitazone 104-117 peroxisome proliferator activated receptor gamma Mus musculus 93-102 19229877-4 2009 The protective effect of rosiglitazone was abrogated by GW9662, a PPAR-gamma antagonist, or a specific PPAR-gamma small interference RNA (siRNA) but not a control scRNA. Rosiglitazone 25-38 peroxisome proliferator activated receptor gamma Mus musculus 66-76 19229877-4 2009 The protective effect of rosiglitazone was abrogated by GW9662, a PPAR-gamma antagonist, or a specific PPAR-gamma small interference RNA (siRNA) but not a control scRNA. Rosiglitazone 25-38 peroxisome proliferator activated receptor gamma Mus musculus 103-113 19229877-8 2009 Rosiglitazone or PPAR-gamma overexpression restored them via PPAR-gamma. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 61-71 19229877-9 2009 Rosiglitazone or PPAR-gamma overexpression preserved phosphorylated Akt and 3-phosphoinositide-dependent kinase-1 (PDK-1) in a PPAR-gamma dependent manner. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 127-137 19576951-6 2009 A diet containing rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, significantly enhanced the number of EGFP(+) adipocytes. Rosiglitazone 18-31 peroxisome proliferator activated receptor gamma Mus musculus 35-83 19423703-5 2009 Consistent with this, compared with cultures from wild type mice, marrow stromal cultures from SRC-2 KO mice formed significantly more mineralized nodules (by 3-fold) in the presence of the PPARgamma agonist, rosiglitazone. Rosiglitazone 209-222 peroxisome proliferator activated receptor gamma Mus musculus 190-199 19506106-2 2009 Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, has been shown to have a broad spectrum of effects in vivo. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 17-65 19324019-1 2009 The thiazolidinedione rosiglitazone, an agonist ligand for the nuclear receptor PPAR-gamma, improves insulin sensitivity in part by stimulating transcription of the insulin-sensitizing adipokine adiponectin. Rosiglitazone 22-35 peroxisome proliferator activated receptor gamma Mus musculus 80-90 19324019-4 2009 The present study demonstrates that IGFBP-3, the hypoxia-mimetic agent cobalt chloride, and TNF-alpha inhibit rosiglitazone-induced adiponectin transcription in mouse embryo fibroblasts that stably express PPAR-gamma2. Rosiglitazone 110-123 peroxisome proliferator activated receptor gamma Mus musculus 206-217 19221061-4 2009 Cilostazol significantly decreased plasma glucose and triglyceride levels, as did rosiglitazone, a PPARgamma agonist. Rosiglitazone 82-95 peroxisome proliferator activated receptor gamma Mus musculus 99-108 19147827-0 2009 Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 95-143 19193937-2 2009 Rosiglitazone (Rosi), a peroxisome proliferator activator receptor gamma (PPARgamma) agonist, has renal protective and antihypertensive effects. Rosiglitazone 0-4 peroxisome proliferator activated receptor gamma Mus musculus 24-72 19193937-2 2009 Rosiglitazone (Rosi), a peroxisome proliferator activator receptor gamma (PPARgamma) agonist, has renal protective and antihypertensive effects. Rosiglitazone 0-4 peroxisome proliferator activated receptor gamma Mus musculus 74-83 19331671-2 2009 The PPARgamma agonist rosiglitazone has been shown to decrease bone mass in mice and thiazolidinediones (TZDs) have recently been found to increase bone loss and fracture risk in humans treated for type 2 diabetes mellitus. Rosiglitazone 22-35 peroxisome proliferator activated receptor gamma Mus musculus 4-13 19221220-9 2009 Promoter analysis and chromatin immunoprecipitation revealed that rosiglitazone induced PPAR-gamma binding to specific regulatory elements on the 14-3-3epsilon promoter and thereby increased 14-3-3epsilon transcription. Rosiglitazone 66-79 peroxisome proliferator activated receptor gamma Mus musculus 88-98 19193937-2 2009 Rosiglitazone (Rosi), a peroxisome proliferator activator receptor gamma (PPARgamma) agonist, has renal protective and antihypertensive effects. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 24-72 19193937-2 2009 Rosiglitazone (Rosi), a peroxisome proliferator activator receptor gamma (PPARgamma) agonist, has renal protective and antihypertensive effects. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 74-83 19226370-6 2009 However, further investigation revealed that p53 expression was also induced in response to rosiglitazone and chromatin immunoprecipitation assays confirm that it is a bona fide target of PPARgamma. Rosiglitazone 92-105 peroxisome proliferator activated receptor gamma Mus musculus 188-197 19245367-1 2009 Rosiglitazone is a commonly prescribed insulin-sensitizing drug with a selective agonistic activity on the peroxisome proliferator-activated receptor-gamma (PPAR-gamma). Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 107-155 19245367-1 2009 Rosiglitazone is a commonly prescribed insulin-sensitizing drug with a selective agonistic activity on the peroxisome proliferator-activated receptor-gamma (PPAR-gamma). Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 157-167 19147827-7 2009 Rosiglitazone-driven adipogenic differentiation of both fibroblasts and preadipocytes was abrogated in the presence of TGF-beta; this effect was accompanied by the concomitant down-regulation of cellular PPAR-gamma mRNA expression. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 204-214 19147827-8 2009 Collectively, these results indicate that rosiglitazone treatment attenuates inflammation, dermal fibrosis, and subcutaneous lipoatrophy via PPAR-gamma in a mouse model of scleroderma and suggest that pharmacological PPAR-gamma ligands, widely used as insulin sensitizers in the treatment of type-2 diabetes mellitus, may be potential therapies for scleroderma. Rosiglitazone 42-55 peroxisome proliferator activated receptor gamma Mus musculus 141-151 19147827-8 2009 Collectively, these results indicate that rosiglitazone treatment attenuates inflammation, dermal fibrosis, and subcutaneous lipoatrophy via PPAR-gamma in a mouse model of scleroderma and suggest that pharmacological PPAR-gamma ligands, widely used as insulin sensitizers in the treatment of type-2 diabetes mellitus, may be potential therapies for scleroderma. Rosiglitazone 42-55 peroxisome proliferator activated receptor gamma Mus musculus 217-227 18643838-5 2009 The peroxisome proliferator-activated receptor-gamma (PPARgamma) antagonist bisphenol A diglycidyl ether significantly abrogated the induction of mRNA, but not protein levels of ATGL by rosiglitazone in differentiated 3T3-L1 adipocytes. Rosiglitazone 186-199 peroxisome proliferator activated receptor gamma Mus musculus 4-52 18643838-5 2009 The peroxisome proliferator-activated receptor-gamma (PPARgamma) antagonist bisphenol A diglycidyl ether significantly abrogated the induction of mRNA, but not protein levels of ATGL by rosiglitazone in differentiated 3T3-L1 adipocytes. Rosiglitazone 186-199 peroxisome proliferator activated receptor gamma Mus musculus 54-63 18643838-9 2009 CONCLUSIONS: Rosiglitazone directly regulates transcription of ATGL, likely through a PPARgamma-mediated mechanism. Rosiglitazone 13-26 peroxisome proliferator activated receptor gamma Mus musculus 86-95 18772483-5 2009 Treatment with rosiglitazone effectively improved glucose tolerance in mice lacking macrophage PPARgamma, suggesting that cell types other than macrophages are the primary mediators of the anti-diabetic effects of PPARgamma agonists in our model system. Rosiglitazone 15-28 peroxisome proliferator activated receptor gamma Mus musculus 95-104 18772483-5 2009 Treatment with rosiglitazone effectively improved glucose tolerance in mice lacking macrophage PPARgamma, suggesting that cell types other than macrophages are the primary mediators of the anti-diabetic effects of PPARgamma agonists in our model system. Rosiglitazone 15-28 peroxisome proliferator activated receptor gamma Mus musculus 214-223 19152448-6 2009 Rosiglitazone, a specific ligand of PPARgamma, was administered via water drinking in experimental group of nude mice. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 36-45 18790715-7 2008 Taken together, these data suggest that leptin has a direct inhibitory effect on the rosiglitazone-induced adipocyte differentiation and PPARgamma expression, in which ERK1/2 MAP kinase and JAK/STAT1 signaling pathways are involved. Rosiglitazone 85-98 peroxisome proliferator activated receptor gamma Mus musculus 137-146 19109165-0 2009 The peroxisome proliferator-activated receptor gamma agonist rosiglitazone ameliorates murine lupus by induction of adiponectin. Rosiglitazone 61-74 peroxisome proliferator activated receptor gamma Mus musculus 4-52 19109165-4 2009 In this report, we show that the PPARgamma agonist rosiglitazone reduces autoantibody production, renal disease, and atherosclerosis in mouse models of SLE. Rosiglitazone 51-64 peroxisome proliferator activated receptor gamma Mus musculus 33-42 19075043-3 2009 Rosiglitazone (RGZ) induced a similar blood pressure (BP)-lowering effect in deoxycorticosterone acetate (DOCA) salt-treated PPARgamma(f/f) and SM22Cre/flox mice, whereas Tie2Cre/flox mice were completely resistant to this effect. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 125-134 18991162-11 2009 Rosiglitazone may ameliorate hepatic fibrosis by activating PPAR gamma, which can inhibit HSC activation and suppress TGF-beta1 and CTGF expression. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 60-70 18948087-0 2008 PPARgamma agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms. Rosiglitazone 18-31 peroxisome proliferator activated receptor gamma Mus musculus 0-9 18948087-2 2008 Thiazolidinedione rosiglitazone is a potent agonist of PPARgamma which was shown to induce neuroprotection in animal models of focal ischemia and spinal cord injury. Rosiglitazone 18-31 peroxisome proliferator activated receptor gamma Mus musculus 55-64 18948087-5 2008 CCI injury increased the cortical PPARgamma mRNA levels which were further elevated by rosiglitazone treatment. Rosiglitazone 87-100 peroxisome proliferator activated receptor gamma Mus musculus 34-43 18840764-5 2008 Moreover, CRBP-III expression was induced in adipose tissue of mice after treatment with the PPARgamma agonist rosiglitazone. Rosiglitazone 111-124 peroxisome proliferator activated receptor gamma Mus musculus 93-102 18783346-6 2008 Treatment of mice with a PPAR-gamma (peroxisome-proliferator-activated receptor-gamma) agonist, rosiglitazone, increased the expression of CTRP1 and decreased CTRP6 transcript levels. Rosiglitazone 96-109 peroxisome proliferator activated receptor gamma Mus musculus 25-35 18783346-6 2008 Treatment of mice with a PPAR-gamma (peroxisome-proliferator-activated receptor-gamma) agonist, rosiglitazone, increased the expression of CTRP1 and decreased CTRP6 transcript levels. Rosiglitazone 96-109 peroxisome proliferator activated receptor gamma Mus musculus 37-85 19041764-5 2008 Rosiglitazone treatment induced aortic expression of Bmal1 mRNA, and ChIP and promoter assays revealed that Bmal1 is a direct PPARgamma target gene. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 126-135 18728224-1 2008 PPARgamma activators such as rosiglitazone (RSG) stimulate adipocyte differentiation and increase subcutaneous adipose tissue mass. Rosiglitazone 29-42 peroxisome proliferator activated receptor gamma Mus musculus 0-9 18728224-1 2008 PPARgamma activators such as rosiglitazone (RSG) stimulate adipocyte differentiation and increase subcutaneous adipose tissue mass. Rosiglitazone 44-47 peroxisome proliferator activated receptor gamma Mus musculus 0-9 18846339-1 2008 The effect of rosiglitazone as the ligand of peroxisome proliferator-activated receptor gamma (PPARgamma) inhibiting the TLR4 expression in ischemic lobes in partial hepatic ischemia/reperfusion injury (IRI) in BALB/C mice and the action of rosiglitazone inhibiting the TLR4 receptor-mediated inherent immune response were investigated. Rosiglitazone 14-27 peroxisome proliferator activated receptor gamma Mus musculus 45-93 18422969-3 2008 Moreover, pretreatment with the synthetic PPARgamma ligand, rosiglitazone did not prevent LPS-mediated downregulation of PPARgamma. Rosiglitazone 60-73 peroxisome proliferator activated receptor gamma Mus musculus 42-51 18927287-5 2008 Recently, using cell-based experiments, we showed that platinum-based drugs and the antidiabetic drug rosiglitazone (PPARgamma ligand) interact synergistically to reduce cancer cell and tumor growth. Rosiglitazone 102-115 peroxisome proliferator activated receptor gamma Mus musculus 117-126 18846339-1 2008 The effect of rosiglitazone as the ligand of peroxisome proliferator-activated receptor gamma (PPARgamma) inhibiting the TLR4 expression in ischemic lobes in partial hepatic ischemia/reperfusion injury (IRI) in BALB/C mice and the action of rosiglitazone inhibiting the TLR4 receptor-mediated inherent immune response were investigated. Rosiglitazone 14-27 peroxisome proliferator activated receptor gamma Mus musculus 95-104 18846339-1 2008 The effect of rosiglitazone as the ligand of peroxisome proliferator-activated receptor gamma (PPARgamma) inhibiting the TLR4 expression in ischemic lobes in partial hepatic ischemia/reperfusion injury (IRI) in BALB/C mice and the action of rosiglitazone inhibiting the TLR4 receptor-mediated inherent immune response were investigated. Rosiglitazone 241-254 peroxisome proliferator activated receptor gamma Mus musculus 45-93 18846339-1 2008 The effect of rosiglitazone as the ligand of peroxisome proliferator-activated receptor gamma (PPARgamma) inhibiting the TLR4 expression in ischemic lobes in partial hepatic ischemia/reperfusion injury (IRI) in BALB/C mice and the action of rosiglitazone inhibiting the TLR4 receptor-mediated inherent immune response were investigated. Rosiglitazone 241-254 peroxisome proliferator activated receptor gamma Mus musculus 95-104 18492776-5 2008 We continuously treated primary cultures of mouse brown (pre)adipocytes with the potent peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist rosiglitazone. Rosiglitazone 157-170 peroxisome proliferator activated receptor gamma Mus musculus 88-136 18755353-2 2008 BACKGROUND: The thiazolidinediones (TZDs) pioglitazone and rosiglitazone are insulin-sensitizing PPARgamma agonists used to treat type 2 diabetes (T2DM). Rosiglitazone 59-72 peroxisome proliferator activated receptor gamma Mus musculus 97-106 18506083-0 2008 Impact of increased PPARgamma activity in adipocytes in vivo on adiposity, insulin sensitivity and the effects of rosiglitazone treatment. Rosiglitazone 114-127 peroxisome proliferator activated receptor gamma Mus musculus 20-29 18492776-5 2008 We continuously treated primary cultures of mouse brown (pre)adipocytes with the potent peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist rosiglitazone. Rosiglitazone 157-170 peroxisome proliferator activated receptor gamma Mus musculus 138-147 18754069-1 2008 In this study we hypothesized that rosiglitazone, an antidiabetic high-affinity agonist for the peroxisome proliferator-activated receptor gamma, affects the plasma membrane (PM) turnover in single 3T3-L1 adipocytes. Rosiglitazone 35-48 peroxisome proliferator activated receptor gamma Mus musculus 96-144 18652780-2 2008 This study investigated the effect of the PPAR-gamma agonist, rosiglitazone, on nasal mucous allergic inflammation and galectin-3 gene expression in a murine model of allergic rhinitis (AR mice). Rosiglitazone 62-75 peroxisome proliferator activated receptor gamma Mus musculus 42-52 18652780-6 2008 These data suggest that the PPAR-gamma agonist, rosiglitazone, may have potential in the development of therapies for allergic rhinitis. Rosiglitazone 48-61 peroxisome proliferator activated receptor gamma Mus musculus 28-38 18509062-7 2008 Treatment of lean or obese mice with the PPARgamma agonist rosiglitazone markedly up-regulates Cidea expression in white adipose tissue (WAT), increasing lipid deposition. Rosiglitazone 59-72 peroxisome proliferator activated receptor gamma Mus musculus 41-50 18585574-1 2008 OBJECTIVES: To investigate the effect of rosiglitazone, a synthetic selective peroxisome proliferator-activated receptor (PPAR)-gamma agonist, for cytokine production and PPAR-gamma expression in nasal mucosa. Rosiglitazone 41-54 peroxisome proliferator activated receptor gamma Mus musculus 171-181 18585574-7 2008 Immunohistochemistry showed that PPAR-gamma protein expression in nasal mucosa was enhanced in the allergic rhinitis group and the rosiglitazone group compared with control mice. Rosiglitazone 131-144 peroxisome proliferator activated receptor gamma Mus musculus 33-43 18585574-8 2008 CONCLUSION: PPAR-gamma activation with rosiglitazone effectively inhibited allergic symptom development, nasal mucosal inflammation, and production of ovoalbumin-specific immunoglobulin E and Th2-type cytokine. Rosiglitazone 39-52 peroxisome proliferator activated receptor gamma Mus musculus 12-22 18473419-9 2008 To further explore the mechanism of rosiglitazone action, we found that rosiglitazone can significantly increase the expression of PPAR gamma [E: -18.212 +/- (-3.909) vs B: -27.315 +/- (-6.348) and C: -25.647 +/- (-5.694), P < 0.05], reduce the NF-kappaB binding activity (E: 88.89 +/- 19.34 vs B: 141.11 +/- 15.37, C: 112.89 +/- 20.17 and D: 108.89 +/- 20.47, P < 0.05), and lower the serum level of TNF-alpha (E: 1.613 +/- 0.420 ng/mL vs B: 2.892 +/- 0.587 ng/mL, C: 2.346 +/- 0.371 ng/mL and D: 2.160 +/- 0.395 ng/mL, P < 0.05) and IL-6 (E: 0.106 +/- 0.021 ng/mL vs B: 0.140 +/- 0.031 ng/mL and C: 0.137 +/- 0.027 ng/mL, P < 0.05) in mice with liver fibrosis. Rosiglitazone 36-49 peroxisome proliferator activated receptor gamma Mus musculus 131-141 18473419-9 2008 To further explore the mechanism of rosiglitazone action, we found that rosiglitazone can significantly increase the expression of PPAR gamma [E: -18.212 +/- (-3.909) vs B: -27.315 +/- (-6.348) and C: -25.647 +/- (-5.694), P < 0.05], reduce the NF-kappaB binding activity (E: 88.89 +/- 19.34 vs B: 141.11 +/- 15.37, C: 112.89 +/- 20.17 and D: 108.89 +/- 20.47, P < 0.05), and lower the serum level of TNF-alpha (E: 1.613 +/- 0.420 ng/mL vs B: 2.892 +/- 0.587 ng/mL, C: 2.346 +/- 0.371 ng/mL and D: 2.160 +/- 0.395 ng/mL, P < 0.05) and IL-6 (E: 0.106 +/- 0.021 ng/mL vs B: 0.140 +/- 0.031 ng/mL and C: 0.137 +/- 0.027 ng/mL, P < 0.05) in mice with liver fibrosis. Rosiglitazone 72-85 peroxisome proliferator activated receptor gamma Mus musculus 131-141 18473419-11 2008 CONCLUSION: The activation of PPAR gamma by its ligand can retard liver fibrosis and suggest the use of rosiglitazone for the treatment of liver fibrosis due to Schistosoma japonicum infection. Rosiglitazone 104-117 peroxisome proliferator activated receptor gamma Mus musculus 30-40 18276752-0 2008 Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reverses the adverse effects of diet-induced obesity on oocyte quality. Rosiglitazone 57-70 peroxisome proliferator activated receptor gamma Mus musculus 0-48 18276752-10 2008 Improved blastocyst quality in obese females treated with rosiglitazone before mating indicates that peroxisome proliferator activated receptor-gamma is a key target for metabolic regulation of ovarian function and oocyte quality. Rosiglitazone 58-71 peroxisome proliferator activated receptor gamma Mus musculus 101-149 17951467-5 2007 One-half of the mice within each zinc group was gavaged daily with the PPARgamma agonist RSG starting 2 d prior to the HF feeding. Rosiglitazone 89-92 peroxisome proliferator activated receptor gamma Mus musculus 71-80 18334011-0 2008 Primary chemoprevention of endometrial hyperplasia with the peroxisome proliferator-activated receptor gamma agonist rosiglitazone in the PTEN heterozygote murine model. Rosiglitazone 117-130 peroxisome proliferator activated receptor gamma Mus musculus 60-108 18334011-3 2008 The purpose of this study was to evaluate the effects of the PPAR-gamma agonist rosiglitazone on both PTEN wild type and PTEN null cell lines and in the PTEN heterozygote((+/-)) murine model. Rosiglitazone 80-93 peroxisome proliferator activated receptor gamma Mus musculus 61-71 18334011-10 2008 PPAR-gamma agonist rosiglitazone inhibits proliferation and induces apoptosis in both PTEN intact and PTEN null cancer cell lines and in hyperplastic endometrial lesions in the PTEN(+/)(-)murine model. Rosiglitazone 19-32 peroxisome proliferator activated receptor gamma Mus musculus 0-10 17848638-6 2007 Rosiglitazone-mediated induction of ATGL mRNA and protein is inhibited by the PPARgamma-specific antagonist GW-9662 and is also significantly reduced following siRNA-mediated knockdown of PPARgamma, supporting the direct transcriptional regulation of ATGL by PPARgamma. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 78-87 17848638-6 2007 Rosiglitazone-mediated induction of ATGL mRNA and protein is inhibited by the PPARgamma-specific antagonist GW-9662 and is also significantly reduced following siRNA-mediated knockdown of PPARgamma, supporting the direct transcriptional regulation of ATGL by PPARgamma. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 188-197 17848638-6 2007 Rosiglitazone-mediated induction of ATGL mRNA and protein is inhibited by the PPARgamma-specific antagonist GW-9662 and is also significantly reduced following siRNA-mediated knockdown of PPARgamma, supporting the direct transcriptional regulation of ATGL by PPARgamma. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 188-197 17909895-0 2007 The peroxisome proliferator activated receptor gamma (PPARgamma) ligand rosiglitazone modulates bronchoalveolar lavage levels of leptin, adiponectin, and inflammatory cytokines in lean and obese mice. Rosiglitazone 72-85 peroxisome proliferator activated receptor gamma Mus musculus 4-52 17909895-0 2007 The peroxisome proliferator activated receptor gamma (PPARgamma) ligand rosiglitazone modulates bronchoalveolar lavage levels of leptin, adiponectin, and inflammatory cytokines in lean and obese mice. Rosiglitazone 72-85 peroxisome proliferator activated receptor gamma Mus musculus 54-63 18059282-8 2007 Moreover, ligand activation of PPAR-gamma by rosiglitazone exacerbates osteoclast differentiation in a receptor-dependent manner. Rosiglitazone 45-58 peroxisome proliferator activated receptor gamma Mus musculus 31-41 18261208-3 2008 Rosiglitazone (RGZ), a synthetic ligand of PPARgamma used in the treatment of Type 2 diabetes, inhibits growth of some tumor cells and is involved in other processes related to cancer progression. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 43-52 18039959-0 2008 Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, prevents microparticle-induced vascular hyporeactivity through the regulation of proinflammatory proteins. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 17-65 18039959-3 2008 This study dissected the effect of either in vitro treatment or short-term oral administration of the peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist, rosiglitazone, on microparticle-induced vascular hyporeactivity of mouse vessels. Rosiglitazone 172-185 peroxisome proliferator activated receptor gamma Mus musculus 102-150 18039959-3 2008 This study dissected the effect of either in vitro treatment or short-term oral administration of the peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist, rosiglitazone, on microparticle-induced vascular hyporeactivity of mouse vessels. Rosiglitazone 172-185 peroxisome proliferator activated receptor gamma Mus musculus 152-161 18039959-10 2008 These results suggest that rosiglitazone, via PPARgamma activation, counteracts vascular dysfunction associated with increased release of proinflammatory proteins elicited by microparticles. Rosiglitazone 27-40 peroxisome proliferator activated receptor gamma Mus musculus 46-55 17951467-12 2007 In vitro studies confirmed that adequate zinc is required for RSG-induced PPARgamma activity to transactivate target genes. Rosiglitazone 62-65 peroxisome proliferator activated receptor gamma Mus musculus 74-83 18269830-1 2007 OBJECTIVE: To explore if PPARgamma agonist rosiglitazone could enhance the anti-atherosclerotic effects of mouse peroxisome proliferator-activated receptor gamma1 (PPARgamma1) gene transfer in apolipoprotein-knock out mice. Rosiglitazone 43-56 peroxisome proliferator activated receptor gamma Mus musculus 25-34 18269830-13 2007 CONCLUSION: Anti-atherosclerotic effects of PPARgamma1 gene transfer in ApoE-knock out mice could be enhanced by PPARgamma agonist rosiglitazone. Rosiglitazone 131-144 peroxisome proliferator activated receptor gamma Mus musculus 44-53 17332064-4 2007 Aging was identified as a confounding factor for rosiglitazone-induced bone loss that correlated with the increased expression of PPARgamma in bone marrow mesenchymal stem cells. Rosiglitazone 49-62 peroxisome proliferator activated receptor gamma Mus musculus 130-139 17563062-8 2007 Rosiglitazone, a PPARgamma agonist, reversed these changes. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 17-26 17463185-0 2007 PPAR-gamma knockout in pancreatic epithelial cells abolishes the inhibitory effect of rosiglitazone on caerulein-induced acute pancreatitis. Rosiglitazone 86-99 peroxisome proliferator activated receptor gamma Mus musculus 0-10 17463185-7 2007 However, rosiglitazone retains its effect in the lungs of the pancreatic-specific PPAR-gamma knockout animals, likely due to direct anti-inflammatory effect on lung parenchyma. Rosiglitazone 9-22 peroxisome proliferator activated receptor gamma Mus musculus 82-92 19936080-5 2007 The data demonstrate that PNU-91325 is indeed much less effective than rosiglitazone at activating PPAR gamma both in vitro and in vivo. Rosiglitazone 71-84 peroxisome proliferator activated receptor gamma Mus musculus 99-109 17463056-4 2007 We found that exposure of pregnant mice to the PPARgamma agonist rosiglitazone for 8 d (embryonic d 10.5-18.5) reduced the weights of wt, but not PPARgamma(+/-) placentas and embryos. Rosiglitazone 65-78 peroxisome proliferator activated receptor gamma Mus musculus 47-56 17463056-4 2007 We found that exposure of pregnant mice to the PPARgamma agonist rosiglitazone for 8 d (embryonic d 10.5-18.5) reduced the weights of wt, but not PPARgamma(+/-) placentas and embryos. Rosiglitazone 65-78 peroxisome proliferator activated receptor gamma Mus musculus 146-155 17654601-2 2007 Rosiglitazone, a selective ligand of peroxisome proliferator-activated receptor gamma (PPARgamma), is an insulin sensitizer drug that has been used in a number of insulin-resistant conditions, including NAFLD. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 37-85 17654601-2 2007 Rosiglitazone, a selective ligand of peroxisome proliferator-activated receptor gamma (PPARgamma), is an insulin sensitizer drug that has been used in a number of insulin-resistant conditions, including NAFLD. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 87-96 17337625-3 2007 Here we show by using two synthetic PPARgamma agonists (rosiglitazone and KR-62776, a novel PPARgamma agonist) that phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a key downstream mediator of PPARgamma signaling. Rosiglitazone 56-69 peroxisome proliferator activated receptor gamma Mus musculus 36-45 17337254-0 2007 The PPARgamma ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice. Rosiglitazone 22-35 peroxisome proliferator activated receptor gamma Mus musculus 4-13 17337254-12 2007 These data demonstrate that the vascular expression of Nox-1, 2, and 4 subunits of NADPH oxidase is increased in db(-)/db(-) mice and that short-term treatment with the PPARgamma agonist, rosiglitazone, has the potential to rapidly suppress vascular NADPH oxidase expression and O(2)(-.) Rosiglitazone 188-201 peroxisome proliferator activated receptor gamma Mus musculus 169-178 17320860-6 2007 K-111 reduced both the IL-6 production and mRNA expression in RAW264.7 cells, and its effect was stronger than that of rosiglitazone, a PPARgamma agonist. Rosiglitazone 119-132 peroxisome proliferator activated receptor gamma Mus musculus 136-145 17510806-0 2007 The PPARgamma agonist rosiglitazone impairs colonic inflammation in mice with experimental colitis. Rosiglitazone 22-35 peroxisome proliferator activated receptor gamma Mus musculus 4-13 17457822-4 2007 RESULTS: Our study demonstrated that the PPARgamma agonist, rosiglitazone, promoted hematoma resolution, decreased neuronal damage, and improved functional recovery in a mouse ICH model. Rosiglitazone 60-73 peroxisome proliferator activated receptor gamma Mus musculus 41-50 17339547-3 2007 We therefore hypothesized that insulin-resistant apoE-deficient (apoE-/-) mice would develop PAH that could be reversed by a peroxisome proliferator-activated receptor-gamma agonist (eg, rosiglitazone). Rosiglitazone 187-200 peroxisome proliferator activated receptor gamma Mus musculus 125-173 17322896-6 2007 We found that rosiglitazone, an activator of the peroxisome proliferator-activated receptor-gamma, which upregulates Abca1 in beta-cells, requires beta-cell Abca1 for its beneficial effects on glucose tolerance. Rosiglitazone 14-27 peroxisome proliferator activated receptor gamma Mus musculus 49-97 17095756-3 2007 However, the highly selective PPAR-gamma ligand rosiglitazone decreased the severity of DSS-induced colitis and suppressed cytokine production in both PPAR-gamma intestinal specific null mice and wild-type littermates. Rosiglitazone 48-61 peroxisome proliferator activated receptor gamma Mus musculus 30-40 17095756-3 2007 However, the highly selective PPAR-gamma ligand rosiglitazone decreased the severity of DSS-induced colitis and suppressed cytokine production in both PPAR-gamma intestinal specific null mice and wild-type littermates. Rosiglitazone 48-61 peroxisome proliferator activated receptor gamma Mus musculus 151-161 16314832-6 2006 Treatment of TRbetaPV/PV mice with a PPARgamma agonist, rosiglitazone, delayed the progression of thyroid carcinogenesis by decreasing cell proliferation and activation of apoptosis. Rosiglitazone 56-69 peroxisome proliferator activated receptor gamma Mus musculus 37-46 17260474-21 2006 CONCLUSION: Heterogeneous rosiglitazone may upregulate the expression of PPARgamma in renal cortex, and remarkably inhibit the expressions of CTGF in the tubulointerstitium and renal cortex in diabetic KKA(y) mice. Rosiglitazone 26-39 peroxisome proliferator activated receptor gamma Mus musculus 73-82 16547072-8 2006 The PPARgamma ligand rosiglitazone decreased the severity of DSS induced colitis and suppressed cytokine production in both PPARgamma(F/F) and PPARgamma(DeltaIEpC) mice. Rosiglitazone 21-34 peroxisome proliferator activated receptor gamma Mus musculus 4-13 16728429-2 2006 Agonists of the peroxisome proliferator-activated receptor-gamma (PPARgamma), such as rosiglitazone, have been recently demonstrated to regulate inflammation by modulating the production of inflammatory mediators and adhesion molecules. Rosiglitazone 86-99 peroxisome proliferator activated receptor gamma Mus musculus 16-64 16728429-2 2006 Agonists of the peroxisome proliferator-activated receptor-gamma (PPARgamma), such as rosiglitazone, have been recently demonstrated to regulate inflammation by modulating the production of inflammatory mediators and adhesion molecules. Rosiglitazone 86-99 peroxisome proliferator activated receptor gamma Mus musculus 66-75 16728429-11 2006 Rosiglitazone had a protective effect via a PPARgamma-dependent pathway in cisplatin-treated HK-2 cells. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 44-53 16597709-7 2006 We show that andrographolide, a bicyclic diterpenoid lactone, and rosiglitazone, a peroxisome proliferator-activated receptor gamma agonist, were able to interfere with NF-kappaB activation in murine DCs. Rosiglitazone 66-79 peroxisome proliferator activated receptor gamma Mus musculus 83-131 16900441-3 2007 METHODS: Wild type (WT) and endothelial NO synthase (eNOS) knockout (KO) mice received 3 mg/kg of the PPARgamma agonist rosiglitazone or vehicle (n = 6-9 in each group) i. p. 45 min before anesthesia. Rosiglitazone 120-133 peroxisome proliferator activated receptor gamma Mus musculus 102-111 16900441-9 2007 CONCLUSION: These results suggest that the cardioprotective effect of the PPARgamma agonist rosiglitazone is mediated via NO by phosphorylation of eNOS. Rosiglitazone 92-105 peroxisome proliferator activated receptor gamma Mus musculus 74-83 16547072-8 2006 The PPARgamma ligand rosiglitazone decreased the severity of DSS induced colitis and suppressed cytokine production in both PPARgamma(F/F) and PPARgamma(DeltaIEpC) mice. Rosiglitazone 21-34 peroxisome proliferator activated receptor gamma Mus musculus 124-133 16547072-8 2006 The PPARgamma ligand rosiglitazone decreased the severity of DSS induced colitis and suppressed cytokine production in both PPARgamma(F/F) and PPARgamma(DeltaIEpC) mice. Rosiglitazone 21-34 peroxisome proliferator activated receptor gamma Mus musculus 124-133 16547072-9 2006 CONCLUSIONS: These studies reveal that PPARgamma expressed in the colonic epithelium has an endogenous role in protection against DSS induced colitis and that rosiglitazone may act through a PPARgamma independent pathway to suppress inflammation. Rosiglitazone 159-172 peroxisome proliferator activated receptor gamma Mus musculus 39-48 16547072-9 2006 CONCLUSIONS: These studies reveal that PPARgamma expressed in the colonic epithelium has an endogenous role in protection against DSS induced colitis and that rosiglitazone may act through a PPARgamma independent pathway to suppress inflammation. Rosiglitazone 159-172 peroxisome proliferator activated receptor gamma Mus musculus 191-200 16609881-0 2006 Regulation of adiponectin receptors in hepatocytes by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Rosiglitazone 115-128 peroxisome proliferator activated receptor gamma Mus musculus 58-106 16609881-2 2006 Rosiglitazone is a peroxisome proliferator-activated receptor-gamma (PPARG) agonist that is widely used in the treatment of type 2 diabetes. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 19-67 16609881-2 2006 Rosiglitazone is a peroxisome proliferator-activated receptor-gamma (PPARG) agonist that is widely used in the treatment of type 2 diabetes. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 69-74 16609881-12 2006 Our data also suggest that the PPARG agonist rosiglitazone can interact functionally with a GR element in the ADIPOR2 promoter to mediate stimulation of transcription. Rosiglitazone 45-58 peroxisome proliferator activated receptor gamma Mus musculus 31-36 16672634-0 2006 Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPARgamma agonist"s effects on edema and weight gain. Rosiglitazone 27-40 peroxisome proliferator activated receptor gamma Mus musculus 119-128 16524877-5 2006 Physiological concentrations of PPARgamma agonists, rosiglitazone and pioglitazone, stimulated NSC growth, whereas antagonists caused cell death in a concentration-dependent manner via activation of the caspase cascade. Rosiglitazone 52-65 peroxisome proliferator activated receptor gamma Mus musculus 32-41 16539667-0 2006 Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Rosiglitazone 116-129 peroxisome proliferator activated receptor gamma Mus musculus 59-107 16539667-3 2006 In the present study, we investigated whether the PPAR-gamma agonist rosiglitazone is neuroprotective against focal ischemic brain injury. Rosiglitazone 69-82 peroxisome proliferator activated receptor gamma Mus musculus 50-60 16539667-11 2006 These results suggest that the PPAR-gamma agonist rosiglitazone has neuroprotective properties that are at least partially mediated via anti-inflammatory actions, and is thus a potential novel therapeutic agent for stroke. Rosiglitazone 50-63 peroxisome proliferator activated receptor gamma Mus musculus 31-41 16364246-5 2006 The PPARgamma agonist, rosiglitazone, increased PPARgamma2 expression, but not PPARgamma1, only in the presence of insulin. Rosiglitazone 23-36 peroxisome proliferator activated receptor gamma Mus musculus 4-13 16364246-5 2006 The PPARgamma agonist, rosiglitazone, increased PPARgamma2 expression, but not PPARgamma1, only in the presence of insulin. Rosiglitazone 23-36 peroxisome proliferator activated receptor gamma Mus musculus 48-58 16391825-12 2006 Both 15-d-PGJ2 and RO significantly inhibited the NO production in T24 and MB49 cells by PPARgamma-independent pathway since it was not antagonized by BADGE. Rosiglitazone 19-21 peroxisome proliferator activated receptor gamma Mus musculus 89-98 16286236-0 2006 The PPARgamma ligand, rosiglitazone, reduces airways hyperresponsiveness in a murine model of allergen-induced inflammation. Rosiglitazone 22-35 peroxisome proliferator activated receptor gamma Mus musculus 4-13 16137931-3 2006 In mice, PPAR-gamma insufficiency results in increased bone mass, whereas administration of the specific PPAR-gamma agonist rosiglitazone leads to bone loss and increased bone marrow adiposity. Rosiglitazone 124-137 peroxisome proliferator activated receptor gamma Mus musculus 105-115 16286236-2 2006 This study examines the effects of a potent synthetic PPARgamma ligand, rosiglitazone (RG), in a murine model of allergen-induced inflammation, to explore its potential regulation of airways inflammation, structure and function. Rosiglitazone 72-85 peroxisome proliferator activated receptor gamma Mus musculus 54-63 16306350-2 2005 PPARalpha activation by its agonist, Wy-14,643, as well as PPARgamma activation by its agonist, rosiglitazone, markedly improved insulin sensitivity. Rosiglitazone 96-109 peroxisome proliferator activated receptor gamma Mus musculus 59-68 16051889-8 2005 Rosiglitazone increased cardiac phosphorylation of p38 mitogen-activated protein kinase independent of PPAR-gamma, whereas rosiglitazone induced phosphorylation of extracellular signal-related kinase 1/2 in the heart dependent of PPAR-gamma. Rosiglitazone 123-136 peroxisome proliferator activated receptor gamma Mus musculus 230-240 17491689-2 2005 Rosiglitazone is an insulin-sensitizing drug that is a ligand for the nuclear receptor peroxisome proliferator-activated receptor-gamma (PPAR-gamma). Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 137-147 16020748-10 2005 CONCLUSIONS: These findings suggest peroxisome proliferator-activated receptor-gamma ligands such as rosiglitazone confer vascular protection independent of their effects on metabolic control. Rosiglitazone 101-114 peroxisome proliferator activated receptor gamma Mus musculus 36-84 15864802-4 2005 In this study, we assessed the effect of two PPARgamma ligands (rosiglitazone and troglitazone) on UV and DMBA/12-O-tetradecanoylphorbol-13-acetate (TPA)-induced mouse skin carcinogenesis, two of the most commonly used mouse skin carcinogenesis models. Rosiglitazone 64-77 peroxisome proliferator activated receptor gamma Mus musculus 45-54 15831367-9 2005 Interestingly, rosiglitazone improved serum insulin levels, but not HF diet-induced hypertension, in PPARgamma E-null mice. Rosiglitazone 15-28 peroxisome proliferator activated receptor gamma Mus musculus 101-110 15956187-4 2005 We found that mice with CD knockout of this receptor were resistant to the rosiglitazone- (RGZ) induced increases in body weight and plasma volume expansion found in control mice expressing PPARgamma in the CD. Rosiglitazone 75-88 peroxisome proliferator activated receptor gamma Mus musculus 190-199 15764598-2 2005 Thiazolidinediones, such as pioglitazone and rosiglitazone, are other hypoglycemic agents that effectively improve peripheral insulin resistance through activation of peroxisome proliferator-activated receptor gamma (PPARgamma). Rosiglitazone 45-58 peroxisome proliferator activated receptor gamma Mus musculus 167-215 15764598-2 2005 Thiazolidinediones, such as pioglitazone and rosiglitazone, are other hypoglycemic agents that effectively improve peripheral insulin resistance through activation of peroxisome proliferator-activated receptor gamma (PPARgamma). Rosiglitazone 45-58 peroxisome proliferator activated receptor gamma Mus musculus 217-226 15764598-5 2005 In addition, glimepride directly bound to PPARgamma in a manner competitive to rosiglitazone, which is a proven ligand for PPARgamma. Rosiglitazone 79-92 peroxisome proliferator activated receptor gamma Mus musculus 42-51 15764598-5 2005 In addition, glimepride directly bound to PPARgamma in a manner competitive to rosiglitazone, which is a proven ligand for PPARgamma. Rosiglitazone 79-92 peroxisome proliferator activated receptor gamma Mus musculus 123-132 15797891-0 2005 Agonist of peroxisome proliferator-activated receptor-gamma, rosiglitazone, reduces renal injury and dysfunction in a murine sepsis model. Rosiglitazone 61-74 peroxisome proliferator activated receptor gamma Mus musculus 11-59 15684043-3 2005 In this study, by using a murine model of inflammation, the carrageenin-induced paw edema in mouse, we show that the anti-inflammatory activity exhibited by the PPAR-gamma agonists rosiglitazone and ciglitazone is reversed by the GR antagonist RU486 (17 beta-hydroxy-11 beta-[4-dimethylamino phenyl]-17 alpha-[1-propynyl]estra-4,9-dien-3-one). Rosiglitazone 181-194 peroxisome proliferator activated receptor gamma Mus musculus 161-171 15831367-10 2005 CONCLUSIONS: These results suggest that PPARgamma in ECs not only is an important regulator of hypertension and HR under stressed conditions mimicking those arising in type 2 diabetics, but also mediates the antihypertensive effects of rosiglitazone. Rosiglitazone 236-249 peroxisome proliferator activated receptor gamma Mus musculus 40-49 15809511-7 2005 For example, dexamethasone (DEX) potently stimulates production of resistin in murine adipose tissue, whereas thiazolidinediones such as rosiglitazone (ROSI), acting via peroxisome proliferator-activated receptor (PPAR)gamma, reportedly inhibit or stimulate resistin expression. Rosiglitazone 137-150 peroxisome proliferator activated receptor gamma Mus musculus 214-224 15684285-1 2005 Thiazolidinedione rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2), are two peroxisome proliferator-activated receptor (PPAR)-gamma ligands. Rosiglitazone 18-31 peroxisome proliferator activated receptor gamma Mus musculus 93-148 15684285-5 2005 Administration of the two PPAR-gamma agonists rosiglitazone (10 mg x kg(-1) i.p.) Rosiglitazone 46-59 peroxisome proliferator activated receptor gamma Mus musculus 26-36 15684285-10 2005 30 min before the rosiglitazone or 15d-PGJ2) significantly antagonised the effect of the two PPAR-gamma agonists. Rosiglitazone 18-31 peroxisome proliferator activated receptor gamma Mus musculus 93-103 15684285-11 2005 These results demonstrate that the two peroxisome proliferator-activated receptor-gamma agonists, rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, significantly reduce lung injury induced by bleomycin in mice. Rosiglitazone 98-111 peroxisome proliferator activated receptor gamma Mus musculus 39-87 15735429-0 2005 The peroxisome proliferator-activated receptor gamma ligand rosiglitazone delays the onset of inflammatory bowel disease in mice with interleukin 10 deficiency. Rosiglitazone 60-73 peroxisome proliferator activated receptor gamma Mus musculus 4-52 15735429-1 2005 AIMS: To test whether the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand rosiglitazone (Ro) has therapeutic activity in the IL-10(-/-) mouse model of inflammatory bowel disease (IBD), and to identify the cellular targets and molecular mechanisms of Ro action. Rosiglitazone 94-107 peroxisome proliferator activated receptor gamma Mus musculus 26-74 15735429-1 2005 AIMS: To test whether the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand rosiglitazone (Ro) has therapeutic activity in the IL-10(-/-) mouse model of inflammatory bowel disease (IBD), and to identify the cellular targets and molecular mechanisms of Ro action. Rosiglitazone 94-107 peroxisome proliferator activated receptor gamma Mus musculus 76-85 15735429-1 2005 AIMS: To test whether the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand rosiglitazone (Ro) has therapeutic activity in the IL-10(-/-) mouse model of inflammatory bowel disease (IBD), and to identify the cellular targets and molecular mechanisms of Ro action. Rosiglitazone 109-111 peroxisome proliferator activated receptor gamma Mus musculus 26-74 15735429-1 2005 AIMS: To test whether the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand rosiglitazone (Ro) has therapeutic activity in the IL-10(-/-) mouse model of inflammatory bowel disease (IBD), and to identify the cellular targets and molecular mechanisms of Ro action. Rosiglitazone 109-111 peroxisome proliferator activated receptor gamma Mus musculus 76-85 15735429-8 2005 Ro increased expression of PPARgamma protein in these cells, suggesting the existence of a positive feedback loop that would potentiate its action in these cells. Rosiglitazone 0-2 peroxisome proliferator activated receptor gamma Mus musculus 27-36 15809511-7 2005 For example, dexamethasone (DEX) potently stimulates production of resistin in murine adipose tissue, whereas thiazolidinediones such as rosiglitazone (ROSI), acting via peroxisome proliferator-activated receptor (PPAR)gamma, reportedly inhibit or stimulate resistin expression. Rosiglitazone 152-156 peroxisome proliferator activated receptor gamma Mus musculus 214-224 15517883-3 2004 Proliferation of DS19 mouse erythroleukemia cells was inhibited by PPAR gamma agonists (4-phenylbutyrate, rosiglitazone, ciglitazone and GW1929) and by potential PPAR gamma antagonists: BADGE (Biphenol A diglycidyl ether), GW9662, PD068235 and diclofenac. Rosiglitazone 106-119 peroxisome proliferator activated receptor gamma Mus musculus 67-77 15571985-5 2004 At 9 months of age, we began administering Tg2576 mice rosiglitazone, an agonist of peroxisome proliferator-activated receptor-gamma that increases peripheral insulin sensitivity, and after 6 weeks of administration the Tg2576 mice had the same response to insulin and increase in serum corticosterone levels after an overnight fast as did wild-type mice. Rosiglitazone 55-68 peroxisome proliferator activated receptor gamma Mus musculus 84-132 15054141-2 2004 To better understand what genes are regulated by PPARgamma, an experimental data set was generated by microarray analysis, in duplicate, of pooled aortic mRNA isolated from mice treated for 21 days with a PPARgamma agonist (rosiglitazone) or vehicle. Rosiglitazone 224-237 peroxisome proliferator activated receptor gamma Mus musculus 49-58 15190061-8 2004 One or more components within the organic extract activated PPARgamma through interaction with its LBD, induced lipid accumulation in 3T3-L1 cells as efficiently as the differentiation mixture, and competed for binding of rosiglitazone to the LBD of PPARgamma. Rosiglitazone 222-235 peroxisome proliferator activated receptor gamma Mus musculus 60-69 15190061-8 2004 One or more components within the organic extract activated PPARgamma through interaction with its LBD, induced lipid accumulation in 3T3-L1 cells as efficiently as the differentiation mixture, and competed for binding of rosiglitazone to the LBD of PPARgamma. Rosiglitazone 222-235 peroxisome proliferator activated receptor gamma Mus musculus 250-259 15296471-1 2004 OBJECTIVE: Rosiglitazone, a thiazolidinedione compound with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-binding affinity, is able to suppress adrenocorticotropic hormone (ACTH) secretion in treated mice and in AtT20 pituitary tumor cells. Rosiglitazone 11-24 peroxisome proliferator activated receptor gamma Mus musculus 60-108 15296471-1 2004 OBJECTIVE: Rosiglitazone, a thiazolidinedione compound with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-binding affinity, is able to suppress adrenocorticotropic hormone (ACTH) secretion in treated mice and in AtT20 pituitary tumor cells. Rosiglitazone 11-24 peroxisome proliferator activated receptor gamma Mus musculus 110-120 15174093-9 2004 Treatment of cftr-/- mice with the PPARgamma ligand rosiglitazone restored both the nuclear localization and binding to DNA, but did not increase RNA levels. Rosiglitazone 52-65 peroxisome proliferator activated receptor gamma Mus musculus 35-44 15073165-4 2004 Insig-1 was induced in subcutaneous (9-fold) and epididymal (4-fold) fat pads from db/db mice treated for 8 days with the PPARgamma agonist rosiglitazone (30 mg/kg/day). Rosiglitazone 140-153 peroxisome proliferator activated receptor gamma Mus musculus 122-131 15137925-4 2004 Two PPARgamma agonists, 15-deoxy-delta(12,14)-prostaglandin (PG) J2 and rosiglitazone, have been shown to have immunomodulatory activity in vitro, including inhibiting IL-12 biosynthesis. Rosiglitazone 72-85 peroxisome proliferator activated receptor gamma Mus musculus 4-13 15137925-8 2004 GW9662, a PPARgamma antagonist, reversed the inhibitory effect of rosiglitazone, but not that of PUFA. Rosiglitazone 66-79 peroxisome proliferator activated receptor gamma Mus musculus 10-19 14985957-0 2004 Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute pancreatitis induced by cerulein. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 31-79 14985957-17 2004 CONCLUSION: These findings support the view that rosiglitazone and other potent PPAR-gamma agonists may be useful in the therapy of acute pancreatitis. Rosiglitazone 49-62 peroxisome proliferator activated receptor gamma Mus musculus 80-90 15054141-2 2004 To better understand what genes are regulated by PPARgamma, an experimental data set was generated by microarray analysis, in duplicate, of pooled aortic mRNA isolated from mice treated for 21 days with a PPARgamma agonist (rosiglitazone) or vehicle. Rosiglitazone 224-237 peroxisome proliferator activated receptor gamma Mus musculus 205-214 14688261-8 2004 Consistent with this hypothesis, administration of rosiglitazone, a potent PPARgamma-selective agonist, efficiently reversed inhibition of implantation by the 12/15-LOX-specific inhibitor. Rosiglitazone 51-64 peroxisome proliferator activated receptor gamma Mus musculus 75-84 14688261-9 2004 Rosiglitazone also induced a number of potential target genes of 12/15-LOX-derived metabolites in the pregnant uterus, indicating their regulation by PPARgamma. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 150-159 14730378-2 2004 Metformin decreases hepatic glucose output, whereas rosiglitazone (RSG) is an agonist for peroxisome proliferator activated receptor (PPAR)gamma, highly expressed in fat. Rosiglitazone 52-65 peroxisome proliferator activated receptor gamma Mus musculus 134-144 14730378-2 2004 Metformin decreases hepatic glucose output, whereas rosiglitazone (RSG) is an agonist for peroxisome proliferator activated receptor (PPAR)gamma, highly expressed in fat. Rosiglitazone 67-70 peroxisome proliferator activated receptor gamma Mus musculus 134-144 14730378-7 2004 Adipocyte PPARgamma gene and protein expression, and adipocyte size were all increased in LIRKO mice treated with RSG, whereas fat-cell size in control animals was decreased by RSG. Rosiglitazone 114-117 peroxisome proliferator activated receptor gamma Mus musculus 10-19 14744930-0 2004 PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Rosiglitazone 20-33 peroxisome proliferator activated receptor gamma Mus musculus 0-11 14695339-4 2004 Using a model of sensitization, based on the intratracheal transfer of ovalbumin (OVA)-pulsed DCs, we show that rosiglitazone, a selective PPAR-gamma agonist, reduces the proliferation of Ag-specific T cells in the draining mediastinal lymph nodes but, surprisingly enough, dramatically increases the production of the immunoregulatory cytokine interleukin (IL)-10 by T cells, as compared to control mice sensitized with OVA-pulsed DCs. Rosiglitazone 112-125 peroxisome proliferator activated receptor gamma Mus musculus 139-149 14551045-1 2004 We tested the hypothesis that short-term treatment of mice with Type 2 diabetes mellitus (DM) with rosiglitazone (ROSI), an agonist of peroxisome proliferator-activated receptor-gamma, ameliorates the impaired coronary arteriolar dilation by reducing oxidative stress via a mechanism unrelated to its effect on hyperglycemia and hyperinsulinemia. Rosiglitazone 99-112 peroxisome proliferator activated receptor gamma Mus musculus 135-183 14551045-1 2004 We tested the hypothesis that short-term treatment of mice with Type 2 diabetes mellitus (DM) with rosiglitazone (ROSI), an agonist of peroxisome proliferator-activated receptor-gamma, ameliorates the impaired coronary arteriolar dilation by reducing oxidative stress via a mechanism unrelated to its effect on hyperglycemia and hyperinsulinemia. Rosiglitazone 114-118 peroxisome proliferator activated receptor gamma Mus musculus 135-183 14758164-0 2004 Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces the development of nonseptic shock induced by zymosan in mice. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 31-79 14758164-3 2004 Rosiglitazone (Avandia) is a PPAR-gamma agonist (the most potent PPAR-gamma agonist of the thiazolidinedione antidiabetics). Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 29-39 14758164-3 2004 Rosiglitazone (Avandia) is a PPAR-gamma agonist (the most potent PPAR-gamma agonist of the thiazolidinedione antidiabetics). Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 65-75 14758164-15 2004 GW 9662 (1 mg/kg administered intraperitoneally 30 mins before treatment with rosiglitazone) significantly antagonized the effect of the PPAR-gamma agonist and thus abolished the protective effect. Rosiglitazone 78-91 peroxisome proliferator activated receptor gamma Mus musculus 137-147 14697247-7 2004 In contrast, haptoglobin mRNA was reduced by nicotinic acid and the PPARgamma agonist, rosiglitazone. Rosiglitazone 87-100 peroxisome proliferator activated receptor gamma Mus musculus 68-77 14709251-6 2003 Ritonavir was coadministered with the peroxisome proliferator-activated receptor alpha (PPARalpha) agonist gemfibrozil and the PPARgamma agonist rosiglitazone for 8 weeks. Rosiglitazone 145-158 peroxisome proliferator activated receptor gamma Mus musculus 127-136 14500573-4 2004 We have demonstrated previously that PPAR-gamma2 activated with rosiglitazone acts as a dominant inhibitor of osteoblastogenesis in murine bone marrow in vitro. Rosiglitazone 64-77 peroxisome proliferator activated receptor gamma Mus musculus 37-48 14713549-1 2004 Thiazolidinedione PPARgamma agonists (troglitazone and rosiglitazone) were previously shown to promote colon tumor formation in C57BL/6J-APC(min)/+ mice, a model for human familial adenomatous polyposis. Rosiglitazone 55-68 peroxisome proliferator activated receptor gamma Mus musculus 18-27 14674008-0 2003 Reduction in the evolution of murine type II collagen-induced arthritis by treatment with rosiglitazone, a ligand of the peroxisome proliferator-activated receptor gamma. Rosiglitazone 90-103 peroxisome proliferator activated receptor gamma Mus musculus 121-169 14674008-2 2003 The thiazolidinedione rosiglitazone is a PPARgamma ligand that modulates the transcription of target genes. Rosiglitazone 22-35 peroxisome proliferator activated receptor gamma Mus musculus 41-50 12665425-2 2003 SR-202 is a selective antagonist at PPAR-gamma, which inhibits the adipocyte differentiation normally seen with the PPAR-gamma agonist rosiglitazone. Rosiglitazone 135-148 peroxisome proliferator activated receptor gamma Mus musculus 36-46 12923776-2 2003 The insulin sensitizer drug, rosiglitazone, has been shown to bind and activate PPAR-gamma1 in adipocytes and PPAR-gamma2 in hepatocytes. Rosiglitazone 29-42 peroxisome proliferator activated receptor gamma Mus musculus 110-121 12787395-3 2003 In the present study we examined whether peroxisome proliferator-activated receptor gamma (PPARgamma) activators/ligands, thiazolidinediones such as ciglitazone, troglitazone, and rosiglitazone, can inhibit cell proliferation by modulating individual steps in the MAPK pathway. Rosiglitazone 180-193 peroxisome proliferator activated receptor gamma Mus musculus 41-89 12805374-5 2003 Inactivation of AZIP liver PPAR gamma also abolished the hypoglycemic and hypolipidemic effects of rosiglitazone, demonstrating that, in the absence of adipose tissue, the liver is a primary and major site of thiazolidinedione action. Rosiglitazone 99-112 peroxisome proliferator activated receptor gamma Mus musculus 27-37 12805374-6 2003 In contrast, rosiglitazone remained effective in non-lipoatrophic mice lacking liver PPAR gamma, suggesting that adipose tissue is the major site of thiazolidinedione action in typical mice with adipose tissue. Rosiglitazone 13-26 peroxisome proliferator activated receptor gamma Mus musculus 85-95 12740443-4 2003 Natural and synthetic PPARgamma agonists, including the thiazolidinedione rosiglitazone (Ro), modestly induced the expression of a surprisingly small number of genes, several of which were also induced by a specific PPARdelta agonist. Rosiglitazone 89-91 peroxisome proliferator activated receptor gamma Mus musculus 22-31 12740443-6 2003 In contrast, Ro inhibited induction of broad subsets of lipopolysaccharide and IFN-gamma target genes in a gene-specific and PPARgamma-dependent manner. Rosiglitazone 13-15 peroxisome proliferator activated receptor gamma Mus musculus 125-134 12740443-7 2003 At high concentrations, Ro inhibited induction of lipopolysaccharide target genes in PPARgamma-deficient macrophages, at least in part by activating PPARdelta. Rosiglitazone 24-26 peroxisome proliferator activated receptor gamma Mus musculus 85-94 12734379-5 2003 Using an experimental murine model of LC migration induced by TNF-alpha, we show that the highly potent PPAR gamma agonist rosiglitazone specifically impairs the departure of LCs from the epidermis. Rosiglitazone 123-136 peroxisome proliferator activated receptor gamma Mus musculus 104-114 12628477-4 2003 YM440, pioglitazone and rosiglitazone displaced [3H]rosiglitazone from PPARgamma with K(i) values of 4.0, 3.1, and 0.20 microM, indicating that YM440 was comparable to pioglitazone and 20-fold less potent than rosiglitazone. Rosiglitazone 24-37 peroxisome proliferator activated receptor gamma Mus musculus 71-80 12628477-4 2003 YM440, pioglitazone and rosiglitazone displaced [3H]rosiglitazone from PPARgamma with K(i) values of 4.0, 3.1, and 0.20 microM, indicating that YM440 was comparable to pioglitazone and 20-fold less potent than rosiglitazone. Rosiglitazone 52-65 peroxisome proliferator activated receptor gamma Mus musculus 71-80 12628477-4 2003 YM440, pioglitazone and rosiglitazone displaced [3H]rosiglitazone from PPARgamma with K(i) values of 4.0, 3.1, and 0.20 microM, indicating that YM440 was comparable to pioglitazone and 20-fold less potent than rosiglitazone. Rosiglitazone 52-65 peroxisome proliferator activated receptor gamma Mus musculus 71-80 12628477-5 2003 Although pioglitazone and rosiglitazone increased both PPARgamma transactivation in cells expressing human full-length PPARgamma2 or GAL4-PPARgamma and mRNA expression of PPARgamma responsive genes in 3T3-L1 cells, YM440 had weak effects on PPARgamma transactivation and mRNA expression being 550- to 790-fold and 36- to 110-fold less active than rosiglitazone, respectively. Rosiglitazone 26-39 peroxisome proliferator activated receptor gamma Mus musculus 119-128 12628477-6 2003 YM440 and rosiglitazone induced interaction between PPARgamma and the transcriptional cofactor, p300 or SRC-1, but YM440 was 151- and 1091-fold less potent than rosiglitazone, respectively. Rosiglitazone 10-23 peroxisome proliferator activated receptor gamma Mus musculus 52-61 12628477-6 2003 YM440 and rosiglitazone induced interaction between PPARgamma and the transcriptional cofactor, p300 or SRC-1, but YM440 was 151- and 1091-fold less potent than rosiglitazone, respectively. Rosiglitazone 161-174 peroxisome proliferator activated receptor gamma Mus musculus 52-61 12618528-5 2003 Rosiglitazone treatment exacerbated the fatty liver in ob/ob-PPARgamma(fl/fl)AlbCre(-) mice compared with livers from nonobese Cre(-) mice; there was no effect of rosiglitazone in ob/ob-PPARgamma(fl/fl)AlbCre(+) mice. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 61-70 12618528-5 2003 Rosiglitazone treatment exacerbated the fatty liver in ob/ob-PPARgamma(fl/fl)AlbCre(-) mice compared with livers from nonobese Cre(-) mice; there was no effect of rosiglitazone in ob/ob-PPARgamma(fl/fl)AlbCre(+) mice. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 186-195 12542724-0 2003 Rosiglitazone (PPARgamma-agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 15-24 12542724-6 2003 After diabetes induction, rosiglitazone (a PPARgamma agonist) was administered by oral gavage to one of the diabetic and one of the non-diabetic groups. Rosiglitazone 26-39 peroxisome proliferator activated receptor gamma Mus musculus 43-52 12665425-2 2003 SR-202 is a selective antagonist at PPAR-gamma, which inhibits the adipocyte differentiation normally seen with the PPAR-gamma agonist rosiglitazone. Rosiglitazone 135-148 peroxisome proliferator activated receptor gamma Mus musculus 116-126 12419282-8 2002 Tuberculin administrations in the forms of BCG and CFA in a manner known to protect NOD mice from diabetes both raised NKT-TCR levels, as did the anti-inflammatory PPAR-gamma agonist rosiglitazone. Rosiglitazone 183-196 peroxisome proliferator activated receptor gamma Mus musculus 164-174 12401879-0 2002 Lipid metabolome-wide effects of the PPARgamma agonist rosiglitazone. Rosiglitazone 55-68 peroxisome proliferator activated receptor gamma Mus musculus 37-46 12401879-3 2002 In this study, a comprehensive metabolomic assessment of lipid metabolites was employed to determine the specific effects of the peroxisome proliferator-activated receptor gamma (PPARgamma) agonist rosiglitazone on structural lipid metabolism in a new mouse model of Type 2 diabetes. Rosiglitazone 198-211 peroxisome proliferator activated receptor gamma Mus musculus 129-177 12401879-3 2002 In this study, a comprehensive metabolomic assessment of lipid metabolites was employed to determine the specific effects of the peroxisome proliferator-activated receptor gamma (PPARgamma) agonist rosiglitazone on structural lipid metabolism in a new mouse model of Type 2 diabetes. Rosiglitazone 198-211 peroxisome proliferator activated receptor gamma Mus musculus 179-188 12401439-4 2002 Synthetic PPARgamma ligands (troglitazone or BRL49653) inhibited TXA(2) production and enhanced PGE(2) production of PBMC and THP-1. Rosiglitazone 45-53 peroxisome proliferator activated receptor gamma Mus musculus 10-19 12479648-5 2002 Three different PPARgamma ligands (troglitazone, pioglitazone, and rosiglitazone) demonstrated beneficial dose-related treatment effects when administered prior to the onset of colitis. Rosiglitazone 67-80 peroxisome proliferator activated receptor gamma Mus musculus 16-25 12144946-2 2002 Here, we investigate effects of PPARgamma specific ligands, rosiglitazone and pioglitazone, on formation of nitrotyrosine and increased expression of inflammatory mediators such as inducible nitric oxide synthase (iNOS), cyclooxygenase-2 and intercellular adhesion molecule-1 (ICAM-1) in adjuvant-induced murine arthritis. Rosiglitazone 60-73 peroxisome proliferator activated receptor gamma Mus musculus 32-41 11994294-9 2002 Combination treatment with both WY14,643 and a PPARgamma ligand, rosiglitazone, did not lower glucose levels more effectively than did treatment with WY14,643 alone. Rosiglitazone 65-78 peroxisome proliferator activated receptor gamma Mus musculus 47-56 12021203-2 2002 Based on evidence that activation of PPAR gamma 2 by rosiglitazone stimulates adipogenesis and inhibits osteoblastogenesis in U-33/gamma 2 cells, a model mesenchymal progenitor of adipocytes and osteoblasts, we postulated that the increase in marrow fat and the decrease in osteoblast number that occur during aging are due to increased PPAR gamma 2 activation. Rosiglitazone 53-66 peroxisome proliferator activated receptor gamma Mus musculus 37-49 11916924-6 2002 The differential expression of a large fraction of the isolated genes was also shown to occur in white adipose tissue of ob/ob mice treated with rosiglitazone; combined, our results suggest that an important effect of rosiglitazone in adipose tissue is based on activation of PPAR-gamma in preexisting preadipocytes found among the mature adipocytes, resulting in subsequent adipocyte differentiation. Rosiglitazone 145-158 peroxisome proliferator activated receptor gamma Mus musculus 276-286 11916924-6 2002 The differential expression of a large fraction of the isolated genes was also shown to occur in white adipose tissue of ob/ob mice treated with rosiglitazone; combined, our results suggest that an important effect of rosiglitazone in adipose tissue is based on activation of PPAR-gamma in preexisting preadipocytes found among the mature adipocytes, resulting in subsequent adipocyte differentiation. Rosiglitazone 218-231 peroxisome proliferator activated receptor gamma Mus musculus 276-286 11901161-8 2002 The antidiabetic thiazolidinedione (TZD) drug rosiglitazone reduced resistin expression with an ED(50) similar to its K(d) for binding to peroxisome proliferator activated receptor gamma (PPARgamma). Rosiglitazone 46-59 peroxisome proliferator activated receptor gamma Mus musculus 138-186 11901161-8 2002 The antidiabetic thiazolidinedione (TZD) drug rosiglitazone reduced resistin expression with an ED(50) similar to its K(d) for binding to peroxisome proliferator activated receptor gamma (PPARgamma). Rosiglitazone 46-59 peroxisome proliferator activated receptor gamma Mus musculus 188-197 12021203-2 2002 Based on evidence that activation of PPAR gamma 2 by rosiglitazone stimulates adipogenesis and inhibits osteoblastogenesis in U-33/gamma 2 cells, a model mesenchymal progenitor of adipocytes and osteoblasts, we postulated that the increase in marrow fat and the decrease in osteoblast number that occur during aging are due to increased PPAR gamma 2 activation. Rosiglitazone 53-66 peroxisome proliferator activated receptor gamma Mus musculus 337-349 12021203-5 2002 The divergent effects of PPAR gamma 2 ligands on osteoblast and adipocyte differentiation were confirmed in primary murine bone marrow cultures using rosiglitazone and GW0072. Rosiglitazone 150-163 peroxisome proliferator activated receptor gamma Mus musculus 25-37 11889020-4 2002 METHODS AND RESULTS: Treatment of cultured cardiac myocytes with PPARgamma ligands such as troglitazone, pioglitazone, and rosiglitazone inhibited Ang II-induced upregulation of skeletal alpha-actin and atrial natriuretic peptide genes and an increase in cell surface area. Rosiglitazone 123-136 peroxisome proliferator activated receptor gamma Mus musculus 65-74 11278270-6 2001 The half-maximal inhibition of 11beta-HSD-1 mRNA expression by the TZD, rosiglitazone, occurred at a concentration that was similar to its K(d) for binding PPARgamma and EC(50) for inducing adipocyte differentiation thereby indicating that this action was PPARgamma-dependent. Rosiglitazone 72-85 peroxisome proliferator activated receptor gamma Mus musculus 156-165 11682067-3 2001 The PPARgamma activators, rosiglitazone or darglitazone, reduced the level of resistin mRNA. Rosiglitazone 26-39 peroxisome proliferator activated receptor gamma Mus musculus 4-13 11754868-4 2002 Prolonged treatment of obese and diabetic mice, but not of lean control mice, with the selective PPARgamma ligands and activators, thiazolidinediones (TZDs), including troglitazone, rosiglitazone, or pioglitazone, has resulted in the development of severe hepatic centrilobular steatosis. Rosiglitazone 182-195 peroxisome proliferator activated receptor gamma Mus musculus 97-106 11278270-6 2001 The half-maximal inhibition of 11beta-HSD-1 mRNA expression by the TZD, rosiglitazone, occurred at a concentration that was similar to its K(d) for binding PPARgamma and EC(50) for inducing adipocyte differentiation thereby indicating that this action was PPARgamma-dependent. Rosiglitazone 72-85 peroxisome proliferator activated receptor gamma Mus musculus 256-265 10871190-3 2000 Troglitazone acts as a partial agonist for PPAR-gamma in transfected muscle (C2C12) and kidney (HEK 293T) cells, producing a submaximal transcriptional response (1.8- to 2.5-fold activation) compared with rosiglitazone (7.4- to 13-fold activation). Rosiglitazone 205-218 peroxisome proliferator activated receptor gamma Mus musculus 43-53 11119715-5 2000 We also show that the PPARgamma activator rosiglitazone does not interfere with the maturation of DCs in vitro nor modifies their ability to activate naive T lymphocytes in vivo. Rosiglitazone 42-55 peroxisome proliferator activated receptor gamma Mus musculus 22-31 11043571-6 2000 The partial agonism of CDDO and the antagonism of CDDO-Me reflect the differences in their capacity to recruit or displace cofactors of transcriptional regulation; CDDO and rosiglitazone both release the nuclear receptor corepressor, NCoR, from PPARgamma, while CDDO-Me does not. Rosiglitazone 173-186 peroxisome proliferator activated receptor gamma Mus musculus 245-254 11043571-7 2000 The differences between CDDO and rosiglitazone as either partial or full agonists, respectively, are seen in the weaker ability of CDDO to recruit the coactivator CREB-binding protein, CBP, to PPARgamma. Rosiglitazone 33-46 peroxisome proliferator activated receptor gamma Mus musculus 193-202 10953027-3 2000 We report here that the PPARgamma-specific agonists rosiglitazone and GW7845 strongly inhibited the development of atherosclerosis in LDL receptor-deficient male mice, despite increased expression of the CD36 scavenger receptor in the arterial wall. Rosiglitazone 52-65 peroxisome proliferator activated receptor gamma Mus musculus 24-33 34607170-2 2021 Here, we aims to find a new natural PPAR-gamma agonist with less adverse reactions than rosiglitazone in db/db mice. Rosiglitazone 88-101 peroxisome proliferator activated receptor gamma Mus musculus 36-46 26362846-0 2015 Rosiglitazone activation of PPARgamma-dependent signaling is neuroprotective in mutant huntingtin expressing cells. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 28-37 26362846-4 2015 We investigated whether the PPARgamma agonist (rosiglitazone) mediates neuroprotection in the mHtt expressing neuroblastoma cell line (N2A). Rosiglitazone 47-60 peroxisome proliferator activated receptor gamma Mus musculus 28-37 26362846-5 2015 Here we show that rosiglitazone upregulated the endogenous expression of PPARgamma, its downstream target genes (including PGC1alpha, NRF-1 and Tfam) and mitochondrial function in mHtt expressing N2A cells. Rosiglitazone 18-31 peroxisome proliferator activated receptor gamma Mus musculus 73-82 10393202-0 1999 Rosiglitazone (BRL49653), a PPARgamma-selective agonist, causes peroxisome proliferator-like liver effects in obese mice. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 28-37 10393202-0 1999 Rosiglitazone (BRL49653), a PPARgamma-selective agonist, causes peroxisome proliferator-like liver effects in obese mice. Rosiglitazone 15-23 peroxisome proliferator activated receptor gamma Mus musculus 28-37 10393202-12 1999 As PPARalpha and PPARgamma recognize similar DNA response elements, it is likely that the effects of rosiglitazone on PPARalpha responsive genes in livers of the ob/ob mice are mediated by PPARgamma2. Rosiglitazone 101-114 peroxisome proliferator activated receptor gamma Mus musculus 17-26 10393202-12 1999 As PPARalpha and PPARgamma recognize similar DNA response elements, it is likely that the effects of rosiglitazone on PPARalpha responsive genes in livers of the ob/ob mice are mediated by PPARgamma2. Rosiglitazone 101-114 peroxisome proliferator activated receptor gamma Mus musculus 189-199 10475242-1 1999 Troglitazone and rosiglitazone (BRL49653), members of the thiazolidinedione (TZD) class of antidiabetic drugs, are peroxisome proliferator-activated receptor gamma (PPARgamma) ligands that induce adipocyte differentiation and increase the expression of PPARgamma protein. Rosiglitazone 17-30 peroxisome proliferator activated receptor gamma Mus musculus 115-163 10475242-1 1999 Troglitazone and rosiglitazone (BRL49653), members of the thiazolidinedione (TZD) class of antidiabetic drugs, are peroxisome proliferator-activated receptor gamma (PPARgamma) ligands that induce adipocyte differentiation and increase the expression of PPARgamma protein. Rosiglitazone 17-30 peroxisome proliferator activated receptor gamma Mus musculus 165-174 10475242-1 1999 Troglitazone and rosiglitazone (BRL49653), members of the thiazolidinedione (TZD) class of antidiabetic drugs, are peroxisome proliferator-activated receptor gamma (PPARgamma) ligands that induce adipocyte differentiation and increase the expression of PPARgamma protein. Rosiglitazone 17-30 peroxisome proliferator activated receptor gamma Mus musculus 253-262 22966222-3 2012 This review summarises experimental evidence that PPARgamma ligands, such as rosiglitazone (RGZ) and pioglitazone (PGZ), inhibit proliferation and inflammatory cytokine production from ASM in vitro. Rosiglitazone 77-90 peroxisome proliferator activated receptor gamma Mus musculus 50-59 34517131-6 2022 Moreover, beige-induced 3T3-L1 adipocytes and stromal vascular fraction (SVF) cells by exposure to the peroxisome proliferator-activated receptor gamma (PPARgamma) agonist rosiglitazone showed a significant increase in mitochondrial thermogenic factors along with peroxisomal proteins including PEX13, and these were confirmed in SVF cells with the beta 3 adrenergic receptor (beta3AR)-selective agonist CL316,243. Rosiglitazone 172-185 peroxisome proliferator activated receptor gamma Mus musculus 103-151 34517131-6 2022 Moreover, beige-induced 3T3-L1 adipocytes and stromal vascular fraction (SVF) cells by exposure to the peroxisome proliferator-activated receptor gamma (PPARgamma) agonist rosiglitazone showed a significant increase in mitochondrial thermogenic factors along with peroxisomal proteins including PEX13, and these were confirmed in SVF cells with the beta 3 adrenergic receptor (beta3AR)-selective agonist CL316,243. Rosiglitazone 172-185 peroxisome proliferator activated receptor gamma Mus musculus 153-162 34607170-8 2021 18:0 Lyso PC, a natural compound, can show a similar hypoglycemic effect to rosiglitazone by activating PPAR-gamma, while eliciting markedly fewer adverse reactions than rosiglitazone. Rosiglitazone 76-89 peroxisome proliferator activated receptor gamma Mus musculus 104-114 34417811-0 2021 Rosiglitazone requires hepatocyte PPARgamma expression to promote steatosis in male mice with diet-induced obesity. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 34-43 34400525-3 2021 In this study, we report the development of an optimized culture system for generating AM-like cells from adult mouse bone marrow and fetal liver cells on in vitro culture in the presence of a combination of GM-CSF, TGF-beta, and peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist rosiglitazone. Rosiglitazone 300-313 peroxisome proliferator activated receptor gamma Mus musculus 230-278 34620682-6 2021 This shift in PPARgamma occupancy increases the antidiabetic efficacy of the PPARgamma agonist rosiglitazone in obesity while diminishing the unwanted weight-gaining effect of the drug. Rosiglitazone 95-108 peroxisome proliferator activated receptor gamma Mus musculus 14-23 34620682-6 2021 This shift in PPARgamma occupancy increases the antidiabetic efficacy of the PPARgamma agonist rosiglitazone in obesity while diminishing the unwanted weight-gaining effect of the drug. Rosiglitazone 95-108 peroxisome proliferator activated receptor gamma Mus musculus 77-86 34118723-8 2021 Compared with rosiglitazone, compound 6b with benzyloxyl meta-substitution and Z benzylidene double bond weakly induced adipogenesis and PPARgamma-targeted gene expression. Rosiglitazone 14-27 peroxisome proliferator activated receptor gamma Mus musculus 137-146 34400525-3 2021 In this study, we report the development of an optimized culture system for generating AM-like cells from adult mouse bone marrow and fetal liver cells on in vitro culture in the presence of a combination of GM-CSF, TGF-beta, and peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist rosiglitazone. Rosiglitazone 300-313 peroxisome proliferator activated receptor gamma Mus musculus 280-290 34245781-7 2021 Rosiglitazone, a classic PPARgamma agonist, increases, while siRNA knockdown of PPARgamma reduces, Nprc expression in 3T3-L1 adipocytes. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 25-34 34097888-10 2021 Although all the studied compounds influenced the expression of Dlk1, Fabp4, Vegfa, Pai-1, Resistin, Adiponectin, and Ppargamma genes, none of them caused gene expression similar to that induced by rosiglitazone or pioglitazone. Rosiglitazone 198-211 peroxisome proliferator activated receptor gamma Mus musculus 118-127 34097888-12 2021 Only rosiglitazone increased Ppargamma protein expression after 14 days of differentiation. Rosiglitazone 5-18 peroxisome proliferator activated receptor gamma Mus musculus 29-38 34398199-2 2021 Methods: Male C57BL/6J mice were fed a standard diet (SD), HFD, or HFD supplemented with the peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist rosiglitazone for various durations. Rosiglitazone 163-176 peroxisome proliferator activated receptor gamma Mus musculus 93-141 34398199-2 2021 Methods: Male C57BL/6J mice were fed a standard diet (SD), HFD, or HFD supplemented with the peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist rosiglitazone for various durations. Rosiglitazone 163-176 peroxisome proliferator activated receptor gamma Mus musculus 143-153 34305596-4 2021 High-fat diet (HFD) induced obese mice, ob/ob mice and cardiomyocytes overexpressing PPARgamma2 were treated with CMHX008 or rosiglitazone. Rosiglitazone 125-138 peroxisome proliferator activated receptor gamma Mus musculus 85-95 34305596-1 2021 The clinical controversy of rosiglitazone as a hypoglycemic agent is potentially associated with heart failure, mainly due to its potent activation of peroxisome proliferator-activated receptor gamma (PPARgamma). Rosiglitazone 28-41 peroxisome proliferator activated receptor gamma Mus musculus 151-199 34305596-1 2021 The clinical controversy of rosiglitazone as a hypoglycemic agent is potentially associated with heart failure, mainly due to its potent activation of peroxisome proliferator-activated receptor gamma (PPARgamma). Rosiglitazone 28-41 peroxisome proliferator activated receptor gamma Mus musculus 201-210 35066304-9 2022 This observation was experimentally supported as loss of adipogenesis was partially rescued by the addition of PPARgamma agonist, rosiglitazone in Kif26b-deficient cells. Rosiglitazone 130-143 peroxisome proliferator activated receptor gamma Mus musculus 111-120 34586974-4 2022 By providing a combination of GM-CSF, TGFbeta and the PPARgamma activator rosiglitazone, we maintain and expand mouse ex vivo cultured AMs, short mexAMs, over several months. Rosiglitazone 74-87 peroxisome proliferator activated receptor gamma Mus musculus 54-63 34320496-8 2021 The increased PPAR-gamma protein in CYP4F2 transgenic mice fed HFD and the activation of rosiglitazone on the luciferase reporter construct of the NKCC2 promoter demonstrated that the increase in NKCC2 mRNA in CYP4F2 transgenic mice fed HFD was a consequence of elevated PPAR-gamma protein induced by the synergy between 20-HETE and HFD. Rosiglitazone 89-102 peroxisome proliferator activated receptor gamma Mus musculus 271-281 35398016-3 2022 Rosiglitazone is a peroxisome proliferator-activated receptor gamma (PPARgamma) agoinst, known to stimulate hyperplasia and to efficiently improve insulin sensitivity. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 19-67 35398016-3 2022 Rosiglitazone is a peroxisome proliferator-activated receptor gamma (PPARgamma) agoinst, known to stimulate hyperplasia and to efficiently improve insulin sensitivity. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 69-78 35526523-4 2022 METHODS: HUVECs were co-cultured with THP-1-derived M1 macrophages pretreated with or without rosiglitazone (RSG), a peroxisome proliferator-activated receptor (PPAR)-gamma agonist. Rosiglitazone 94-107 peroxisome proliferator activated receptor gamma Mus musculus 117-172 35450368-1 2022 Thiazolidinedione PPARgamma agonists such as rosiglitazone and pioglitazone are effective antidiabetic drugs, but side effects have limited their use. Rosiglitazone 45-58 peroxisome proliferator activated receptor gamma Mus musculus 18-27 35436993-3 2022 The PPARgamma agonist rosiglitazone-induced ACBP/DBI upregulation, as well as weight gain, that could be prevented by knockout of Acbp/Dbi in mice. Rosiglitazone 22-35 peroxisome proliferator activated receptor gamma Mus musculus 4-13 35340872-10 2022 Additionally, treatment with RSG promoted the activation of the nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway, upregulated peroxisome proliferator-activated receptor gamma and inhibited activation of the inflammasome NOD-like receptor protein 3 (NLRP3). Rosiglitazone 29-32 peroxisome proliferator activated receptor gamma Mus musculus 146-194 35198079-10 2022 Notably, the PPAR-gamma agonist rosiglitazone reversed the metastatic properties of FABP4-deficient GC cells in vitro and demonstrated viable therapeutic potential in multiple mouse models. Rosiglitazone 32-45 peroxisome proliferator activated receptor gamma Mus musculus 13-23 35111067-2 2021 In this study, we found that PPARgamma ligands (rosiglitazone or pioglitazone) increased NGBR expression in hepatic cells and HUVECs. Rosiglitazone 48-61 peroxisome proliferator activated receptor gamma Mus musculus 29-38 33918196-9 2021 In line with these data, we also observed that activation of PPARgamma in wild-type mice by the PPARgamma-specific ligand, rosiglitazone, significantly reduced both pulmonary granuloma and inflammatory mediator production. Rosiglitazone 123-136 peroxisome proliferator activated receptor gamma Mus musculus 61-70 34055059-0 2021 Rosiglitazone alleviates lipopolysaccharide-induced inflammation in RAW264.7 cells via inhibition of NF-kappaB and in a PPARgamma-dependent manner. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 120-129 34055059-1 2021 Rosiglitazone is a synthetic peroxisome proliferator-activated receptor (PPAR)gamma agonist widely used for the treatment of type 2 diabetes. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 29-83 34055059-12 2021 However, rosiglitazone-mediated inhibitory effects were reversed by PPARgamma knockdown. Rosiglitazone 9-22 peroxisome proliferator activated receptor gamma Mus musculus 68-77 34055059-13 2021 The results of the present study demonstrated that rosiglitazone significantly inhibited LPS-induced inflammatory responses in RAW264.7 macrophage cells, which was dependent on PPARgamma activation and NF-kappaB suppression. Rosiglitazone 51-64 peroxisome proliferator activated receptor gamma Mus musculus 177-186 33722775-6 2021 The 8 kb sequence upstream of Sost gene transcription start site possesses multiple PPARG binding elements (PPREs) with at least two of them binding PPARG with dynamics reflecting its activation with full agonist rosiglitazone and correlating with increased levels of Sost transcript and sclerostin protein expression (Pearson"s r = 0.9910, p = 0.001). Rosiglitazone 213-226 peroxisome proliferator activated receptor gamma Mus musculus 149-154 34004356-3 2021 We investigated herein the involvement of mTORC1 as a mediator of the actions of the PPARgamma ligand rosiglitazone in subcutaneous inguinal white adipose tissue (iWAT) mass, endocrine function, lipidome, transcriptome and branched-chain amino acid (BCAA) metabolism. Rosiglitazone 102-115 peroxisome proliferator activated receptor gamma Mus musculus 85-94 33918196-9 2021 In line with these data, we also observed that activation of PPARgamma in wild-type mice by the PPARgamma-specific ligand, rosiglitazone, significantly reduced both pulmonary granuloma and inflammatory mediator production. Rosiglitazone 123-136 peroxisome proliferator activated receptor gamma Mus musculus 96-105 33296744-3 2021 In this study, we assessed the anti-inflammatory effect of peroxisome proliferator activated receptor gamma (PPAR gamma) agonist, rosiglitazone (RGZ), in LPS-treated mouse embryos. Rosiglitazone 145-148 peroxisome proliferator activated receptor gamma Mus musculus 109-119 33717177-7 2021 Activation of PPARgamma is achieved by using its agonist Rosiglitazone or adenoviral vectors that could mediate overexpression of PPARgamma. Rosiglitazone 57-70 peroxisome proliferator activated receptor gamma Mus musculus 14-23 33717177-15 2021 Therefore, regulation of PPARgamma-Egr-1-pro-inflammatory mediators axis by PPARgamma agonist Rosiglitazone may represent a novel strategy for blockade of acute lung injury. Rosiglitazone 94-107 peroxisome proliferator activated receptor gamma Mus musculus 25-34 33717177-15 2021 Therefore, regulation of PPARgamma-Egr-1-pro-inflammatory mediators axis by PPARgamma agonist Rosiglitazone may represent a novel strategy for blockade of acute lung injury. Rosiglitazone 94-107 peroxisome proliferator activated receptor gamma Mus musculus 76-85 33382528-0 2021 Enhancement of select cognitive domains with rosiglitazone implicates dorsal hippocampus circuitry sensitive to PPARgamma agonism in an Alzheimer"s mouse model. Rosiglitazone 45-58 peroxisome proliferator activated receptor gamma Mus musculus 112-121 33296744-3 2021 In this study, we assessed the anti-inflammatory effect of peroxisome proliferator activated receptor gamma (PPAR gamma) agonist, rosiglitazone (RGZ), in LPS-treated mouse embryos. Rosiglitazone 130-143 peroxisome proliferator activated receptor gamma Mus musculus 59-107 33296744-3 2021 In this study, we assessed the anti-inflammatory effect of peroxisome proliferator activated receptor gamma (PPAR gamma) agonist, rosiglitazone (RGZ), in LPS-treated mouse embryos. Rosiglitazone 130-143 peroxisome proliferator activated receptor gamma Mus musculus 109-119 33296744-3 2021 In this study, we assessed the anti-inflammatory effect of peroxisome proliferator activated receptor gamma (PPAR gamma) agonist, rosiglitazone (RGZ), in LPS-treated mouse embryos. Rosiglitazone 145-148 peroxisome proliferator activated receptor gamma Mus musculus 59-107 33296744-10 2021 Through immunostaining, it was shown that LPS could prevent the translocation of PPARgamma to nucleus; and translocation was facilitated by RGZ and this effect was reversed by GW9662. Rosiglitazone 140-143 peroxisome proliferator activated receptor gamma Mus musculus 81-90 33754076-8 2021 Results: The PPARgamma agonists rosiglitazone and pioglitazone blocked glutaminolysis but not glycolysis under Th17-skewing conditions, as indicated by the detection of intracellular lactate and alpha-KG and the fluorescence ratios of BCECF-AM. Rosiglitazone 32-45 peroxisome proliferator activated receptor gamma Mus musculus 13-22 33754076-13 2021 However, the limitation of PPARgamma agonists on the mRNA expression of RORgammat was unable to be stopped by 2-HG but was attributed to GSH/ROS signals subsequent to GLS1. Rosiglitazone 141-144 peroxisome proliferator activated receptor gamma Mus musculus 27-36 33754076-15 2021 Conclusion: PPARgamma agonists repressed Th17 responses by counteracting GLS1-mediated glutaminolysis/2-HG/H3K4me3 and GSH/ROS signals, which is beneficial for Th17 cell-related immune dysregulation. Rosiglitazone 123-126 peroxisome proliferator activated receptor gamma Mus musculus 12-21 33432549-0 2021 Obestatin and Rosiglitazone Differentially Modulate Lipid Metabolism Through Peroxisome Proliferator-activated Receptor-gamma (PPARgamma) in Pre-adipose and Mature 3T3-L1 Cells. Rosiglitazone 14-27 peroxisome proliferator activated receptor gamma Mus musculus 77-125 33432549-0 2021 Obestatin and Rosiglitazone Differentially Modulate Lipid Metabolism Through Peroxisome Proliferator-activated Receptor-gamma (PPARgamma) in Pre-adipose and Mature 3T3-L1 Cells. Rosiglitazone 14-27 peroxisome proliferator activated receptor gamma Mus musculus 127-136 33432549-5 2021 We postulated they would act synergistically by obestatin increasing PPARgamma expression and rosiglitazone enhancing PPARgamma activity. Rosiglitazone 94-107 peroxisome proliferator activated receptor gamma Mus musculus 118-127 33278514-2 2021 Chronic ethanol exposure increases cellular oxidative stress in AM via upregulation of NADPH oxidase (Nox) 4, and treatment with the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand, rosiglitazone, decreased ethanol-induced Nox4. Rosiglitazone 202-215 peroxisome proliferator activated receptor gamma Mus musculus 133-181 33444819-0 2021 Hepatocyte-specific loss of PPARgamma protects mice from NASH, and increases the therapeutic effects of rosiglitazone in the liver. Rosiglitazone 104-117 peroxisome proliferator activated receptor gamma Mus musculus 28-37 33038450-3 2021 Rosiglitazone (Rosi), an agonist of the peroxisome proliferator-activated receptor gamma (PPARgamma), is known to be a potent browning inducer in subcutaneous WAT. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 40-88 33038450-3 2021 Rosiglitazone (Rosi), an agonist of the peroxisome proliferator-activated receptor gamma (PPARgamma), is known to be a potent browning inducer in subcutaneous WAT. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 90-99 33038450-3 2021 Rosiglitazone (Rosi), an agonist of the peroxisome proliferator-activated receptor gamma (PPARgamma), is known to be a potent browning inducer in subcutaneous WAT. Rosiglitazone 0-4 peroxisome proliferator activated receptor gamma Mus musculus 40-88 33038450-3 2021 Rosiglitazone (Rosi), an agonist of the peroxisome proliferator-activated receptor gamma (PPARgamma), is known to be a potent browning inducer in subcutaneous WAT. Rosiglitazone 0-4 peroxisome proliferator activated receptor gamma Mus musculus 90-99 33444819-6 2021 RESULTS: HFCF diet increased PPARgamma expression in hepatocytes, and rosiglitazone further activated PPARgamma in hepatocytes of HFCF-fed mice in vivo and in vitro. Rosiglitazone 70-83 peroxisome proliferator activated receptor gamma Mus musculus 102-111 32973516-10 2020 These phenotypes were ameliorated after the transcription activity of PPARgamma was restored by rosiglitazone, a PPARgamma agonist. Rosiglitazone 96-109 peroxisome proliferator activated receptor gamma Mus musculus 70-79 33137425-2 2020 Rosiglitazone (RGZ), a thiazolidinedione agonist of PPARgamma, is widely used in the treatment of type 2 diabetes mellitus by stimulating genes which favor storage of triglycerides. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 52-61 33137425-2 2020 Rosiglitazone (RGZ), a thiazolidinedione agonist of PPARgamma, is widely used in the treatment of type 2 diabetes mellitus by stimulating genes which favor storage of triglycerides. Rosiglitazone 15-18 peroxisome proliferator activated receptor gamma Mus musculus 52-61 33219735-4 2020 Our molecular and physiological studies show that long-term treatment of mice at 14 months of age with low doses of the PPARgamma ligand rosiglitazone (Rosi) improved glucose metabolism and mitochondrial functionality. Rosiglitazone 137-150 peroxisome proliferator activated receptor gamma Mus musculus 120-129 33219735-4 2020 Our molecular and physiological studies show that long-term treatment of mice at 14 months of age with low doses of the PPARgamma ligand rosiglitazone (Rosi) improved glucose metabolism and mitochondrial functionality. Rosiglitazone 152-156 peroxisome proliferator activated receptor gamma Mus musculus 120-129 32128893-8 2020 Wild-type C57BL/6 mice were fed a high-fat diet to induce NAFLD and given rosiglitazone to regulate PPAR-gamma activity in vivo. Rosiglitazone 74-87 peroxisome proliferator activated receptor gamma Mus musculus 100-110 32845528-4 2021 Thiazolidinediones (e.g., rosiglitazone) are anti-diabetic therapies that promote adipogenesis through PPARgamma activation. Rosiglitazone 26-39 peroxisome proliferator activated receptor gamma Mus musculus 103-112 33416183-6 2021 3T3-L1 preadipocytes differentiated into beige adipocytes upon PPARgamma activation (rosiglitazone) displaying characteristics that morphologically resembled brown/beige adipocytes. Rosiglitazone 85-98 peroxisome proliferator activated receptor gamma Mus musculus 63-72 32463311-8 2020 In our experiments, 10 nM VGVAPG added for differentiating to adipocytes increased the expression of Pref-1, serpin E1, and adiponectin as compared to rosiglitazone (PPARgamma agonist)-treated group and simultaneously decreased the expression of VEGF and resistin as compared to the rosiglitazone-treated group. Rosiglitazone 151-164 peroxisome proliferator activated receptor gamma Mus musculus 166-175 33108252-3 2020 Specifically, treatment of obese mice with the PPARgamma agonist rosiglitazone (a thiazolidinedione, TZD) in combination with the GPR120 agonist compound A synergistically improves glucose tolerance and insulin sensitivity. Rosiglitazone 65-78 peroxisome proliferator activated receptor gamma Mus musculus 47-56 32945426-3 2020 PPAR-gamma was activated by rosiglitazone, and was inhibited by GW9662. Rosiglitazone 28-41 peroxisome proliferator activated receptor gamma Mus musculus 0-10 32973516-10 2020 These phenotypes were ameliorated after the transcription activity of PPARgamma was restored by rosiglitazone, a PPARgamma agonist. Rosiglitazone 96-109 peroxisome proliferator activated receptor gamma Mus musculus 113-122 32522588-2 2020 PPARgamma agonists, e.g., rosiglitazone (RSG), enhance adipocyte browning. Rosiglitazone 26-39 peroxisome proliferator activated receptor gamma Mus musculus 0-9 32522588-2 2020 PPARgamma agonists, e.g., rosiglitazone (RSG), enhance adipocyte browning. Rosiglitazone 41-44 peroxisome proliferator activated receptor gamma Mus musculus 0-9 32413335-3 2020 Here, we show that treatment with the PPARgamma agonist rosiglitazone (Rosi) plus the GPR120 agonist Compound A leads to additive effects to improve glucose tolerance and insulin sensitivity, but at lower doses of Rosi, thus avoiding its known side effects. Rosiglitazone 56-69 peroxisome proliferator activated receptor gamma Mus musculus 38-47 31846359-11 2020 Additionally, positive modulation of PPAR-gamma expression and activity by rosiglitazone correspondingly influenced the effects of rhein on inflammatory factors and NF-kappaB expression. Rosiglitazone 75-88 peroxisome proliferator activated receptor gamma Mus musculus 37-47 31776610-13 2020 Ovariectomised female Seipin+/- mice displayed glucose intolerance and deficits in insulin synthesis and secretion, with a decline in islet PPARgamma level; these deleterious effects were reversed by administration of oestradiol or rosiglitazone. Rosiglitazone 232-245 peroxisome proliferator activated receptor gamma Mus musculus 140-149 32188494-12 2020 The PPARgamma agonist rosiglitazone treatment significantly upregulated the serum levels of lipocalin 2, suggesting a potential regulatory role of PPARgamma in the aberrant expression of lipocalin 2. Rosiglitazone 22-35 peroxisome proliferator activated receptor gamma Mus musculus 4-13 32188494-12 2020 The PPARgamma agonist rosiglitazone treatment significantly upregulated the serum levels of lipocalin 2, suggesting a potential regulatory role of PPARgamma in the aberrant expression of lipocalin 2. Rosiglitazone 22-35 peroxisome proliferator activated receptor gamma Mus musculus 147-156 31756041-2 2019 Rosiglitazone(RSG), a widely used antidiabetic drug that activates peroxisome proliferator-activated receptor-gamma (PPAR-gamma), has been shown to protect against cerebral ischemia through promoting poststroke microglial polarization toward the beneficial anti-inflammatory phenotype. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 67-115 31756041-2 2019 Rosiglitazone(RSG), a widely used antidiabetic drug that activates peroxisome proliferator-activated receptor-gamma (PPAR-gamma), has been shown to protect against cerebral ischemia through promoting poststroke microglial polarization toward the beneficial anti-inflammatory phenotype. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 117-127 31317231-5 2019 RESULTS: Combined treatment with the peroxisome proliferator-activated receptor gamma (PPARgamma) agonist rosiglitazone, the SMAD3 inhibitor SIS3 and the adrenergic receptor agonist noradrenaline (norepinephrine) synergistically induced Ucp1, Fgf21 and Cited1 expression, triggering brown adipogenesis. Rosiglitazone 106-119 peroxisome proliferator activated receptor gamma Mus musculus 37-85 31561855-0 2019 Rosiglitazone ameliorates bile duct ligation-induced liver fibrosis by down-regulating NF-kappaB-TNF-alpha signaling pathway in a PPARgamma-dependent manner. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 130-139 31561855-2 2019 One of its therapeutic targets is peroxisome proliferator-activated receptor gamma (PPARgamma), with its ligands including rosiglitazone being tested in pre-clinical and clinical studies. Rosiglitazone 123-136 peroxisome proliferator activated receptor gamma Mus musculus 34-82 31561855-2 2019 One of its therapeutic targets is peroxisome proliferator-activated receptor gamma (PPARgamma), with its ligands including rosiglitazone being tested in pre-clinical and clinical studies. Rosiglitazone 123-136 peroxisome proliferator activated receptor gamma Mus musculus 84-93 31561855-7 2019 Mechanistically, rosiglitazone reduced BDL-induced collagen content by downregulating fibrotic related genes including transforming growth factor beta1, alpha-smooth muscle actin and collagen type I alpha1, and decreased inflammation cytokine tumor necrosis factor alpha level by inhibiting phosphorylation of nuclear factor-kappaB in a PPARgamma-dependent manner. Rosiglitazone 17-30 peroxisome proliferator activated receptor gamma Mus musculus 337-346 31561855-8 2019 Based on findings above, we demonstrated that rosiglitazone can ameliorate BDL-induced liver fibrosis in mice and confirmed its critical functions on fibrosis by regulating NF-kappaB-TNF-alpha pathway in a PPARgamma-dependent manner. Rosiglitazone 46-59 peroxisome proliferator activated receptor gamma Mus musculus 206-215 31799666-12 2019 The PPARgamma agonist rosiglitazone also suppressed the malignant properties of FE1.2 cells. Rosiglitazone 22-35 peroxisome proliferator activated receptor gamma Mus musculus 4-13 31317231-5 2019 RESULTS: Combined treatment with the peroxisome proliferator-activated receptor gamma (PPARgamma) agonist rosiglitazone, the SMAD3 inhibitor SIS3 and the adrenergic receptor agonist noradrenaline (norepinephrine) synergistically induced Ucp1, Fgf21 and Cited1 expression, triggering brown adipogenesis. Rosiglitazone 106-119 peroxisome proliferator activated receptor gamma Mus musculus 87-96 31201956-12 2019 PPAR-gamma agonist rosiglitazone treatment reduced the morbidity of eyelid, as well as corneal pathological changes and MG inflammation in ApoE-/- mice. Rosiglitazone 19-32 peroxisome proliferator activated receptor gamma Mus musculus 0-10 31301768-7 2019 TRIM37 overexpression showed similar effects as thrombin on BV-2 cells, and PPARgamma agonist rosiglitazone abolished the effects of TRIM37. Rosiglitazone 94-107 peroxisome proliferator activated receptor gamma Mus musculus 76-85 30910747-6 2019 Neuronal seipin deletion increased activities of GSK3beta and Akt/mTOR signaling, which were corrected by the administration of PPARgamma agonist rosiglitazone for 7 days. Rosiglitazone 146-159 peroxisome proliferator activated receptor gamma Mus musculus 128-137 31315888-9 2019 Additional experiment showed that LPS, which activated NF-kappaB, suppressed rosiglitazone-induced activation of peroxisome proliferator-activated receptor-gamma (PPARgamma) in mice placentas and human placental trophoblasts. Rosiglitazone 77-90 peroxisome proliferator activated receptor gamma Mus musculus 113-161 31315888-9 2019 Additional experiment showed that LPS, which activated NF-kappaB, suppressed rosiglitazone-induced activation of peroxisome proliferator-activated receptor-gamma (PPARgamma) in mice placentas and human placental trophoblasts. Rosiglitazone 77-90 peroxisome proliferator activated receptor gamma Mus musculus 163-172 31263138-5 2019 Here we show that treatment with PPARgamma agonists (rosiglitazone or pioglitazone) in primary cultures of mouse glial cells reversed EcoHIV-induced inflammatory genes (TNFalpha, IL-1beta, CCL2, CCL3, CXCL10) and indicator of oxidative stress (iNOS). Rosiglitazone 53-66 peroxisome proliferator activated receptor gamma Mus musculus 33-42 31212694-0 2019 The PPARgamma Agonist Rosiglitazone Suppresses Syngeneic Mouse SCC (Squamous Cell Carcinoma) Tumor Growth through an Immune-Mediated Mechanism. Rosiglitazone 22-35 peroxisome proliferator activated receptor gamma Mus musculus 4-13 31212694-3 2019 At higher cell numbers (5 x 106 PDV cells), progressively growing tumors were established in 14 of 15 vehicle treated mice while treatment of mice with the PPARgamma agonist rosiglitazone resulted in increased tumor rejection (5 of 14 tumors), a significant decrease in PDV tumor size, and a significant decrease in tumor cell Ki67 labeling. Rosiglitazone 174-187 peroxisome proliferator activated receptor gamma Mus musculus 156-165 31212694-7 2019 Overall, our data provides evidence that the PPARgamma agonist rosiglitazone promotes immune-mediated anti-neoplastic activity against tumors derived from this immunogenic CSCC cell line. Rosiglitazone 63-76 peroxisome proliferator activated receptor gamma Mus musculus 45-54 30673982-2 2019 Rosiglitazone (RGZ) is a highly potent agonist of PPARgamma. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 50-59 30311190-0 2019 Rosiglitazone up-regulates glial fibrillary acidic protein via HB-EGF secreted from astrocytes and neurons through PPARgamma pathway and reduces apoptosis in high-fat diet-fed mice. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 115-124 30311190-1 2019 The anti-diabetic drug and peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist, rosiglitazone, alters astrocyte activation; however, its mechanism remains less-known. Rosiglitazone 97-110 peroxisome proliferator activated receptor gamma Mus musculus 27-75 30311190-1 2019 The anti-diabetic drug and peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist, rosiglitazone, alters astrocyte activation; however, its mechanism remains less-known. Rosiglitazone 97-110 peroxisome proliferator activated receptor gamma Mus musculus 77-86 30311190-7 2019 Probing whether these effects of rosiglitazone were PPARgamma-linked, revealed potential PPARgamma-responsive elements within HB-EGF gene. Rosiglitazone 33-46 peroxisome proliferator activated receptor gamma Mus musculus 52-61 30311190-7 2019 Probing whether these effects of rosiglitazone were PPARgamma-linked, revealed potential PPARgamma-responsive elements within HB-EGF gene. Rosiglitazone 33-46 peroxisome proliferator activated receptor gamma Mus musculus 89-98 30311190-11 2019 Overall, our study indicates that rosiglitazone may protect the brain, via a PPARgamma-dependent HB-EGF/EGFR signaling and increased GFAP. Rosiglitazone 34-47 peroxisome proliferator activated receptor gamma Mus musculus 77-86 31160894-0 2019 Rosiglitazone promotes ENaC-mediated alveolar fluid clearance in acute lung injury through the PPARgamma/SGK1 signaling pathway. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 95-104 31160894-3 2019 The peroxisome proliferator-activated receptor gamma (PPARgamma) agonist rosiglitazone was shown to stimulate ENaC-mediated salt absorption in the kidney. Rosiglitazone 73-86 peroxisome proliferator activated receptor gamma Mus musculus 4-52 31160894-3 2019 The peroxisome proliferator-activated receptor gamma (PPARgamma) agonist rosiglitazone was shown to stimulate ENaC-mediated salt absorption in the kidney. Rosiglitazone 73-86 peroxisome proliferator activated receptor gamma Mus musculus 54-63 31160894-15 2019 Rosiglitazone significantly ameliorated the lung injury, decreasing the TNF-alpha and IL-1beta levels in the BALF, enhancing AFC, and promoting the expressions of alphaENaC and SGK1 in ALI mice, which were abolished by the specific PPARgamma blocker GW9662. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 232-241 31160894-18 2019 Conclusions: Rosiglitazone ameliorated the lung injury and promoted ENaC-mediated AFC via a PPARgamma/SGK1-dependent signaling pathway, alleviating pulmonary edema in a mouse model of ALI. Rosiglitazone 13-26 peroxisome proliferator activated receptor gamma Mus musculus 92-101 31072366-12 2019 Sera from mice dosed with rosiglitazone induced PPRE transcriptional activity in the SPAA in a dose-dependent and PPARgamma-dependent manner. Rosiglitazone 26-39 peroxisome proliferator activated receptor gamma Mus musculus 114-123 30935639-12 2019 Rosiglitazone, a PPAR-gamma agonist, significantly inhibited lncR-30245-induced CTGF upregulation and collagen production in CFs. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 17-27 30710547-2 2019 To gain better understanding of mechanisms underlying this effect, the impact of rosiglitazone (RSG), a PPAR-gamma agonist, on CD4+ effector (Teff) and Foxp3-expressing regulatory (Treg) T cells in a mouse model of allergic asthma was studied. Rosiglitazone 81-94 peroxisome proliferator activated receptor gamma Mus musculus 104-114 30710547-5 2019 RSG reduced but did not abolish the OVA-induced increase in the count of CD4+ Teff cells in the mediastinal lymph nodes (MLNs) and lungs, and this effect was PPAR-gamma-dependent. Rosiglitazone 0-3 peroxisome proliferator activated receptor gamma Mus musculus 158-168 30511276-11 2019 Both pioglitazone and rosiglitazone increased beta-Gal and Ppargamma protein expression in mouse astrocytes in vitro, and this effect was reduced by the VGVAPG peptide. Rosiglitazone 22-35 peroxisome proliferator activated receptor gamma Mus musculus 59-68 30700583-9 2019 The PPAR-gamma agonist rosiglitazone elicited similar changes in macrophage cytokine production and neutrophil migration as exogenous AC. Rosiglitazone 23-36 peroxisome proliferator activated receptor gamma Mus musculus 4-14 30700583-13 2019 PPAR-gamma agonists, such as rosiglitazone, may therefore be effective treatments for inducing arthritis resolution. Rosiglitazone 29-42 peroxisome proliferator activated receptor gamma Mus musculus 0-10 30906248-6 2019 We show that increasing RGC but not glial Ucp2 expression in transgenic animals decreases glaucomatous RGC death, but also that the PPAR-gamma agonist rosiglitazone (RSG), an endogenous transcriptional activator of Ucp2, does not significantly alter RGC loss during glaucoma. Rosiglitazone 151-164 peroxisome proliferator activated receptor gamma Mus musculus 132-142 30930764-7 2019 To achieve our objective, 8-months old mice were left untreated or treated with the FDA-approved PPARgamma agonist, rosiglitazone then tested for context discrimination learning and memory, followed by immunofluorescence evaluation of hippocampal SGZ cell proliferation and neuron survival. Rosiglitazone 116-129 peroxisome proliferator activated receptor gamma Mus musculus 97-106 30930772-9 2019 1,8-Cineole and rosiglitazone blocked the LPS-induced IkappaBalpha degradation and NF-kappaB p65 nucleus translocation, which could be reversed by the pretreatment of GW9662 or silence of PPAR-gamma gene. Rosiglitazone 16-29 peroxisome proliferator activated receptor gamma Mus musculus 188-198 30906248-6 2019 We show that increasing RGC but not glial Ucp2 expression in transgenic animals decreases glaucomatous RGC death, but also that the PPAR-gamma agonist rosiglitazone (RSG), an endogenous transcriptional activator of Ucp2, does not significantly alter RGC loss during glaucoma. Rosiglitazone 166-169 peroxisome proliferator activated receptor gamma Mus musculus 132-142 30606762-0 2019 Endothelial Cell-Targeted Deletion of PPARgamma Blocks Rosiglitazone-Induced Plasma Volume Expansion and Vascular Remodeling in Adipose Tissue. Rosiglitazone 55-68 peroxisome proliferator activated receptor gamma Mus musculus 38-47 30606762-3 2019 Compared with Pparg-floxed wild-type control (Pparg f/f) mice, Pparg DeltaEC treated with rosiglitazone are resistant to an increase in extracellular fluid, water content in epididymal and inguinal white adipose tissue, and plasma volume expansion. Rosiglitazone 90-103 peroxisome proliferator activated receptor gamma Mus musculus 14-19 30606762-3 2019 Compared with Pparg-floxed wild-type control (Pparg f/f) mice, Pparg DeltaEC treated with rosiglitazone are resistant to an increase in extracellular fluid, water content in epididymal and inguinal white adipose tissue, and plasma volume expansion. Rosiglitazone 90-103 peroxisome proliferator activated receptor gamma Mus musculus 46-51 30606762-3 2019 Compared with Pparg-floxed wild-type control (Pparg f/f) mice, Pparg DeltaEC treated with rosiglitazone are resistant to an increase in extracellular fluid, water content in epididymal and inguinal white adipose tissue, and plasma volume expansion. Rosiglitazone 90-103 peroxisome proliferator activated receptor gamma Mus musculus 46-51 30606762-4 2019 Interestingly, histologic assessment confirmed significant rosiglitazone-mediated capillary dilation within white adipose tissue of Pparg f/f mice, but not Pparg DeltaEC mice. Rosiglitazone 59-72 peroxisome proliferator activated receptor gamma Mus musculus 132-137 30606762-7 2019 Together, these results indicate that rosiglitazone has direct effects on the endothelium via PPARgamma activation and point toward a critical role for PPARgamma in ECs during rosiglitazone-mediated plasma volume expansion. Rosiglitazone 38-51 peroxisome proliferator activated receptor gamma Mus musculus 94-103 30606762-7 2019 Together, these results indicate that rosiglitazone has direct effects on the endothelium via PPARgamma activation and point toward a critical role for PPARgamma in ECs during rosiglitazone-mediated plasma volume expansion. Rosiglitazone 176-189 peroxisome proliferator activated receptor gamma Mus musculus 152-161 30316815-5 2018 Rosiglitazone abolished the increase in serum BCAA induced by adipocyte PPARgamma deletion. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 72-81 30544130-0 2018 Peroxisome Proliferator Activated Receptor gamma (PPARgamma) Agonist Rosiglitazone Ameliorate Airway Inflammation by Inhibiting Toll-Like Receptor 2 (TLR2)/Nod-Like Receptor with Pyrin Domain Containing 3 (NLRP3) Inflammatory Corpuscle Activation in Asthmatic Mice. Rosiglitazone 69-82 peroxisome proliferator activated receptor gamma Mus musculus 0-48 30544130-0 2018 Peroxisome Proliferator Activated Receptor gamma (PPARgamma) Agonist Rosiglitazone Ameliorate Airway Inflammation by Inhibiting Toll-Like Receptor 2 (TLR2)/Nod-Like Receptor with Pyrin Domain Containing 3 (NLRP3) Inflammatory Corpuscle Activation in Asthmatic Mice. Rosiglitazone 69-82 peroxisome proliferator activated receptor gamma Mus musculus 50-59 30544130-9 2018 CONCLUSIONS PPARgamma rosiglitazone ameliorates airway inflammation by inhibiting NF-kappaB expression in asthmatic mice, and further inhibits the activation of TLR2/NLRP3 inflammatory corpuscles. Rosiglitazone 22-35 peroxisome proliferator activated receptor gamma Mus musculus 12-21 30627576-1 2018 Rosiglitazone (RG) is a well-known activator of peroxisome proliferator-activated receptor-gamma (PPARgamma) and used to treat hyperglycemia and type 2 diabetes; however, its clinical application has been confounded by adverse side effects. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 48-96 30627576-1 2018 Rosiglitazone (RG) is a well-known activator of peroxisome proliferator-activated receptor-gamma (PPARgamma) and used to treat hyperglycemia and type 2 diabetes; however, its clinical application has been confounded by adverse side effects. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 98-107 30193945-10 2018 TET2 gain-of-function was sufficient to promote insulin sensitivity while loss-of-function was necessary to facilitate insulin sensitization in response to the PPARgamma agonist Rosiglitazone (Rosi) in cultured adipocytes. Rosiglitazone 178-191 peroxisome proliferator activated receptor gamma Mus musculus 160-169 30193945-10 2018 TET2 gain-of-function was sufficient to promote insulin sensitivity while loss-of-function was necessary to facilitate insulin sensitization in response to the PPARgamma agonist Rosiglitazone (Rosi) in cultured adipocytes. Rosiglitazone 178-182 peroxisome proliferator activated receptor gamma Mus musculus 160-169 30193945-12 2018 Furthermore, TET2 was necessary to sustain PPARgamma binding to target loci upon activation with Rosi via physical interaction with PPARgamma. Rosiglitazone 97-101 peroxisome proliferator activated receptor gamma Mus musculus 43-52 30193945-12 2018 Furthermore, TET2 was necessary to sustain PPARgamma binding to target loci upon activation with Rosi via physical interaction with PPARgamma. Rosiglitazone 97-101 peroxisome proliferator activated receptor gamma Mus musculus 132-141 30154104-8 2018 Furthermore, Ppar-gamma activation (by a selective agonist, rosiglitazone) upregulated Cyp2a5 expression in Hepa-1c1c7 cells, whereas Ppar-gamma knockdown downregulated Cyp2a5 expression. Rosiglitazone 60-73 peroxisome proliferator activated receptor gamma Mus musculus 13-23 29891333-5 2018 Three days before DSS treatment, mice were treated with the PPARgamma agonist rosiglitazone (Ro) orally at 20 mg kg-1 day-1. Rosiglitazone 78-91 peroxisome proliferator activated receptor gamma Mus musculus 60-69 30137026-7 2018 Pharmacologic intervention by either apoptosis inhibitor or PPARgamma agonist rosiglitazone prevented smoking-induced crypt apoptosis and Paneth cell defects in T300A mice and mice with conditional Paneth cell-specific knockout of Atg16l1. Rosiglitazone 78-91 peroxisome proliferator activated receptor gamma Mus musculus 60-69 30348686-9 2018 GGOH also enhanced adipogenesis induced by rosiglitazone, a thiazolidinedione class PPARgamma agonist. Rosiglitazone 43-56 peroxisome proliferator activated receptor gamma Mus musculus 84-93 30143592-11 2018 Conversely, PPARgamma activation with rosiglitazone selectively suppressed IFN-beta expression in activated macrophages. Rosiglitazone 38-51 peroxisome proliferator activated receptor gamma Mus musculus 12-21 30333041-2 2018 Rosiglitazone (RSG) is a member of the thiazolidinedione family and is a peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 73-121 30333041-2 2018 Rosiglitazone (RSG) is a member of the thiazolidinedione family and is a peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 123-132 30333041-2 2018 Rosiglitazone (RSG) is a member of the thiazolidinedione family and is a peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist. Rosiglitazone 15-18 peroxisome proliferator activated receptor gamma Mus musculus 73-121 30333041-2 2018 Rosiglitazone (RSG) is a member of the thiazolidinedione family and is a peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist. Rosiglitazone 15-18 peroxisome proliferator activated receptor gamma Mus musculus 123-132 30333041-15 2018 These findings provide insights into the cytoprotective effects of RSG on Sertoli cells and suggest that PPARgamma activation may be a useful therapeutic method for the treatment of Sertoli cell dysfunction caused by dyslipidemia. Rosiglitazone 67-70 peroxisome proliferator activated receptor gamma Mus musculus 105-114 29649924-9 2018 Rosiglitazone-induced PPAR-gamma activation promoted microglia polarization to the M2 phenotype, which reduced the inflammatory response, attenuated axonal injury in the cerebral cortex, and improved neurological function. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 22-32 29908181-5 2018 Based on these observations we hypothesized that activation of PPARgamma via administration of the PPARgamma-specific ligand rosiglitazone would limit MWCNT-induced granuloma formation and promote PPARgamma-dependent pathways. Rosiglitazone 125-138 peroxisome proliferator activated receptor gamma Mus musculus 99-108 29908181-5 2018 Based on these observations we hypothesized that activation of PPARgamma via administration of the PPARgamma-specific ligand rosiglitazone would limit MWCNT-induced granuloma formation and promote PPARgamma-dependent pathways. Rosiglitazone 125-138 peroxisome proliferator activated receptor gamma Mus musculus 63-72 29908181-5 2018 Based on these observations we hypothesized that activation of PPARgamma via administration of the PPARgamma-specific ligand rosiglitazone would limit MWCNT-induced granuloma formation and promote PPARgamma-dependent pathways. Rosiglitazone 125-138 peroxisome proliferator activated receptor gamma Mus musculus 99-108 29908181-8 2018 PPARgamma activation via rosiglitazone also prevents the MWCNT-induced deficiency of PPARgamma-regulated ATP-binding cassette lipid transporter-G1 (ABCG1) expression. Rosiglitazone 25-38 peroxisome proliferator activated receptor gamma Mus musculus 0-9 29908181-8 2018 PPARgamma activation via rosiglitazone also prevents the MWCNT-induced deficiency of PPARgamma-regulated ATP-binding cassette lipid transporter-G1 (ABCG1) expression. Rosiglitazone 25-38 peroxisome proliferator activated receptor gamma Mus musculus 85-94 29791764-8 2018 Therefore, combination of the PPARgamma agonist rosiglitazone with radiotherapy enhances the effectiveness of radiotherapy to improve local tumor control, decrease distant metastasis risks and delay tumor recurrence. Rosiglitazone 48-61 peroxisome proliferator activated receptor gamma Mus musculus 30-39 29993312-7 2018 Induction of resolving macrophages with rosiglitazone, a PPAR-gamma agonist, led to reduced bone resorption during inflammatory stimulation and increased bone formation during healing. Rosiglitazone 40-53 peroxisome proliferator activated receptor gamma Mus musculus 57-67 30066924-0 2018 PPARgamma agonist rosiglitazone alters the temporal and spatial distribution of inflammation during abdominal aortic aneurysm formation. Rosiglitazone 18-31 peroxisome proliferator activated receptor gamma Mus musculus 0-9 30463649-1 2018 Objective To evaluate the therapeutic effect and possible mechanism of PPARgamma agonist rosiglitazone on 2, 4, 6-trinitrobenzenesulfonic acid (TNBS)-induced colitis in mice. Rosiglitazone 89-102 peroxisome proliferator activated receptor gamma Mus musculus 71-80 29740932-2 2018 There is growing evidence that the peroxisome proliferator-activated receptor gamma (PPARgamma) agonist rosiglitazone prevents lipopolysaccharide (LPS)-induced microglial activation. Rosiglitazone 104-117 peroxisome proliferator activated receptor gamma Mus musculus 35-83 29740932-2 2018 There is growing evidence that the peroxisome proliferator-activated receptor gamma (PPARgamma) agonist rosiglitazone prevents lipopolysaccharide (LPS)-induced microglial activation. Rosiglitazone 104-117 peroxisome proliferator activated receptor gamma Mus musculus 85-94 29849538-1 2018 Although therapeutic effects of the peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonists rosiglitazone and pioglitazone against Cushing"s disease have been reported, their effects are still controversial and inconsistent. Rosiglitazone 107-120 peroxisome proliferator activated receptor gamma Mus musculus 36-84 30320193-1 2018 Traditional thiazolidinediones (TZDs), such as rosiglitazone, are peroxisome proliferator-activated receptor gamma (PPARgamma) potent agonists that can be used to treat type 2 diabetes but carry unwanted effects, including increased risk for fracture. Rosiglitazone 47-60 peroxisome proliferator activated receptor gamma Mus musculus 66-114 30320193-1 2018 Traditional thiazolidinediones (TZDs), such as rosiglitazone, are peroxisome proliferator-activated receptor gamma (PPARgamma) potent agonists that can be used to treat type 2 diabetes but carry unwanted effects, including increased risk for fracture. Rosiglitazone 47-60 peroxisome proliferator activated receptor gamma Mus musculus 116-125 30320193-3 2018 A TR-FRET PPARgamma competitive binding assay was used to compare the binding affinity between CMHX008 and rosiglitazone. Rosiglitazone 107-120 peroxisome proliferator activated receptor gamma Mus musculus 10-19 30320193-7 2018 Mice treated with CMHX008 showed insulin sensitization similar to that of mice treated with rosiglitazone, which was related to the significant inhibition of PPARgamma Ser273 phosphorylation and improved insulin sensitivity by facilitating the phosphorylation of insulin receptor and Akt in adipose tissues. Rosiglitazone 92-105 peroxisome proliferator activated receptor gamma Mus musculus 158-167 29910772-5 2018 Adipocytes from inguinal WAT display maximal UCP1 expression and mitochondrial uncoupling only when treated with a combination of the PPARgamma activator rosiglitazone and a beta3-adrenoceptor agonist. Rosiglitazone 154-167 peroxisome proliferator activated receptor gamma Mus musculus 134-143 29670081-9 2018 In seipin-nKO mice, the phosphorylation of GSK3beta was increased at Tyr216 and was reduced at Ser9, which was corrected by the PPARgamma agonist rosiglitazone. Rosiglitazone 146-159 peroxisome proliferator activated receptor gamma Mus musculus 128-137 29849538-1 2018 Although therapeutic effects of the peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonists rosiglitazone and pioglitazone against Cushing"s disease have been reported, their effects are still controversial and inconsistent. Rosiglitazone 107-120 peroxisome proliferator activated receptor gamma Mus musculus 86-96 29414316-0 2018 PPARgamma agonist rosiglitazone switches fuel preference to lipids in promoting thermogenesis under cold exposure in C57BL/6 mice. Rosiglitazone 18-31 peroxisome proliferator activated receptor gamma Mus musculus 0-9 29434029-6 2018 In agreement, defects in myelination of FASN-deficient SCs could be ameliorated by treatment with the PPARgamma agonist rosiglitazone ex vivo and in vivo. Rosiglitazone 120-133 peroxisome proliferator activated receptor gamma Mus musculus 102-111 29414316-9 2018 SIGNIFICANCE: In current study, for the first time, PPARgamma agonism by rosiglitazone was proved to promote thermogenesis under near-freezing conditions and enhance the heat generating response against cold-induced hypothermia in mice by switching the fuel preference from carbohydrates to lipids. Rosiglitazone 73-86 peroxisome proliferator activated receptor gamma Mus musculus 52-61 29197521-4 2018 Pretreatment with PPARgamma agonist rosiglitazone significantly reversed high phosphate-induced VSMCs calcification. Rosiglitazone 36-49 peroxisome proliferator activated receptor gamma Mus musculus 18-27 29344670-4 2018 To investigate this hypothesis, db/db diabetic mice were used to establish a DKD model and the PPARgamma agonist rosiglitazone was employed to induce PGC-1alpha expression in vivo. Rosiglitazone 113-126 peroxisome proliferator activated receptor gamma Mus musculus 95-104 29396370-7 2018 Adipogenesis was induced using the Ppar-gamma agonist rosiglitazone, a thiazolidinedione (TZD). Rosiglitazone 54-67 peroxisome proliferator activated receptor gamma Mus musculus 35-45 28871412-4 2018 Blockade of RAGE with its antibody and inhibition of NF-kappaB signaling with PDTC as well as activation of PPARgamma with rosiglitazone significantly decreased Abeta transport across the BBB from the periphery to the brain. Rosiglitazone 123-136 peroxisome proliferator activated receptor gamma Mus musculus 108-117 29721374-4 2018 Treatment of mutant KRASG12V mice with the PPARgamma-agonist rosiglitazone augmented M1 macrophage numbers, reduced IL4 expression and diminished polyp load in mice. Rosiglitazone 61-74 peroxisome proliferator activated receptor gamma Mus musculus 43-52 29338785-16 2018 Functional assays further showed that T0070907 almost abolished PPARgamma transcriptional activity induced by rosiglitazone (RGZ), but it did not affect the activity of VCE-003.2 in a Gal4-Luc system. Rosiglitazone 110-123 peroxisome proliferator activated receptor gamma Mus musculus 64-73 29127035-9 2018 In contrast, rosiglitazone, a known PPARgamma agonist, induced TG accumulation in a PPARgamma-dependent manner and enhanced mitochondrial function. Rosiglitazone 13-26 peroxisome proliferator activated receptor gamma Mus musculus 36-45 29127035-9 2018 In contrast, rosiglitazone, a known PPARgamma agonist, induced TG accumulation in a PPARgamma-dependent manner and enhanced mitochondrial function. Rosiglitazone 13-26 peroxisome proliferator activated receptor gamma Mus musculus 84-93 29222348-10 2018 PPARgamma activator rosiglitazone (RSZ) or AMPK activator AICAR increased the expression level of IDE and decreased Abeta levels in mice with AD and T2D. Rosiglitazone 20-33 peroxisome proliferator activated receptor gamma Mus musculus 0-9 29222348-10 2018 PPARgamma activator rosiglitazone (RSZ) or AMPK activator AICAR increased the expression level of IDE and decreased Abeta levels in mice with AD and T2D. Rosiglitazone 35-38 peroxisome proliferator activated receptor gamma Mus musculus 0-9 28970184-0 2018 The PPARgamma agonist rosiglitazone promotes the induction of brite adipocytes, increasing beta-adrenoceptor-mediated mitochondrial function and glucose uptake. Rosiglitazone 22-35 peroxisome proliferator activated receptor gamma Mus musculus 4-13 28970184-9 2018 In conclusion, the PPARgamma agonist rosiglitazone promotes the induction and function of brite adipocytes cultured from inguinal and epididymal white adipose depots. Rosiglitazone 37-50 peroxisome proliferator activated receptor gamma Mus musculus 19-28 28083810-7 2017 The similarity in gene expression and functional changes in response to MEHP and rosiglitazone suggested that MEHP influenced bioenergetics and adipokine network mainly via PPARgamma. Rosiglitazone 81-94 peroxisome proliferator activated receptor gamma Mus musculus 173-182 28322133-3 2017 The PPARgamma has proven anti-inflammatory functions and its activation via rosiglitazone significantly downregulated the systemic inflammatory response and reduced PTB and stillbirth rate by 30% and 41%, respectively, in our model. Rosiglitazone 76-89 peroxisome proliferator activated receptor gamma Mus musculus 4-13 28973641-9 2017 Similar to PPARgamma overexpression, rosiglitazone (a PPARgamma agonist) alleviated the effects of PFOS on the EMT-related features, whereas GW9662 (a PPARgamma antagonist) mimicked the effects. Rosiglitazone 37-50 peroxisome proliferator activated receptor gamma Mus musculus 54-63 28973641-9 2017 Similar to PPARgamma overexpression, rosiglitazone (a PPARgamma agonist) alleviated the effects of PFOS on the EMT-related features, whereas GW9662 (a PPARgamma antagonist) mimicked the effects. Rosiglitazone 37-50 peroxisome proliferator activated receptor gamma Mus musculus 54-63 29165364-9 2017 ROS-like effects of 1 in 3T3-L1 cells were suppressed by the addition of bisphenol A diglycidyl ether (BADGE), one of a peroxisome proliferator-activated receptor gamma (PPARgamma) antagonists, suggesting that the action of 1 on adipocytes is mediated by PPARgamma. Rosiglitazone 0-3 peroxisome proliferator activated receptor gamma Mus musculus 120-168 29165364-9 2017 ROS-like effects of 1 in 3T3-L1 cells were suppressed by the addition of bisphenol A diglycidyl ether (BADGE), one of a peroxisome proliferator-activated receptor gamma (PPARgamma) antagonists, suggesting that the action of 1 on adipocytes is mediated by PPARgamma. Rosiglitazone 0-3 peroxisome proliferator activated receptor gamma Mus musculus 170-179 29165364-9 2017 ROS-like effects of 1 in 3T3-L1 cells were suppressed by the addition of bisphenol A diglycidyl ether (BADGE), one of a peroxisome proliferator-activated receptor gamma (PPARgamma) antagonists, suggesting that the action of 1 on adipocytes is mediated by PPARgamma. Rosiglitazone 0-3 peroxisome proliferator activated receptor gamma Mus musculus 255-264 29404511-7 2018 Chromatin immunoprecipitation analysis demonstrated binding of peroxisome proliferator-activated receptor gamma to Ceacam1 promoter in response to rosiglitazone and exenatide. Rosiglitazone 147-160 peroxisome proliferator activated receptor gamma Mus musculus 63-111 28868898-6 2017 p16INK4a-deficient mice developed more epicardial adipose tissue in response to the adipogenic peroxisome proliferator activated receptor gamma agonist rosiglitazone. Rosiglitazone 152-165 peroxisome proliferator activated receptor gamma Mus musculus 95-143 28973666-7 2017 Activation of PPARgamma by administration of rosiglitazone recovered the decrease in Akt phosphorylation, but not GLUT4 expression. Rosiglitazone 45-58 peroxisome proliferator activated receptor gamma Mus musculus 14-23 29073887-3 2017 Secondly, osteogenic abilities of MMSCs and SMMSCs treated with rosiglitazone (a PPARgamma2 agonist) to induce osteogenic changes were observed, and negative correlation of PPARgamma2 with OGN was evaluated. Rosiglitazone 64-77 peroxisome proliferator activated receptor gamma Mus musculus 81-91 29228682-10 2017 In addition, the PPARgamma agonist rosiglitazone reversed UVB-induced systemic immunosuppression (UV-IS) as well as UV-induced growth of B16F10 melanoma tumor cells in syngeneic mice. Rosiglitazone 35-48 peroxisome proliferator activated receptor gamma Mus musculus 17-26 28959186-8 2017 Rosiglitazone"s autophagy promotion and neuroprotective effects were found to be reversed by the PPARgamma antagonist T0070907 in primary neurons and by PPARgamma knockdown in an N2a cell line. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 97-106 28959186-8 2017 Rosiglitazone"s autophagy promotion and neuroprotective effects were found to be reversed by the PPARgamma antagonist T0070907 in primary neurons and by PPARgamma knockdown in an N2a cell line. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 153-162 28651330-4 2017 Because thiazolidinediones such as rosiglitazone (Rosi) are used clinically to improve insulin sensitivity by activating PPARgamma, with particular efficacy in subcutaneous white adipose tissue, we hypothesized that Rosi would improve glucose metabolism in mice losing weight with 10,12 CLA. Rosiglitazone 35-48 peroxisome proliferator activated receptor gamma Mus musculus 121-130 28651330-4 2017 Because thiazolidinediones such as rosiglitazone (Rosi) are used clinically to improve insulin sensitivity by activating PPARgamma, with particular efficacy in subcutaneous white adipose tissue, we hypothesized that Rosi would improve glucose metabolism in mice losing weight with 10,12 CLA. Rosiglitazone 50-54 peroxisome proliferator activated receptor gamma Mus musculus 121-130 28651330-4 2017 Because thiazolidinediones such as rosiglitazone (Rosi) are used clinically to improve insulin sensitivity by activating PPARgamma, with particular efficacy in subcutaneous white adipose tissue, we hypothesized that Rosi would improve glucose metabolism in mice losing weight with 10,12 CLA. Rosiglitazone 216-220 peroxisome proliferator activated receptor gamma Mus musculus 121-130 28597936-6 2017 Rosiglitazone and pioglitazone are thiazolidinedione (TZD) compounds that have been used clinically as insulin-sensitizing drugs and are generally believed to mediate their effects via activation of the peroxisome proliferator-activated receptor gamma (PPARgamma). Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 203-251 28597936-6 2017 Rosiglitazone and pioglitazone are thiazolidinedione (TZD) compounds that have been used clinically as insulin-sensitizing drugs and are generally believed to mediate their effects via activation of the peroxisome proliferator-activated receptor gamma (PPARgamma). Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 253-262 28240605-1 2017 Obesity causes insulin resistance, and PPARgamma ligands such as rosiglitazone are insulin sensitizing, yet the mechanisms remain unclear. Rosiglitazone 65-78 peroxisome proliferator activated receptor gamma Mus musculus 39-48 27956741-7 2017 Rosiglitazone, a blood-brain barrier-impermeant PPARgamma-selective agonist, elicited antidepressant- and anxiolytic-like behavioral effects in wild-type mice, with a concurrent increase in plasma adiponectin levels. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 48-57 27956741-8 2017 These effects of rosiglitazone were absent in mice lacking adiponectin but having normal PPARgamma expression in adipose tissue and brain. Rosiglitazone 17-30 peroxisome proliferator activated receptor gamma Mus musculus 89-98 27956741-9 2017 Moreover, pretreatment with the PPARgamma-selective antagonist GW9662 blocked rosiglitazone-induced adiponectin expression and antidepressant/anxiolytic-like effects. Rosiglitazone 78-91 peroxisome proliferator activated receptor gamma Mus musculus 32-41 27956741-10 2017 Together, these results suggest that the behavioral responses to rosiglitazone are mediated through PPARgamma-dependent induction of adiponectin. Rosiglitazone 65-78 peroxisome proliferator activated receptor gamma Mus musculus 100-109 28481288-1 2017 It is well-documented that CL316,243 (a beta3 agonist) or rosiglitazone (a PPARgamma agonist) can induce white adipocyte populations to brown-like adipocytes, thus increasing energy consumption and combating obesity. Rosiglitazone 58-71 peroxisome proliferator activated receptor gamma Mus musculus 75-84 28330868-9 2017 Supplementing with PPARgamma agonists rosiglitazone and GW1929 was sufficient to restore M2 differentiation in vivo and in vitro and abrogated the difference in survival between wild-type and PRMT1 knock-out mice. Rosiglitazone 38-51 peroxisome proliferator activated receptor gamma Mus musculus 19-28 27807703-9 2017 PPARgamma activation by rosiglitazone rescued LXRalpha and ABCG1 expression and reduced TLR4-induced inflammation and lipid accumulation. Rosiglitazone 24-37 peroxisome proliferator activated receptor gamma Mus musculus 0-9 28536637-14 2017 This work demonstrates that compared to the 3T3-L1 cell line, fetal ovine preadipocytes require a longer exposure to the differentiation cocktail, and the need for IMBX, dexamethasone, and/or the PPARgamma agonist rosiglitazone through the terminal differentiation phase. Rosiglitazone 214-227 peroxisome proliferator activated receptor gamma Mus musculus 196-205 28352663-5 2017 RNA sequencing revealed that RBP7 was required to mediate induction of a subset of PPARgamma target genes by rosiglitazone in the endothelium including adiponectin. Rosiglitazone 109-122 peroxisome proliferator activated receptor gamma Mus musculus 83-92 28017862-9 2017 Addition of PPARgamma agonist rosiglitazone and peroxisome-related lipid species to Pex16-silenced 3T3-L1 cells rescued adipogenesis. Rosiglitazone 30-43 peroxisome proliferator activated receptor gamma Mus musculus 12-21 28344789-1 2017 OBJECTIVE: Because of its anti-inflammatory, anti-fibrotic, anti-apoptotic and anti-neoplastic properties, the PPAR-gamma agonist rosiglitazone is an interesting drug for investigating for use in the prevention and treatment of radiation-induced intestinal damage. Rosiglitazone 130-143 peroxisome proliferator activated receptor gamma Mus musculus 111-121 28095325-8 2017 Rosiglitazone (Ros) treatment, which is an agonist of NR1C3, caused an opposite effect on liver-to-body weight ratio. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 54-59 28095325-8 2017 Rosiglitazone (Ros) treatment, which is an agonist of NR1C3, caused an opposite effect on liver-to-body weight ratio. Rosiglitazone 0-3 peroxisome proliferator activated receptor gamma Mus musculus 54-59 28107868-0 2017 Effect of PPARgamma agonist (rosiglitazone) on the secretion of Th2 cytokine in asthma mice. Rosiglitazone 29-42 peroxisome proliferator activated receptor gamma Mus musculus 10-19 28056085-12 2017 Treatment with rosiglitazone, PPARgamma-agonist, enhanced CRH (P < 0.05) in both Tie2-sEH Tr and wild type (WT) mice. Rosiglitazone 15-28 peroxisome proliferator activated receptor gamma Mus musculus 30-39 27866976-2 2017 The aim of the present study was to investigate the effects of rosiglitazone (RSG), a synthetic PPAR-gamma agonist, on acetaminophen (APAP)-induced acute liver injury. Rosiglitazone 63-76 peroxisome proliferator activated receptor gamma Mus musculus 96-106 27866976-2 2017 The aim of the present study was to investigate the effects of rosiglitazone (RSG), a synthetic PPAR-gamma agonist, on acetaminophen (APAP)-induced acute liver injury. Rosiglitazone 78-81 peroxisome proliferator activated receptor gamma Mus musculus 96-106 27612006-10 2017 In SS mouse lung or in hemin-treated HPAECs, activation of PPARgamma with RSG attenuated reductions in PPARgamma and increases in miR-27a, ET-1, and markers of endothelial dysfunction. Rosiglitazone 74-77 peroxisome proliferator activated receptor gamma Mus musculus 59-68 27612006-10 2017 In SS mouse lung or in hemin-treated HPAECs, activation of PPARgamma with RSG attenuated reductions in PPARgamma and increases in miR-27a, ET-1, and markers of endothelial dysfunction. Rosiglitazone 74-77 peroxisome proliferator activated receptor gamma Mus musculus 103-112 28566629-6 2017 We further show that treatment with an agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) (rosiglitazone) at an early stage of differentiation increases the percentage of Oil red O-stained cells in TSOD-MEFs differentiated into adipocytes. Rosiglitazone 112-125 peroxisome proliferator activated receptor gamma Mus musculus 50-98 28566629-6 2017 We further show that treatment with an agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) (rosiglitazone) at an early stage of differentiation increases the percentage of Oil red O-stained cells in TSOD-MEFs differentiated into adipocytes. Rosiglitazone 112-125 peroxisome proliferator activated receptor gamma Mus musculus 100-109 29181403-7 2017 The PPARgamma agonist, rosiglitazone (ROSI), promoted apoptosis and inhibited cell proliferation. Rosiglitazone 23-36 peroxisome proliferator activated receptor gamma Mus musculus 4-13 29181403-7 2017 The PPARgamma agonist, rosiglitazone (ROSI), promoted apoptosis and inhibited cell proliferation. Rosiglitazone 38-42 peroxisome proliferator activated receptor gamma Mus musculus 4-13 28107868-1 2017 OBJECTIVE: To explore the effect of PPARgamma agonist (rosiglitazone) on the secretion of Th2 cytokines and the proportion of immune cell subsets in asthma mice. Rosiglitazone 55-68 peroxisome proliferator activated receptor gamma Mus musculus 36-45 27810934-14 2016 PPARgamma agonists such as rosiglitazone and pioglitazone are in clinical use for the treatment of insulin resistance. Rosiglitazone 27-40 peroxisome proliferator activated receptor gamma Mus musculus 0-9 28024724-1 2017 BACKGROUND: Due to its anti-inflammatory, antifibrotic and antineoplastic properties, the PPAR gamma agonist rosiglitazone is of interest in prevention and therapy of radiation-induced toxicities. Rosiglitazone 109-122 peroxisome proliferator activated receptor gamma Mus musculus 90-100 27992530-7 2016 Consistently, the PPAR-gamma agonist rosiglitazone suppressed cytokine-induced CXCL2 release from mature adipocytes, but not from early 3T3-L1 adipocyte stages. Rosiglitazone 37-50 peroxisome proliferator activated receptor gamma Mus musculus 18-28 27992530-8 2016 The inhibitory effect of PPAR-gamma activation on CXCL2 release appeared to be a general anti-inflammatory effect in mature adipocytes, as cytokine-induced cyclooxygenase (Cox)-2 was simultaneously repressed by rosiglitazone. Rosiglitazone 211-224 peroxisome proliferator activated receptor gamma Mus musculus 25-35 27734035-3 2016 The selective PPARgamma agonist rosiglitazone (RSG) has been used to treat diabetes. Rosiglitazone 32-45 peroxisome proliferator activated receptor gamma Mus musculus 14-23 27780754-6 2016 Rosiglitazone (RGZ), a strong PPARgamma agonist, synergistically promoted PPARgamma dephosphorylation and adipogenesis in lipin-1-overexpressing 3T3-L1 preadipocytes. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 30-39 27780754-6 2016 Rosiglitazone (RGZ), a strong PPARgamma agonist, synergistically promoted PPARgamma dephosphorylation and adipogenesis in lipin-1-overexpressing 3T3-L1 preadipocytes. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 74-83 27884413-8 2016 The effects of d-delta-tocotrienol on intracellular triglyceride content and glucose uptake were attenuated by rosiglitazone, an agonist of PPARgamma, but not supplemental mevalonate (100 mumol/L). Rosiglitazone 111-124 peroxisome proliferator activated receptor gamma Mus musculus 140-149 27771463-4 2016 Activation of PPARgamma by rosiglitazone, a specific ligand of PPARgamma, rescues LPS-induced destabilization of SIRT1, with a concomitant decrease in phosphorylation of residue Ser-46, which is targeted by JNK-1 to promote proteasome-mediated degradation of SIRT1. Rosiglitazone 27-40 peroxisome proliferator activated receptor gamma Mus musculus 14-23 27771463-4 2016 Activation of PPARgamma by rosiglitazone, a specific ligand of PPARgamma, rescues LPS-induced destabilization of SIRT1, with a concomitant decrease in phosphorylation of residue Ser-46, which is targeted by JNK-1 to promote proteasome-mediated degradation of SIRT1. Rosiglitazone 27-40 peroxisome proliferator activated receptor gamma Mus musculus 63-72 27783989-10 2016 Finally, similar to CT26 supernatant stimulation, peroxisome proliferator-activated receptor-gamma (PPARgamma) activation by rosiglitazone induced M2 polarization of RAW264.7 macrophages through MFHAS1-dependent pathway. Rosiglitazone 125-138 peroxisome proliferator activated receptor gamma Mus musculus 50-98 27783989-10 2016 Finally, similar to CT26 supernatant stimulation, peroxisome proliferator-activated receptor-gamma (PPARgamma) activation by rosiglitazone induced M2 polarization of RAW264.7 macrophages through MFHAS1-dependent pathway. Rosiglitazone 125-138 peroxisome proliferator activated receptor gamma Mus musculus 100-109 27687725-0 2016 Protein Phosphatase PP5 Controls Bone Mass and the Negative Effects of Rosiglitazone on Bone through Reciprocal Regulation of PPARgamma (Peroxisome Proliferator-activated Receptor gamma) and RUNX2 (Runt-related Transcription Factor 2). Rosiglitazone 71-84 peroxisome proliferator activated receptor gamma Mus musculus 126-135 27687725-0 2016 Protein Phosphatase PP5 Controls Bone Mass and the Negative Effects of Rosiglitazone on Bone through Reciprocal Regulation of PPARgamma (Peroxisome Proliferator-activated Receptor gamma) and RUNX2 (Runt-related Transcription Factor 2). Rosiglitazone 71-84 peroxisome proliferator activated receptor gamma Mus musculus 137-185 27687725-8 2016 In the presence of rosiglitazone, PP5 translocates to the nucleus, binds to PPARgamma and RUNX2, and dephosphorylates both factors, resulting in activation of PPARgamma adipocytic and suppression of RUNX2 osteoblastic activities. Rosiglitazone 19-32 peroxisome proliferator activated receptor gamma Mus musculus 76-85 27687725-8 2016 In the presence of rosiglitazone, PP5 translocates to the nucleus, binds to PPARgamma and RUNX2, and dephosphorylates both factors, resulting in activation of PPARgamma adipocytic and suppression of RUNX2 osteoblastic activities. Rosiglitazone 19-32 peroxisome proliferator activated receptor gamma Mus musculus 159-168 27877129-10 2016 Furthermore, curcumin and rosiglitazone upregulated PPAR-gamma and downregulated PDGFR-beta expression in mouse lung fibroblasts. Rosiglitazone 26-39 peroxisome proliferator activated receptor gamma Mus musculus 52-62 27752121-6 2016 The ligand-binding domain (LBD) of PPARgamma was responsible for this interaction, which was followed by repression of PPARgamma-induced transcriptional activity, even in the presence of rosiglitazone. Rosiglitazone 187-200 peroxisome proliferator activated receptor gamma Mus musculus 35-44 27752121-6 2016 The ligand-binding domain (LBD) of PPARgamma was responsible for this interaction, which was followed by repression of PPARgamma-induced transcriptional activity, even in the presence of rosiglitazone. Rosiglitazone 187-200 peroxisome proliferator activated receptor gamma Mus musculus 119-128 27373852-6 2016 Pre-stimulation of cells with rosiglitazone or adenovirus carrying PPAR-gamma cDNA (AdPPAR-gamma) blocked PDGF-AA-stimulated cell proliferation, this effect was particularly coupled to PPAR-gamma inhibition of AKT phosphorylation and skp2 expression. Rosiglitazone 30-43 peroxisome proliferator activated receptor gamma Mus musculus 86-96 27734035-3 2016 The selective PPARgamma agonist rosiglitazone (RSG) has been used to treat diabetes. Rosiglitazone 47-50 peroxisome proliferator activated receptor gamma Mus musculus 14-23 27734035-6 2016 RSG stimulates cardiac hypertrophy and oxidative stress in cardiomyocyte-specific PPARgamma knockout mice, implying that RSG might stimulate cardiac hypertrophy independently of cardiomyocyte PPARgamma. Rosiglitazone 0-3 peroxisome proliferator activated receptor gamma Mus musculus 82-91 27734035-11 2016 In vivo, specific ablation of PPARgamma in adipocytes was sufficient to blunt hypertrophy induced by RSG treatment. Rosiglitazone 101-104 peroxisome proliferator activated receptor gamma Mus musculus 30-39 27602490-6 2016 Activation of PPAR-gamma by its agonists of rosiglitazone and 15d-PGJ2 or genetic overexpression of PPAR-gamma prevented the loss of the epithelial phenotype induced by TGF-beta1 in line with the inhibition of oxidative stress. Rosiglitazone 44-57 peroxisome proliferator activated receptor gamma Mus musculus 14-24 27638207-6 2016 This complex phenotype triggered by HF diet at the interface between the microbiota and the mucosal surface was reversed when the diet was switched back to standard composition or when mice were treated for 1 wk with rosiglitazone, a specific agonist of peroxisome proliferator-activated receptor-gamma (PPAR-gamma). Rosiglitazone 217-230 peroxisome proliferator activated receptor gamma Mus musculus 254-302 27638207-6 2016 This complex phenotype triggered by HF diet at the interface between the microbiota and the mucosal surface was reversed when the diet was switched back to standard composition or when mice were treated for 1 wk with rosiglitazone, a specific agonist of peroxisome proliferator-activated receptor-gamma (PPAR-gamma). Rosiglitazone 217-230 peroxisome proliferator activated receptor gamma Mus musculus 304-314 27692066-4 2016 Here we report that macrophage PPARgamma deletion in mice not only exacerbates mammary tumor development but also impairs the anti-tumor effects of rosiglitazone. Rosiglitazone 148-161 peroxisome proliferator activated receptor gamma Mus musculus 31-40 27442117-0 2016 FKBP51 Null Mice Are Resistant to Diet-Induced Obesity and the PPARgamma Agonist Rosiglitazone. Rosiglitazone 81-94 peroxisome proliferator activated receptor gamma Mus musculus 63-72 27273607-13 2016 Co-treatment of cells with the selective PPARgamma antagonist GW9662 inhibits BPS-, BPA-, ROSI- but not dexamethasone-dependent adipogenic differentiation. Rosiglitazone 90-94 peroxisome proliferator activated receptor gamma Mus musculus 41-50 27531629-8 2016 Addition of rosiglitazone (10-50 muM) significantly increased lipid production (P<.05) in meibocytes, associated with SUMO1 sumoylation and cytoplasmic accumulation of the 72 kDa PPARgamma. Rosiglitazone 12-25 peroxisome proliferator activated receptor gamma Mus musculus 182-191 27531629-9 2016 Rosiglitazone also increased the localization of PPARgamma to the cytoplasm and up-regulated of PPARgamma, ADP and ADFP mRNA. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 49-58 27531629-9 2016 Rosiglitazone also increased the localization of PPARgamma to the cytoplasm and up-regulated of PPARgamma, ADP and ADFP mRNA. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 96-105 27378422-11 2016 Use of the PPARgamma agonist Rosiglitazone, reversed the effects of Sirt1 on osteogenic differentiation. Rosiglitazone 29-42 peroxisome proliferator activated receptor gamma Mus musculus 11-20 27208887-1 2016 Rosiglitazone is a selective ligand for peroxisome proliferator-activated receptor-gamma (PPAR-gamma), which serves diverse biological functions. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 40-88 27208887-1 2016 Rosiglitazone is a selective ligand for peroxisome proliferator-activated receptor-gamma (PPAR-gamma), which serves diverse biological functions. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 90-100 27583776-9 2016 Involvement of PPARgamma in the modulation of CRH was demonstrated using a PPARgamma-antagonist (T0070907) and a PPARgamma-agonist (rosiglitazone). Rosiglitazone 132-145 peroxisome proliferator activated receptor gamma Mus musculus 15-24 27545964-7 2016 Rosiglitazone fully blocked progression of WAT inflammation and activated PPARgamma significantly in WAT. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 74-83 27273607-12 2016 However, BPS but not BPA was able to competitively inhibit rosiglitazone (ROSI)-activated PPARgamma, suggesting that BPS interacts with PPARgamma distinctly from BPA. Rosiglitazone 59-72 peroxisome proliferator activated receptor gamma Mus musculus 90-99 27273607-12 2016 However, BPS but not BPA was able to competitively inhibit rosiglitazone (ROSI)-activated PPARgamma, suggesting that BPS interacts with PPARgamma distinctly from BPA. Rosiglitazone 59-72 peroxisome proliferator activated receptor gamma Mus musculus 136-145 27273607-12 2016 However, BPS but not BPA was able to competitively inhibit rosiglitazone (ROSI)-activated PPARgamma, suggesting that BPS interacts with PPARgamma distinctly from BPA. Rosiglitazone 74-78 peroxisome proliferator activated receptor gamma Mus musculus 90-99 27273607-12 2016 However, BPS but not BPA was able to competitively inhibit rosiglitazone (ROSI)-activated PPARgamma, suggesting that BPS interacts with PPARgamma distinctly from BPA. Rosiglitazone 74-78 peroxisome proliferator activated receptor gamma Mus musculus 136-145 27530514-0 2016 Cardioprotective role of peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone in a unique murine model of diabetic cardiopathy. Rosiglitazone 83-96 peroxisome proliferator activated receptor gamma Mus musculus 25-73 27442117-8 2016 In WT mice, rosiglitazone induced whole-body weight gain, increased WAT mass, a shift of substrate oxidation to lipids, and elevated expression of PPARgamma-regulated lipogenic genes in WAT. Rosiglitazone 12-25 peroxisome proliferator activated receptor gamma Mus musculus 147-156 27471493-9 2016 Following treatment with the anti-diabetes drug rosiglitazone - a PPARgamma-agonist known to increase MAT and fracture risk - mice demonstrate a fivefold higher femur MAT volume compared to the controls. Rosiglitazone 48-61 peroxisome proliferator activated receptor gamma Mus musculus 66-75 27094504-3 2016 Additionally, honokiol is capable of activating PPARgamma/RXR heterodimers synergistically in the presence of rosiglitazone in 3T3-L1 adipocyte and HLE human hepatoma cells. Rosiglitazone 110-123 peroxisome proliferator activated receptor gamma Mus musculus 48-57 27125895-3 2016 Using a gene transfer approach and mice fed a high-fat diet (HFD) as an animal model, we demonstrate that mice with low levels of PPAR-gamma expression in the liver are resistant to HFD-induced development of fatty liver when treated with rosiglitazone. Rosiglitazone 239-252 peroxisome proliferator activated receptor gamma Mus musculus 130-140 27287266-12 2016 Treatment of the seipin-KO mice with the PPARgamma agonist rosiglitazone (rosi) could prevent Abeta25-35/1-42-induced neuroinflammation and neurotoxicity, which was blocked by the PPARgamma antagonist GW9962. Rosiglitazone 59-72 peroxisome proliferator activated receptor gamma Mus musculus 41-50 27287266-12 2016 Treatment of the seipin-KO mice with the PPARgamma agonist rosiglitazone (rosi) could prevent Abeta25-35/1-42-induced neuroinflammation and neurotoxicity, which was blocked by the PPARgamma antagonist GW9962. Rosiglitazone 59-72 peroxisome proliferator activated receptor gamma Mus musculus 180-189 27287266-12 2016 Treatment of the seipin-KO mice with the PPARgamma agonist rosiglitazone (rosi) could prevent Abeta25-35/1-42-induced neuroinflammation and neurotoxicity, which was blocked by the PPARgamma antagonist GW9962. Rosiglitazone 59-63 peroxisome proliferator activated receptor gamma Mus musculus 41-50 27287266-12 2016 Treatment of the seipin-KO mice with the PPARgamma agonist rosiglitazone (rosi) could prevent Abeta25-35/1-42-induced neuroinflammation and neurotoxicity, which was blocked by the PPARgamma antagonist GW9962. Rosiglitazone 59-63 peroxisome proliferator activated receptor gamma Mus musculus 180-189 26983922-8 2016 We further found that BVC occupies a novel alternative binding site in addition to the canonical site of synthetic agonists of PPAR, and that the synthetic PPAR-gamma agonist rosiglitazone can block BVC binding to this canonical site but not to the alternative site. Rosiglitazone 175-188 peroxisome proliferator activated receptor gamma Mus musculus 156-166 27125895-4 2016 Conversely, rosiglitazone treatment actually exacerbates liver steatosis in obese mice that have a higher level of PPAR-gamma. Rosiglitazone 12-25 peroxisome proliferator activated receptor gamma Mus musculus 115-125 27125895-7 2016 These results provide evidence in support of the importance of PPAR-gamma in the liver when rosiglitazone is considered for the treatment of fatty liver disease. Rosiglitazone 92-105 peroxisome proliferator activated receptor gamma Mus musculus 63-73 27176632-5 2016 Rosiglitazone-induced interaction between PPARgamma ligand binding domain (LBD) and coactivator SRC-1 was blocked by LFE or FSB, whereas reduced NCoR-1 binding to PPARgamma by rosiglitazone was reversed in the presence of LFE or FSB. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 42-51 27176632-5 2016 Rosiglitazone-induced interaction between PPARgamma ligand binding domain (LBD) and coactivator SRC-1 was blocked by LFE or FSB, whereas reduced NCoR-1 binding to PPARgamma by rosiglitazone was reversed in the presence of LFE or FSB. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 163-172 27176632-5 2016 Rosiglitazone-induced interaction between PPARgamma ligand binding domain (LBD) and coactivator SRC-1 was blocked by LFE or FSB, whereas reduced NCoR-1 binding to PPARgamma by rosiglitazone was reversed in the presence of LFE or FSB. Rosiglitazone 176-189 peroxisome proliferator activated receptor gamma Mus musculus 42-51 27176632-5 2016 Rosiglitazone-induced interaction between PPARgamma ligand binding domain (LBD) and coactivator SRC-1 was blocked by LFE or FSB, whereas reduced NCoR-1 binding to PPARgamma by rosiglitazone was reversed in the presence of LFE or FSB. Rosiglitazone 176-189 peroxisome proliferator activated receptor gamma Mus musculus 163-172 26818512-14 2016 The PPARgamma agonist rosiglitazone can ameliorate spatial cognitive deficits and rescue the LTP induction in seipin knock-out mice by restoring AMPA receptor expression and ERK-CREB activities. Rosiglitazone 22-35 peroxisome proliferator activated receptor gamma Mus musculus 4-13 26618986-5 2016 The PPARgamma agonist rosiglitazone treatment improved clinical status and mortality, while increasing IL-10 production and decreasing TNF-alpha and IL-6 levels, and peritoneal neutrophil accumulation 24 h after CLP. Rosiglitazone 22-35 peroxisome proliferator activated receptor gamma Mus musculus 4-13 26618986-7 2016 Polymorphonuclear leukocytes (PMN) incubated with LPS or Escherichia coli and rosiglitazone increased peritoneal neutrophil extracellular trap (NET)-mediated bacterial killing, an effect reversed by the PPARgamma antagonist (GW 9662) treatment. Rosiglitazone 78-91 peroxisome proliferator activated receptor gamma Mus musculus 203-212 26618986-9 2016 Rosiglitazone modulated the inflammatory response and increased bacterial clearance through PPARgamma activation and NET formation, combining immunomodulatory and host-dependent anti-bacterial effects and, therefore, warrants further study as a potential therapeutic agent in sepsis. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 92-101 26773728-9 2016 Further analysis showed that pretreatment with rosiglitazone, which activated placental PPAR-gamma signaling, simultaneously suppressed LPS-evoked nuclear factor kappa B (NF-kappaB) activation and blocked nuclear translocation of NF-kappaB p65 and p50 subunits in trophoblast giant cells of the labyrinth layer. Rosiglitazone 47-60 peroxisome proliferator activated receptor gamma Mus musculus 88-98 26893620-14 2016 Short-term treatment of mice with rosiglitazone, a potent PPARgamma agonist, confers protective effects against hepatic I/R-associated metastasis. Rosiglitazone 34-47 peroxisome proliferator activated receptor gamma Mus musculus 58-67 28955832-3 2016 One of the proline-type fullerene derivatives (P3) harboring three carboxy groups significantly inhibited lipid accumulation and the expression of adipocyte-specific genes, such as aP2, induced by the PPARgamma agonist rosiglitazone. Rosiglitazone 219-232 peroxisome proliferator activated receptor gamma Mus musculus 201-210 26566726-6 2016 The loss of ACh responsiveness was partially improved by pretreatment of the vessels with the PPAR-gamma agonist rosiglitazone or in E-WT. Rosiglitazone 113-126 peroxisome proliferator activated receptor gamma Mus musculus 94-104 26507867-7 2016 KEY RESULTS: Treatment with PPARgamma agonists, rosiglitazone (0.8 mg kg(-1) ) and pioglitazone (9.0 mg kg(-1) ), for 6 weeks significantly increased Abeta efflux and decreased Abeta influx across the BBB in db/db mice. Rosiglitazone 48-61 peroxisome proliferator activated receptor gamma Mus musculus 28-37 26872126-10 2016 Most importantly, the PPARgamma-specific agonist rosiglitazone significantly suppressed inflammation and mitochondrial dysfunction induced by CGI-58 deficiency. Rosiglitazone 49-62 peroxisome proliferator activated receptor gamma Mus musculus 22-31 27012212-3 2016 Our previous study suggested that when acetylated LDL (AC-LDL) was co-applied with a PPARgamma agonist, rosiglitazone (ROSI), many oil red O-positive macrophages could be observed. Rosiglitazone 104-117 peroxisome proliferator activated receptor gamma Mus musculus 85-94 27012212-3 2016 Our previous study suggested that when acetylated LDL (AC-LDL) was co-applied with a PPARgamma agonist, rosiglitazone (ROSI), many oil red O-positive macrophages could be observed. Rosiglitazone 119-123 peroxisome proliferator activated receptor gamma Mus musculus 85-94 27012212-4 2016 However, addition of cyclic phosphatidic acid (cPA) to ROSI-stimulated macrophages completely abolished oil red O-stained cells, indicating that cPA inhibits PPARgamma-regulated AC-LDL uptake. Rosiglitazone 55-59 peroxisome proliferator activated receptor gamma Mus musculus 158-167 26214491-5 2015 After treatment with rosiglitazone, PPARgamma mRNA expression increased by 78% (P < 0.05), while AKT mRNA expression decreased by 71% (P < 0.05). Rosiglitazone 21-34 peroxisome proliferator activated receptor gamma Mus musculus 36-45 26508640-12 2015 Treatment with the PPAR-gamma agonist rosiglitazone reversed the phenotype. Rosiglitazone 38-51 peroxisome proliferator activated receptor gamma Mus musculus 19-29 26199136-9 2015 Stimulation of PPAR-gamma in vivo (rosiglitazone) significantly attenuates biliary damage and inflammation in Cftr-knockout mice exposed to a dextran sodium sulfate-induced portal endotoxemia. Rosiglitazone 35-48 peroxisome proliferator activated receptor gamma Mus musculus 15-25 26342083-4 2015 J11-Cl bound to the ligand binding domain of PPARgamma in the same manner as 15d-PGJ2 and rosiglitazone, and significantly increased transcriptional activity of PPARgamma. Rosiglitazone 90-103 peroxisome proliferator activated receptor gamma Mus musculus 45-54 25573805-5 2015 Moreover, in LPS-stimulated macrophages, the downregulation of peroxisome proliferator-activated receptor gamma (PPAR-gamma) was reversed by SsnB dose-dependently; and SsnB had synergistic inhibitory effects with rosiglitazone, a PPAR-gamma agonist, on TNF-alpha and IL-6 expression in LPS-stimulated macrophages. Rosiglitazone 213-226 peroxisome proliferator activated receptor gamma Mus musculus 63-111 25573805-5 2015 Moreover, in LPS-stimulated macrophages, the downregulation of peroxisome proliferator-activated receptor gamma (PPAR-gamma) was reversed by SsnB dose-dependently; and SsnB had synergistic inhibitory effects with rosiglitazone, a PPAR-gamma agonist, on TNF-alpha and IL-6 expression in LPS-stimulated macrophages. Rosiglitazone 213-226 peroxisome proliferator activated receptor gamma Mus musculus 113-123 26099551-2 2015 This study aims at investigating the potential role of rosiglitazone, a strong PPAR-gamma agonist in a murine model of bronchial asthma. Rosiglitazone 55-68 peroxisome proliferator activated receptor gamma Mus musculus 79-89 26492476-4 2015 METHODS: The PPARgamma agonist rosiglitazone (rosi) was injected at the incision site of diabetic (db/db) mice with resolvin (Rv) D1, a lipid mediator involved in resolution of inflammation. Rosiglitazone 31-44 peroxisome proliferator activated receptor gamma Mus musculus 13-22 26492476-4 2015 METHODS: The PPARgamma agonist rosiglitazone (rosi) was injected at the incision site of diabetic (db/db) mice with resolvin (Rv) D1, a lipid mediator involved in resolution of inflammation. Rosiglitazone 31-35 peroxisome proliferator activated receptor gamma Mus musculus 13-22 26398946-4 2015 We show that the proliferative capability of stem cells in seipin-nKO mice was substantially reduced compared to in wild-type (WT) mice, and that this could be rescued by the PPARgamma agonist rosiglitazone (rosi). Rosiglitazone 193-206 peroxisome proliferator activated receptor gamma Mus musculus 175-184 26398946-4 2015 We show that the proliferative capability of stem cells in seipin-nKO mice was substantially reduced compared to in wild-type (WT) mice, and that this could be rescued by the PPARgamma agonist rosiglitazone (rosi). Rosiglitazone 193-197 peroxisome proliferator activated receptor gamma Mus musculus 175-184 26791799-1 2015 PURPOSE/OBJECTIVE(S): Due to its anti-inflammatory, antifibrotic and antineoplastic properties, the PPAR-gamma agonist rosiglitazone is of interest in the prevention and therapy of radiation-induced pulmonary injury. Rosiglitazone 119-132 peroxisome proliferator activated receptor gamma Mus musculus 100-110 26386117-1 2015 Rosiglitazone (RGZ), a peroxisome proliferator-activated receptor-gamma (PPARgamma) ligand, is a novel dilator of small airways in mouse precision cut lung slices (PCLS). Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 23-71 26386117-1 2015 Rosiglitazone (RGZ), a peroxisome proliferator-activated receptor-gamma (PPARgamma) ligand, is a novel dilator of small airways in mouse precision cut lung slices (PCLS). Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 73-82 26116229-0 2015 Rosiglitazone inhibition of calvaria-derived osteoblast differentiation is through both of PPARgamma and GPR40 and GSK3beta-dependent pathway. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 91-100 26116229-4 2015 Peroxisome proliferators-activated receptor gamma (PPARgamma) siRNA significantly reversed the inhibitory effect of RSG on osteogenic differentiation. Rosiglitazone 116-119 peroxisome proliferator activated receptor gamma Mus musculus 0-49 26116229-4 2015 Peroxisome proliferators-activated receptor gamma (PPARgamma) siRNA significantly reversed the inhibitory effect of RSG on osteogenic differentiation. Rosiglitazone 116-119 peroxisome proliferator activated receptor gamma Mus musculus 51-60 26116229-8 2015 RSG-induced GSK3beta activation was mediated through both PPARgamma and GPR40. Rosiglitazone 0-3 peroxisome proliferator activated receptor gamma Mus musculus 58-67 26116229-9 2015 These results suggest that both PPARgamma and GRP40 are required for RSG-induced inhibition of mouse calvaria osteoblast differentiation, which is mediated through GSK3beta-dependent pathway. Rosiglitazone 69-72 peroxisome proliferator activated receptor gamma Mus musculus 32-41 26011171-5 2015 RESULTS: DSP-8658 reduced the expression of PPARgamma-target gene 11 beta hydroxysteroid dehydrogenase type 1 with an EC50 value 2.1-fold that of pioglitazone and 28.4-fold that of rosiglitazone. Rosiglitazone 181-194 peroxisome proliferator activated receptor gamma Mus musculus 44-53 26396687-1 2015 The thiazolidinediones (TZD) typified by rosiglitazone are the only approved therapeutics targeting PPARgamma for the treatment of type-2 diabetes (T2DM). Rosiglitazone 41-54 peroxisome proliferator activated receptor gamma Mus musculus 100-109 25940785-0 2015 Rosiglitazone-activated PPARgamma induces neurotrophic factor-alpha1 transcription contributing to neuroprotection. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 24-33 25940785-4 2015 Here, we show that the neuroprotective protein neurotrophic factor-alpha1 (NF-alpha1), which also induces the expression of BCL-2, has a promoter that contains PPARgamma-binding sites that are activated by rosiglitazone. Rosiglitazone 206-219 peroxisome proliferator activated receptor gamma Mus musculus 160-169 25940785-8 2015 These results demonstrate that rosiglitazone-activated PPARgamma directly induces the transcription of NF-alpha1, contributing to neuroprotection in neurons. Rosiglitazone 31-44 peroxisome proliferator activated receptor gamma Mus musculus 55-64 25940785-9 2015 We proposed the following cascade for neuroprotection against oxidative stress by rosiglitazone: Rosiglitazone enters the neuron and binds to peroxisome proliferator-activated receptor gamma (PPARgamma) in the nucleus. Rosiglitazone 82-95 peroxisome proliferator activated receptor gamma Mus musculus 142-190 25940785-9 2015 We proposed the following cascade for neuroprotection against oxidative stress by rosiglitazone: Rosiglitazone enters the neuron and binds to peroxisome proliferator-activated receptor gamma (PPARgamma) in the nucleus. Rosiglitazone 82-95 peroxisome proliferator activated receptor gamma Mus musculus 192-201 25940785-9 2015 We proposed the following cascade for neuroprotection against oxidative stress by rosiglitazone: Rosiglitazone enters the neuron and binds to peroxisome proliferator-activated receptor gamma (PPARgamma) in the nucleus. Rosiglitazone 97-110 peroxisome proliferator activated receptor gamma Mus musculus 142-190 25940785-9 2015 We proposed the following cascade for neuroprotection against oxidative stress by rosiglitazone: Rosiglitazone enters the neuron and binds to peroxisome proliferator-activated receptor gamma (PPARgamma) in the nucleus. Rosiglitazone 97-110 peroxisome proliferator activated receptor gamma Mus musculus 192-201 25940785-10 2015 The PPARgamma-rosiglitazone complex binds to the neurotrophic factor-alpha1 (NF-alpha1) promoter and activates the transcription of NF-alpha1 mRNA which is then translated to the protein. Rosiglitazone 14-27 peroxisome proliferator activated receptor gamma Mus musculus 4-13 25932594-11 2015 Application of either a PPARgamma antagonist (T0070907) or an RXR antagonist (HX531) significantly reduced rosiglitazone-induced suppression of bone nodule formation. Rosiglitazone 107-120 peroxisome proliferator activated receptor gamma Mus musculus 24-33 25749778-2 2015 A novel PPAR-gamma ligand, KR62980 have been recently focused on due to the lower undesirable effects than other PPAR-gamma ligands such as rosiglitazone and pioglitazone. Rosiglitazone 140-153 peroxisome proliferator activated receptor gamma Mus musculus 8-18 25559266-13 2015 PPARgamma deletion or antagonization restored rosiglitazone-dependent inhibition of CTL cytotoxicity. Rosiglitazone 46-59 peroxisome proliferator activated receptor gamma Mus musculus 0-9 25739357-6 2015 PPARgamma agonist (Rosiglitazone)-induced relaxation in HS-A2AAR(+/+) mice was attenuated by KATP channel blocker. Rosiglitazone 19-32 peroxisome proliferator activated receptor gamma Mus musculus 0-9 25531136-1 2015 BACKGROUND/AIMS: Thiazolidinediones (TZDs, like rosiglitazone (RGZ)) are peroxisome proliferator-activated receptor gamma (PPARgamma) agonists used to treat type 2 diabetes. Rosiglitazone 48-61 peroxisome proliferator activated receptor gamma Mus musculus 73-121 25257948-1 2015 Rosiglitazone is an insulin-sensitizing thiazolidinedione (TZD) that activates the transcription factor peroxisome proliferator-activated receptor gamma (PPARgamma). Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 104-152 25257948-1 2015 Rosiglitazone is an insulin-sensitizing thiazolidinedione (TZD) that activates the transcription factor peroxisome proliferator-activated receptor gamma (PPARgamma). Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 154-163 25257948-4 2015 Rosiglitazone-activated PPARgamma, however, also stimulates osteoclast formation. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 24-33 25257948-7 2015 Confirming it activates the nuclear receptor in osteoclasts, rosiglitazone enhances expression of the PPARgamma target gene, CD36. Rosiglitazone 61-74 peroxisome proliferator activated receptor gamma Mus musculus 102-111 25703056-1 2015 BACKGROUND: Rosiglitazone (RO), a second-generation thiazolidinedione used mainly in the treatment of non-insulin-dependent diabetes mellitus, has been discovered to be a high-affinity ligand for peroxisome proliferator-activated receptor-gamma (PPAR-gamma). Rosiglitazone 12-25 peroxisome proliferator activated receptor gamma Mus musculus 196-244 25703056-1 2015 BACKGROUND: Rosiglitazone (RO), a second-generation thiazolidinedione used mainly in the treatment of non-insulin-dependent diabetes mellitus, has been discovered to be a high-affinity ligand for peroxisome proliferator-activated receptor-gamma (PPAR-gamma). Rosiglitazone 12-25 peroxisome proliferator activated receptor gamma Mus musculus 246-256 25510319-2 2015 Pharmacologic agonist of the nuclear receptor, peroxisomal proliferator-activating receptor gamma (PPARgamma), that is, rosiglitazone (rosi), are insulin sensitizing agents that improve memory in Alzheimer"s disease. Rosiglitazone 120-133 peroxisome proliferator activated receptor gamma Mus musculus 47-97 25510319-2 2015 Pharmacologic agonist of the nuclear receptor, peroxisomal proliferator-activating receptor gamma (PPARgamma), that is, rosiglitazone (rosi), are insulin sensitizing agents that improve memory in Alzheimer"s disease. Rosiglitazone 120-133 peroxisome proliferator activated receptor gamma Mus musculus 99-108 25510319-2 2015 Pharmacologic agonist of the nuclear receptor, peroxisomal proliferator-activating receptor gamma (PPARgamma), that is, rosiglitazone (rosi), are insulin sensitizing agents that improve memory in Alzheimer"s disease. Rosiglitazone 120-124 peroxisome proliferator activated receptor gamma Mus musculus 47-97 25510319-2 2015 Pharmacologic agonist of the nuclear receptor, peroxisomal proliferator-activating receptor gamma (PPARgamma), that is, rosiglitazone (rosi), are insulin sensitizing agents that improve memory in Alzheimer"s disease. Rosiglitazone 120-124 peroxisome proliferator activated receptor gamma Mus musculus 99-108 25619395-9 2015 Furthermore, rosiglitazone administration significantly increased PPARgamma, HO-1 and p21 expression and HO-1 activity, decreased MMP-2 and MMP-9 activities in airway tissue. Rosiglitazone 13-26 peroxisome proliferator activated receptor gamma Mus musculus 66-75 25619395-11 2015 CONCLUSION: Rosiglitazone effectively attenuates airway inflammation and remodeling in OVA-induced asthma of mice by activating PPARgamma/HO-1 signaling pathway. Rosiglitazone 12-25 peroxisome proliferator activated receptor gamma Mus musculus 128-137 25446101-4 2015 Thus, ATF3 effectively repressed rosiglitazone-stimulated expression of adipocyte fatty acid binding protein (aP2), PPARgamma target gene, in 3T3-L1 cells. Rosiglitazone 33-46 peroxisome proliferator activated receptor gamma Mus musculus 116-125 25446101-8 2015 Chromatin immunoprecipitation assay showed that overexpression of ATF3 blocked both binding of PPARgamma and recruitment of p300 to PPRE on aP2 promoter induced by rosiglitazone treatment in 3T3-L1 cells. Rosiglitazone 164-177 peroxisome proliferator activated receptor gamma Mus musculus 95-104 25287014-3 2014 Additionally, we analyzed the effects of drug treatment using the specific PPARgamma ligand rosiglitazone. Rosiglitazone 92-105 peroxisome proliferator activated receptor gamma Mus musculus 75-84 25431031-0 2014 Rosiglitazone, a PPARgamma agonist, ameliorates palmitate-induced insulin resistance and apoptosis in skeletal muscle cells. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 17-26 25431031-2 2014 Rosiglitazone (RSG), a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, can activate both pro-apoptotic and anti-apoptotic pathways in different cells; however, its effect on palmitate-induced apoptosis in skeletal muscle cells remains to be elucidated. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 23-71 25431031-2 2014 Rosiglitazone (RSG), a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, can activate both pro-apoptotic and anti-apoptotic pathways in different cells; however, its effect on palmitate-induced apoptosis in skeletal muscle cells remains to be elucidated. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 73-82 25431031-2 2014 Rosiglitazone (RSG), a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, can activate both pro-apoptotic and anti-apoptotic pathways in different cells; however, its effect on palmitate-induced apoptosis in skeletal muscle cells remains to be elucidated. Rosiglitazone 15-18 peroxisome proliferator activated receptor gamma Mus musculus 23-71 25431031-2 2014 Rosiglitazone (RSG), a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, can activate both pro-apoptotic and anti-apoptotic pathways in different cells; however, its effect on palmitate-induced apoptosis in skeletal muscle cells remains to be elucidated. Rosiglitazone 15-18 peroxisome proliferator activated receptor gamma Mus musculus 73-82 25889730-9 2015 Cotreatment with ROSI significantly reduced breast tumour progression among PPARgamma-WTs, correlating with increased BRCA1 and decreased VEGF and COX-2 protein expression levels in breast tumours; whereas, surprisingly DMBA + ROSI-treated PPARgamma-MG KOs showed increased breast tumourigenesis, correlating with activation of COX-2. Rosiglitazone 17-21 peroxisome proliferator activated receptor gamma Mus musculus 240-249 25827822-6 2015 In vitro, F12016 effectively increased glucose uptake and blocked cyclin-dependent kinase 5-mediated phosphorylation of PPARgamma at Ser273, but slightly triggered adipogenesis and less inhibited osteoblastogenesis than rosiglitazone. Rosiglitazone 220-233 peroxisome proliferator activated receptor gamma Mus musculus 120-129 25799429-7 2015 The insulin sensitizer, rosiglitazone, returns the physiological and molecular changes associated with the diabetic phenotype to normal levels through peroxisome proliferator-activated receptor gamma (PPARgamma) rather than PPARalpha. Rosiglitazone 24-37 peroxisome proliferator activated receptor gamma Mus musculus 151-199 25799429-7 2015 The insulin sensitizer, rosiglitazone, returns the physiological and molecular changes associated with the diabetic phenotype to normal levels through peroxisome proliferator-activated receptor gamma (PPARgamma) rather than PPARalpha. Rosiglitazone 24-37 peroxisome proliferator activated receptor gamma Mus musculus 201-210 25788674-1 2015 Peroxisome proliferator-activated receptor gamma (PPARgamma) is clinically targeted for type II diabetes treatment; however, rosiglitazone (ROSI), a PPARgamma agonist, increases food intake and body/fat mass as side-effects. Rosiglitazone 125-138 peroxisome proliferator activated receptor gamma Mus musculus 0-48 25788674-1 2015 Peroxisome proliferator-activated receptor gamma (PPARgamma) is clinically targeted for type II diabetes treatment; however, rosiglitazone (ROSI), a PPARgamma agonist, increases food intake and body/fat mass as side-effects. Rosiglitazone 125-138 peroxisome proliferator activated receptor gamma Mus musculus 50-59 25788674-1 2015 Peroxisome proliferator-activated receptor gamma (PPARgamma) is clinically targeted for type II diabetes treatment; however, rosiglitazone (ROSI), a PPARgamma agonist, increases food intake and body/fat mass as side-effects. Rosiglitazone 125-138 peroxisome proliferator activated receptor gamma Mus musculus 149-158 25788674-1 2015 Peroxisome proliferator-activated receptor gamma (PPARgamma) is clinically targeted for type II diabetes treatment; however, rosiglitazone (ROSI), a PPARgamma agonist, increases food intake and body/fat mass as side-effects. Rosiglitazone 140-144 peroxisome proliferator activated receptor gamma Mus musculus 0-48 25788674-1 2015 Peroxisome proliferator-activated receptor gamma (PPARgamma) is clinically targeted for type II diabetes treatment; however, rosiglitazone (ROSI), a PPARgamma agonist, increases food intake and body/fat mass as side-effects. Rosiglitazone 140-144 peroxisome proliferator activated receptor gamma Mus musculus 149-158 25852474-11 2015 Finally, rosiglitazone, a PPARgamma ligand, increases PPARbeta/delta level, suggesting a possible cooperation between these two PPARs in the control of cell fate behavior. Rosiglitazone 9-22 peroxisome proliferator activated receptor gamma Mus musculus 26-35 25619395-0 2015 The PPARgamma agonist, rosiglitazone, attenuates airway inflammation and remodeling via heme oxygenase-1 in murine model of asthma. Rosiglitazone 23-36 peroxisome proliferator activated receptor gamma Mus musculus 4-13 25619395-1 2015 AIM: Rosiglitazone is one of the specific PPARgamma agonists showing potential therapeutic effects in asthma. Rosiglitazone 5-18 peroxisome proliferator activated receptor gamma Mus musculus 42-51 25619395-3 2015 This study was aimed to investigate whether heme oxygenase-1 (HO-1) related pathways were involved in rosiglitazone-activated PPARgamma signaling in asthma treatment. Rosiglitazone 102-115 peroxisome proliferator activated receptor gamma Mus musculus 126-135 25448844-15 2015 The sulfonated PFAAs produced numerous, strong changes in gene expression similar to the effects after treatment with the PPARgamma agonist rosiglitazone. Rosiglitazone 140-153 peroxisome proliferator activated receptor gamma Mus musculus 122-131 26236713-11 2015 Both EE and the PPAR-gamma agonist, rosiglitazone, attenuated sevoflurane-induced neuronal apoptosis, neurogenesis inhibition, and learning and memory impairment. Rosiglitazone 36-49 peroxisome proliferator activated receptor gamma Mus musculus 16-26 26587016-3 2015 Currently, there is no effective therapy for AD; however several studies have shown that the treatments with the peroxisome proliferators activated receptor-gamma (PPARgamma) agonists known as thiazolidinedione drugs (TZDs), like rosiglitazone and pioglitazone, attenuate neurodegeneration and improve cognition in mouse models and patients with mild-to-moderate AD. Rosiglitazone 230-243 peroxisome proliferator activated receptor gamma Mus musculus 113-162 26587016-3 2015 Currently, there is no effective therapy for AD; however several studies have shown that the treatments with the peroxisome proliferators activated receptor-gamma (PPARgamma) agonists known as thiazolidinedione drugs (TZDs), like rosiglitazone and pioglitazone, attenuate neurodegeneration and improve cognition in mouse models and patients with mild-to-moderate AD. Rosiglitazone 230-243 peroxisome proliferator activated receptor gamma Mus musculus 164-173 25371737-0 2014 Glypican 4 may be involved in the adipose tissue redistribution in high-fat feeding C57BL/6J mice with peroxisome proliferators-activated receptor gamma agonist rosiglitazone treatment. Rosiglitazone 161-174 peroxisome proliferator activated receptor gamma Mus musculus 103-152 25371737-4 2014 C57BL/6J mice were fed with a high-fat diet for eight weeks and treated with a peroxisome proliferators-activated receptor gamma (PPARgamma) agonist, rosiglitazone, for another four weeks. Rosiglitazone 150-163 peroxisome proliferator activated receptor gamma Mus musculus 79-128 25371737-4 2014 C57BL/6J mice were fed with a high-fat diet for eight weeks and treated with a peroxisome proliferators-activated receptor gamma (PPARgamma) agonist, rosiglitazone, for another four weeks. Rosiglitazone 150-163 peroxisome proliferator activated receptor gamma Mus musculus 130-139 25445963-3 2014 The purpose of the present study was to investigate the potential protective role of the PPARgamma agonist rosiglitazone in pathogen accelerated atherosclerosis in an apolipoprotein E-deficient (ApoE-/-) mouse model. Rosiglitazone 107-120 peroxisome proliferator activated receptor gamma Mus musculus 89-98 25445963-8 2014 In both P. gingivalis-treated and -untreated ApoE-/- mice, rosiglitazone treatment was associated with less atherosclerotic plaque formation; lower serum inflammatory cytokines, total cholesterol, and low density lipoprotein cholesterol; higher levels of PPARgamma, lower amounts of TLR2/4 and downregulated nuclear factor-kappaB activity in aortic tissues. Rosiglitazone 59-72 peroxisome proliferator activated receptor gamma Mus musculus 255-264 25009233-7 2014 Induction of PPARgamma, shown to play a role in AAM development, by the PPARgamma agonist rosiglitazone or treatment of mice with the macrolide antibiotic AZM, also reported to skew macrophage differentiation to an AAM phenotype, increased the AAM markers and mitigated RSV-induced lung pathology. Rosiglitazone 90-103 peroxisome proliferator activated receptor gamma Mus musculus 13-22 25009233-7 2014 Induction of PPARgamma, shown to play a role in AAM development, by the PPARgamma agonist rosiglitazone or treatment of mice with the macrolide antibiotic AZM, also reported to skew macrophage differentiation to an AAM phenotype, increased the AAM markers and mitigated RSV-induced lung pathology. Rosiglitazone 90-103 peroxisome proliferator activated receptor gamma Mus musculus 72-81 25361524-7 2014 RESULTS: ECs and PACs isolated from diabetic db/db mice displayed a reduced angiogenic potential in ex vivo and in vitro assays, the effect partially rescued by incubation of cells with rosiglitazone (PPARgamma activator). Rosiglitazone 186-199 peroxisome proliferator activated receptor gamma Mus musculus 201-210 25361524-10 2014 CONCLUSIONS: In summary, activation of PPARgamma by rosiglitazone improves angiogenic potential of diabetic ECs and PACs, but decreased expression of PPARgamma in diabetes does not impair angiogenesis. Rosiglitazone 52-65 peroxisome proliferator activated receptor gamma Mus musculus 39-48 25531136-1 2015 BACKGROUND/AIMS: Thiazolidinediones (TZDs, like rosiglitazone (RGZ)) are peroxisome proliferator-activated receptor gamma (PPARgamma) agonists used to treat type 2 diabetes. Rosiglitazone 48-61 peroxisome proliferator activated receptor gamma Mus musculus 123-132 24858619-6 2014 Activation of PPAR-gamma by rosiglitazone reduced IL-13-induced collagen expression by suppression of STAT6-driven PDGF production. Rosiglitazone 28-41 peroxisome proliferator activated receptor gamma Mus musculus 14-24 24530807-8 2014 MCZ may compete with rosiglitazone and HL005 for PPARgamma, but IMI showed no affinity. Rosiglitazone 21-34 peroxisome proliferator activated receptor gamma Mus musculus 49-58 25134730-6 2014 Moreover, in order to target microglia polarization, we evaluated the effect of the peroxisome-proliferator-activated receptor (PPAR)-gamma agonist rosiglitazone, which has been shown to exert neuroprotective effects on nigral dopaminergic neurons in PD models, and acts as a modulator of cytokine production and phenotype in peripheral macrophages. Rosiglitazone 148-161 peroxisome proliferator activated receptor gamma Mus musculus 128-132 25047837-6 2014 Readdition of BMP4 overcame the inhibitory effect of ISL1 on the expression of PPARgamma but not aP2, a gene downstream of PPARgamma, and BMP4 also partially rescued ISL1 inhibition of adipogenesis, an effect which is additive with rosiglitazone. Rosiglitazone 232-245 peroxisome proliferator activated receptor gamma Mus musculus 79-88 25101993-8 2014 The PPARgamma agonist rosiglitazone rescues Sdc1-/- intradermal adipose tissue, placing PPARgamma downstream of Sdc1 in triggering adipocyte differentiation. Rosiglitazone 22-35 peroxisome proliferator activated receptor gamma Mus musculus 4-13 25101993-8 2014 The PPARgamma agonist rosiglitazone rescues Sdc1-/- intradermal adipose tissue, placing PPARgamma downstream of Sdc1 in triggering adipocyte differentiation. Rosiglitazone 22-35 peroxisome proliferator activated receptor gamma Mus musculus 88-97 24651066-10 2014 The PPARgamma agonist rosiglitazone alleviated affective disorders in male seipin-nKO mice. Rosiglitazone 22-35 peroxisome proliferator activated receptor gamma Mus musculus 4-13 24449420-1 2014 This study aims to test the hypothesis that thiazolidinedione rosiglitazone (RSG), a selective peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, causes cardiotoxicity independently of PPARgamma. Rosiglitazone 62-75 peroxisome proliferator activated receptor gamma Mus musculus 95-143 24859974-4 2014 Although the PPARgamma agonist rosiglitazone induces the expression of PIK3R1, the transcriptional regulation of PIK3R1 in adipocytes remains unknown. Rosiglitazone 31-44 peroxisome proliferator activated receptor gamma Mus musculus 13-22 25197359-3 2014 Rosiglitazone and normal saline were administered in the PPAR-gamma group and the control group respectively. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 57-67 24188042-2 2014 Because chronic treatment with the synthetic peroxisome proliferator activated receptor (PPAR)gamma agonist rosiglitazone (RGZ) inhibits airway hyperresponsiveness in mouse models of allergic airways disease, we tested the hypothesis that RGZ causes acute airway relaxation by measuring changes in small airway size in mouse lung slices. Rosiglitazone 108-121 peroxisome proliferator activated receptor gamma Mus musculus 89-99 24456224-2 2014 We have previously shown that the PPARgamma agonist rosiglitazone is beneficial when used early in prevention of disease in murine models of systemic lupus erythematosus (SLE) and SLE-related atherosclerosis. Rosiglitazone 52-65 peroxisome proliferator activated receptor gamma Mus musculus 34-43 24424383-3 2014 Exposure to Tat via the internal carotid artery (ICA) disrupted permeability across the BBB; however, this effect was attenuated in mice treated with fenofibrate (PPARalpha agonist) or rosiglitazone (PPARgamma agonist). Rosiglitazone 185-198 peroxisome proliferator activated receptor gamma Mus musculus 200-209 24338629-0 2014 Rosiglitazone-induced CD36 up-regulation resolves inflammation by PPARgamma and 5-LO-dependent pathways. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 66-75 24449420-1 2014 This study aims to test the hypothesis that thiazolidinedione rosiglitazone (RSG), a selective peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, causes cardiotoxicity independently of PPARgamma. Rosiglitazone 62-75 peroxisome proliferator activated receptor gamma Mus musculus 145-154 24449420-1 2014 This study aims to test the hypothesis that thiazolidinedione rosiglitazone (RSG), a selective peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, causes cardiotoxicity independently of PPARgamma. Rosiglitazone 77-80 peroxisome proliferator activated receptor gamma Mus musculus 95-143 24449420-1 2014 This study aims to test the hypothesis that thiazolidinedione rosiglitazone (RSG), a selective peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, causes cardiotoxicity independently of PPARgamma. Rosiglitazone 77-80 peroxisome proliferator activated receptor gamma Mus musculus 145-154 24449420-10 2014 In conclusion, this study demonstrates that RSG at supratherapeutic concentrations causes cardiotoxicity via a PPARgamma-independent mechanism involving oxidative stress-induced mitochondrial dysfunction in mouse hearts. Rosiglitazone 44-47 peroxisome proliferator activated receptor gamma Mus musculus 111-120 24287404-4 2014 Rosiglitazone treatment induced volume expansion and CH in wild-type and PPARgamma heterozygous knockout (Pparg(+/-)) mice, but not in mice defective for ligand binding (Pparg(P465L/+)). Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 73-82 24485891-6 2014 Prior treatment of mice with PPARgamma agonist rosiglitazone significantly suppressed LPS-induced ALI and reversed the elevation of HMGB1 and RAGE; these were accompanied with the induction of HO-1. Rosiglitazone 47-60 peroxisome proliferator activated receptor gamma Mus musculus 29-38 24338020-1 2014 Rosiglitazone, a well known insulin sensitizer, stimulates adipocyte differentiation via the activation of peroxisome proliferator-activated receptor gamma (PPARgamma). Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 107-155 24779192-3 2014 In addition, DMPB was observed to decrease the PPAR-gamma transcription activity, which was increased by rosiglitazone, in a concentration-dependent manner. Rosiglitazone 105-118 peroxisome proliferator activated receptor gamma Mus musculus 47-57 24757676-2 2014 However, the mechanisms by which PPARgamma agonist rosiglitazone interferes with inflammation and cancer via phosphatase and tensin homolog-(PTEN)-dependent pathway remain unclear. Rosiglitazone 51-64 peroxisome proliferator activated receptor gamma Mus musculus 33-42 24338020-1 2014 Rosiglitazone, a well known insulin sensitizer, stimulates adipocyte differentiation via the activation of peroxisome proliferator-activated receptor gamma (PPARgamma). Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 157-166 24338020-7 2014 PPARgamma antagonists (bisphenol A diglycidyl ether or GW9662) blunted the effects of rosiglitazone on PHD regulation. Rosiglitazone 86-99 peroxisome proliferator activated receptor gamma Mus musculus 0-9 24338020-8 2014 Furthermore, putative PPARgamma binding sites were identified in the promoter region of PHDs by ChIP-PCR, implying that rosiglitazone may induce PHD up-regulation directly by PPARgamma activation. Rosiglitazone 120-133 peroxisome proliferator activated receptor gamma Mus musculus 22-31 24338020-8 2014 Furthermore, putative PPARgamma binding sites were identified in the promoter region of PHDs by ChIP-PCR, implying that rosiglitazone may induce PHD up-regulation directly by PPARgamma activation. Rosiglitazone 120-133 peroxisome proliferator activated receptor gamma Mus musculus 175-184 24338020-10 2014 These results suggest that rosiglitazone increases PHD expression in a PPARgamma-dependent manner and that this leads to the commitment of anti-adipogenic proteins to the ubiquitination-proteasomal pathway and to the subsequent induction of adipocyte differentiation. Rosiglitazone 27-40 peroxisome proliferator activated receptor gamma Mus musculus 71-80 24323842-7 2014 Contrary, PPARgamma activity, either basal or rosiglitazone activated, was inhibited by oleuropein. Rosiglitazone 46-59 peroxisome proliferator activated receptor gamma Mus musculus 10-19 24269293-0 2014 Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates airway inflammation by inhibiting the proliferation of effector T cells in a murine model of neutrophilic asthma. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 17-65 24269293-12 2014 These findings suggest that the therapeutic effect of rosiglitazone in neutrophilic asthma is partially due to the role of the PPARgamma pathway in regulating T cell proliferation and differentiation. Rosiglitazone 54-67 peroxisome proliferator activated receptor gamma Mus musculus 127-136 24244514-7 2013 Hypoxia-induced increases in miR-27a were attenuated in mice treated with the PPARgamma ligand, rosiglitazone (RSG, 10 mg/kg/d) by gavage for the final 10 d of exposure. Rosiglitazone 96-109 peroxisome proliferator activated receptor gamma Mus musculus 78-87 24370585-0 2014 Rosiglitazone promotes neurite outgrowth and mitochondrial function in N2A cells via PPARgamma pathway. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 85-94 24370585-2 2014 However, to date, the effects of a synthetic PPARgamma agonist (Rosiglitazone, Rosi) on neurite outgrowth have not yet been well described. Rosiglitazone 64-77 peroxisome proliferator activated receptor gamma Mus musculus 45-54 24370585-2 2014 However, to date, the effects of a synthetic PPARgamma agonist (Rosiglitazone, Rosi) on neurite outgrowth have not yet been well described. Rosiglitazone 64-68 peroxisome proliferator activated receptor gamma Mus musculus 45-54 24135932-0 2013 N2 neutrophils, novel players in brain inflammation after stroke: modulation by the PPARgamma agonist rosiglitazone. Rosiglitazone 102-115 peroxisome proliferator activated receptor gamma Mus musculus 84-93 24135932-4 2013 We hypothesize that peroxisome proliferator-activated receptor-gamma activation with rosiglitazone induces changes in neutrophilic mobilization and phenotype that might influence stroke outcome. Rosiglitazone 85-98 peroxisome proliferator activated receptor gamma Mus musculus 20-68 24135932-9 2013 After treatment with the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone, most neutrophils ( 77%) acquired an N2 phenotype. Rosiglitazone 82-95 peroxisome proliferator activated receptor gamma Mus musculus 25-73 24244514-7 2013 Hypoxia-induced increases in miR-27a were attenuated in mice treated with the PPARgamma ligand, rosiglitazone (RSG, 10 mg/kg/d) by gavage for the final 10 d of exposure. Rosiglitazone 111-114 peroxisome proliferator activated receptor gamma Mus musculus 78-87 23897951-5 2013 Rosiglitazone, an antidiabetic PPARgamma ligand, ameliorated these effects. Rosiglitazone 0-13 peroxisome proliferator activated receptor gamma Mus musculus 31-40 23789962-1 2013 Genetically diabetic Akita mice, kept on a high-fat and high-cholesterol diet, and treated with the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone (10 mg/kg per day during 4 months), displayed rosiglitazone-induced side effects, similar to those observed in patients, including weight and fat gain and early signs of hypertrophic cardiomyopathy. Rosiglitazone 157-170 peroxisome proliferator activated receptor gamma Mus musculus 100-148 23789962-1 2013 Genetically diabetic Akita mice, kept on a high-fat and high-cholesterol diet, and treated with the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone (10 mg/kg per day during 4 months), displayed rosiglitazone-induced side effects, similar to those observed in patients, including weight and fat gain and early signs of hypertrophic cardiomyopathy. Rosiglitazone 217-230 peroxisome proliferator activated receptor gamma Mus musculus 100-148 23494891-12 2013 We also demonstrated osteoclasts show characteristic M2 phenotype and can be further promoted by PPARgamma ligands, especially rosiglitazone. Rosiglitazone 127-140 peroxisome proliferator activated receptor gamma Mus musculus 97-106 23885013-9 2013 Administration of the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone (Rosi) restored adipogenic gene expression. Rosiglitazone 79-92 peroxisome proliferator activated receptor gamma Mus musculus 22-70 23885013-9 2013 Administration of the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone (Rosi) restored adipogenic gene expression. Rosiglitazone 94-98 peroxisome proliferator activated receptor gamma Mus musculus 22-70 23791978-2 2013 However, PPARgamma agonists currently in clinical use, including rosiglitazone (RSG), are often associated with severe side effects that limit their therapeutic use. Rosiglitazone 65-78 peroxisome proliferator activated receptor gamma Mus musculus 9-18 23791978-2 2013 However, PPARgamma agonists currently in clinical use, including rosiglitazone (RSG), are often associated with severe side effects that limit their therapeutic use. Rosiglitazone 80-83 peroxisome proliferator activated receptor gamma Mus musculus 9-18 23640045-6 2013 The PPARg-agonist rosiglitazone prevented tumor formation in mice irrespectively of the Cav1 status and upregulated expression of the Ras-inhibitory protein docking protein-1. Rosiglitazone 18-31 peroxisome proliferator activated receptor gamma Mus musculus 4-9 23866284-1 2013 OBJECTIVE: To investigate the effects of peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist rosiglitazone on the expression of cyclin D1 in lung tissue, and the proliferation of airway smooth muscle cells (ASMCs) in mice with bronchial asthma. Rosiglitazone 110-123 peroxisome proliferator activated receptor gamma Mus musculus 41-89 23562554-4 2013 PPARgamma agonist rosiglitazone induced FAM3A expression in primary cultured mouse hepatocytes and human HepG2 cells. Rosiglitazone 18-31 peroxisome proliferator activated receptor gamma Mus musculus 0-9 23866284-1 2013 OBJECTIVE: To investigate the effects of peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist rosiglitazone on the expression of cyclin D1 in lung tissue, and the proliferation of airway smooth muscle cells (ASMCs) in mice with bronchial asthma. Rosiglitazone 110-123 peroxisome proliferator activated receptor gamma Mus musculus 91-100